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Summary 
Background: Lymphatic filariasis (LF), a mosquito-transmitted parasitic disease caused by 
filarial worms, is a leading cause of disability worldwide. In 1997, at the 50th World Health 
Assembly, a resolution was passed to eliminate LF as a public health problem by 2020. To 
reach established elimination targets, LF programmes conduct annual community-wide mass 
drug administration (MDA). At the start of the Global Programme to Eliminate Lymphatic 
Filariasis (GPELF), an estimated 120 million individuals were infected, and approximately 1.4 
billion people were at risk for filarial infection. Since then, mainly through MDA programmes, 
the number of people at risk of infection has been reduced to 856.4 million. By the end of 
2016, MDA had been implemented in 63 of 72 LF-endemic countries. Demonstrating success 
of LF programmes depends on rigorous monitoring and evaluation (M&E) of programme 
activities. As prevalence declines, it is important to identify sensitive diagnostic tools and 
robust surveillance strategies to detect any possible recrudescence of infection as early as 
possible. Existing recommendations for LF surveillance are adequate for making the decision 
to stop MDA, but may not be sufficient for documenting that elimination endpoints have been 
met. Programme strategies need to be refined in order to establish a more robust M&E 
framework.  
Goals and objectives: The overarching goal of this PhD thesis was to provide 
recommendations on approaches for conducting surveillance for LF elimination programmes. 
There were two interlinked objectives: (i) to determine the utility of serologic tools during the 
post-MDA surveillance period within communities that have received multiple rounds of LF 
MDA; and (ii) to determine the utility of the transmission assessment survey (TAS) and other 
activities during the post-MDA surveillance period as platforms for integrated disease 
surveillance. The specific aims were (i) to compare LF antigen and antifilarial antibody 
responses during the post-MDA surveillance period; (ii) to determine the appropriate age 
group(s) to monitor during the post-MDA period; (iii) to compare diagnostic tools for use 
during the surveillance period to determine the most appropriate diagnostic tool(s) to use for 
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LF surveillance; and (iv) to assess the feasibility of using existing disease programme 
infrastructures as platforms for multi-disease surveillance. 
Methods: To compare the utility of parasitological and serological indicators for measuring 
LF programme endpoints, samples from participants (2-100 years old) in 10 sentinel sites in 
coastal Kenya were examined for circulating filarial antigen (CFA) and filarial antibodies. To 
evaluate the use of antibody responses as a way to measure the impact of MDA, serum 
samples collected at three time points from children 1-5 years of age in western Kenya were 
tested for antibody responses to two schistosome antigens by multiplex bead assay (MBA). 
In American Samoa, CFA and antibody results from children enrolled in LF TAS conducted 4 
years apart were analysed to determine whether interruption of LF transmission has been 
achieved. A study was carried out in The Gambia among populations living in 15 villages with 
a history of high LF prevalence. Samples were collected and tested for CFA and filarial 
antibodies to evaluate the use of serological tools to confirm interruption of LF transmission. 
Published data from previously conducted studies in American Samoa were analysed to 
evaluate the relationship between human serological indicators and filarial DNA in 
mosquitoes. In Haiti, to evaluate the feasibility of using TAS as a platform to collect 
information about other tropical diseases, samples were collected to test for LF and malaria. 
In addition to LF testing, samples collected during the sentinel site surveys in coastal Kenya 
were used for the detection of antibodies against antigens from several parasitic infections as 
well as markers for immunity to vaccine-preventable diseases to determine the utility of 
integrated serosurveillance. 
Results: The overall prevalence of filarial antigenaemia in coastal Kenya was low (1.3%). 
CFA prevalence among children under 10 years old was very low (<1%). However, 
quantitative antibody levels among children were higher in areas with suspected LF 
transmission. Antibodies to Schistosoma spp. antigens among children declined after MDA. 
There was a significant decrease in the proportion of 1-year olds with positive antibody 
responses from 33.1% in year 1 to 13.2% in year 3. In American Samoa, a total of 1,134 and 
864 children (5-10 years old) were enrolled in TAS 1 (2011) and TAS 2 (2015), respectively. 
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Two CFA-positive children were identified in TAS 1, and one CFA-positive child was 
identified in TAS 2. In 2011, overall prevalence of antibody responses to Wb123, Bm14, and 
Bm33 was 1.0%, 6.8% and 12.0%, respectively. In 2015, overall prevalence of positive Bm14 
and Bm33 responses declined significantly to 3.0% and 7.8%, respectively. However, there 
were persistent antibody responses in some schools. In The Gambia, a total of 2,612 dried 
blood spots (DBS) collected from individuals aged 1 year and above was tested for 
antibodies to Wb123 by enzyme-linked immunosorbent assay (ELISA). Overall, prevalence 
of Wb123 was low (1.5%). In seven of 15 villages, there were no Wb123-positive individuals 
identified. In American Samoa, there was a significant relationship between the presence of 
filarial DNA in mosquitoes and villages with individuals with responses to Wb123. It was 
feasible to add malaria testing to TAS in Haiti. A total of 16,655 children were tested for LF 
and 14,795 for malaria in 14 TAS. In Kenya, utilising a multiplex approach, antibody 
responses to 10 antigens representing six parasitic infections and three antigens to assess 
immunity to vaccine preventable diseases were generated from a single sample collected 
from each participant. 
Conclusions: As prevalence declines, using parasitological indicators to determine LF 
programme endpoints becomes challenging and there is a need to identify alternative 
indicators to use during the surveillance period. Results from this PhD thesis support the use 
of antibody tools to determine the status of LF transmission and suggest that serological 
tools can have a role in guiding programmatic decision-making. The absence of antibody 
responses strongly suggests that LF transmission has been interrupted and, in contrast, the 
presence of antibody in children is an important indicator that programmes have not reached 
elimination. Finally, existing LF programme activities can provide a platform both to introduce 
the use of antibody testing into TAS and to conduct integrated assessments.  
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1 Introduction 
Neglected tropical diseases (NTDs), a diverse group of diseases, are widespread throughout 
the tropics and subtropics and affect more than 1 billion people worldwide (Herricks et al., 
2017; WHO, 2018). These diseases are most prevalent among the poorest and most 
marginalized populations and can cause significant physical and emotional suffering (Engels 
and Savioli, 2006; Hotez et al., 2006b; 2006a; Utzinger et al., 2012; Houweling et al., 2016). 
NTDs impede the ability to work, impact quality of life, prevent communities from thriving, and 
contribute to significant economic loss in populations already living in fragile environments 
(Hotez et al., 2009; Conteh et al., 2010). Not only are these diseases co-endemic in 
countries, but individuals can often be affected by multiple NTDs (Keiser et al., 2002; Raso et 
al., 2004; Hürlimann et al., 2014; Madinga et al., 2017). While the impact of these diseases 
can be devastating, there has been considerable effort to control and in some cases 
eliminate these diseases (WHO, 2017a, 2017b). In 2005, the World Health Organization 
(WHO) called for the integration of NTD programmes, in order to take advantage of the 
common features of control and elimination strategies (WHO, 2006a). Some NTDs, lymphatic 
filariasis (LF), onchocerciasis, trachoma, schistosomiasis, and soil-transmitted helminthiasis 
(STH), can be effectively controlled and potentially eliminated using safe and effective drugs 
and other complementary interventions, making it feasible to implement large-scale 
preventive chemotherapy programmes. In 2012, governments, non-governmental 
organisations (NGOs), philanthropic groups, international coalitions, private donor 
foundations, and pharmaceutical companies formally committed to control or eliminate as 
many NTDs as possible by 2020 (NTDs, 2012). Toward this end, in 2016, 1.4 billion 
treatments were delivered to 1 billion individuals, a remarkable public health achievement 
(WHO, 2017a). While the number of treatments delivered is impressive, it is essential that 
programmes be monitored carefully in order to track and document progress. Inherent 
features of NTDs including the fact that most infections are asymptomatic and that diagnostic 
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tools are inadequate make surveillance complex, and hence, commonly used strategies need 
to be adapted to make them suitable for NTDs. Carefully designed epidemiological methods 
and appropriate use of diagnostic tools must be coupled with programmatic feasibility in 
order to provide actionable information for achieving control and elimination targets. Although 
there is general optimism that the global burden of NTDs can be reduced, it is critical to 
continually review existing knowledge and to adapt monitoring and surveillance strategies to 
fit programme needs.  
This PhD thesis aims to explore approaches for conducting surveillance for LF, one of 
the preventive chemotherapy (PC) NTDs. Through large scale interventions, significant 
progress has been made towards the elimination of LF. However, as prevalence declines, it 
is essential to identify appropriate diagnostic tools and surveillance strategies to accurately 
assess population-wide LF status to document elimination targets have been met. As 
programmes near LF elimination endpoints, recommended strategies need to be refined in 
order to establish a robust framework for sustaining achievements made to date.  
1.1 Aetiology of lymphatic filariasis  
LF is a parasitic disease caused by three main species of filarial nematodes: Wuchereria 
bancrofti, responsible for more than 90% of all infections worldwide, Brugia malayi, and B. 
timori (Taylor et al., 2010). The parasite is transmitted to humans by multiple mosquito 
species including Aedes spp., Anopheles spp., Culex spp., and Mansonia spp. (Sasa, 1976), 
and the complete parasite life cycle requires development stages in both the definitive human 
host and the intermediate vector mosquito. During a blood meal, infective larvae penetrate 
into the bite wound and typically migrate to the lymphatic vessels and lymph nodes where 
they develop into adult worms. Upon maturation, female worms measure 80 mm to 100 mm 
in length while male worms are markedly shorter, measuring an average of 40 mm in length 
(Sasa, 1976). Adult worms often congregate in the lymphatics to form worm nests and can 
live for several years with fecundity lasting on average 6 to 8 years. Upon mating, female 
worms produce millions of microfilariae (MF) that migrate to the lymph and blood channels 
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where they can then be picked up by a mosquito taking a blood meal. After MF are ingested 
by the mosquito, they migrate through the midgut until they reach the thoracic muscles. The 
MF continue to develop into infective third stage larvae, but there is no multiplication or 
sexual reproduction of the parasite in the mosquito (Sasa, 1976). The infective larvae migrate 
through the haemocoele to the mosquito’s proboscis upon which the mosquito can transmit 
the parasite to a person when it takes a blood meal. The complete life cycle of W. bancrofti is 
illustrated in Figure 1.1. 
 
Figure 1.1 Life cycle of Wuchereria bancrofti 
source: https://www.cdc.gov/parasites/lymphaticfilariasis/biology_w_bancrofti.html  
1.2 Pathology of lymphatic filariasis 
Filarial infection can cause a variety of clinical manifestations, most commonly lymphedema 
of the limbs and hydrocele among adult males (Addiss and Brady, 2007). However, most 
infections are asymptomatic, and the majority of infected individuals will never develop overt 
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clinical signs. Despite the absence of apparent clinical indications, nearly all infected persons 
have some degree of subclinical lymphatic damage that can eventually lead to permanent, 
chronic complications (Witt and Ottesen, 2001; Nutman, 2013). However, this subclinical 
damage is potentially reversible in children if infections are treated early (Shenoy et al., 2009; 
Shenoy and Bockarie, 2011; Kar et al., 2017).  
1.2.1 Lymphedema 
A proportion of infected individuals will develop lymphedema caused by improper functioning 
of the lymph system. In these individuals, adult worms cause lymphatic vessel dilatation 
resulting in lymphatic dysfunction that leads to collection of fluid and swelling in the areas of 
accumulation (Dreyer et al., 2000; Taylor et al., 2010). Swelling is generally gradual and 
observed primarily in the lower limbs. Although most lymphedema develops in the legs, it can 
also occur in the arms and breasts (Pani et al., 1990; 1991; Gyapong et al., 1994; Addiss and 
Brady, 2007). Swelling of the limbs is commonly unilateral, but bilateral involvement can 
occur. In such cases, swelling tends to be asymmetrical (Shenoy, 2008). In addition to 
swelling, lymphedema can be associated with skin changes including thickened skin, knobs, 
mossy lesions, and folds (Olszewski et al., 1993; Burri et al., 1996; Nutman, 2013) (Figure 
1.2).   
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Figure 1.2 Skin changes associated with lymphedema: (a) unilateral swelling (b) knobs (c) 
mossy lesions (d) folds 
Some individuals with lymphedema may experience progression to elephantiasis, extreme 
swelling and hardening of the skin, but the mechanism for progression from infection to 
lymphedema to elephantiasis is not well understood (Shenoy, 2008; Nutman, 2013). Of note, 
in most cases, individuals with lymphedema and elephantiasis do not have evidence of MF in 
the blood (Lammie et al., 1993; Addiss et al., 1995; Dissanayake, 2001). This is likely a result 
of the length of time required for disease progression to occur. Basic lymphedema 
management includes simple measures such as washing, skin care, and elevation of the 
affected limb(s) (McPherson et al., 2006; Ottesen, 2006). 
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1.2.2 Hydrocele 
Among men infected with W. bancrofti, hydrocele is the most  
common clinical manifestation (Simonsen et al., 1995; Michael 
et al., 1996; Addiss and Brady, 2007; Njenga et al., 2007), but 
hydroceles among men with Brugian filariasis are uncommon 
(Nutman, 2013). Hydroceles result from the accumulation of 
fluid in the tunica vaginalis (Dreyer et al., 2000; Mand et al., 
2011). Swelling may disappear after initial acute episodes 
(Noroes et al., 2003; Hussein et al., 2004), but over time the 
scrotum becomes enlarged and thickened due to excess fluid 
around the testicles, and the hydrocele becomes progressively 
larger. Onset is often silent, but may be preceded by an acute episode(s) of funiculitis 
(Estambale et al., 1994; Wamae et al., 1998). Similar to lymphedema, most cases are 
unilateral and bilateral involvement is often asymmetrical (Figure 1.3). Additionally, studies 
have shown that males living in endemic areas who have normal clinical examinations can 
have subclinical hydroceles (Simonsen et al., 2002; Mand et al., 2011). Rarely, a chylocele 
may form if lymph fluid from a ruptured lymphatic vessel enters the hydrocele (Dreyer et al., 
2000). While unaddressed hydroceles can have significant impact on quality of life, simple 
surgery can be performed to drain and repair hydroceles (Addiss and Brady, 2007; Lim et al., 
2015).  
Figure 1.3 Hydrocele 
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1.2.3 Acute dermatolymphangioadenitis  
Lymphatic vessel damage and lymphatic dysfunction caused by LF often predispose 
individuals to recurrent bacterial infections (Olszewski et al., 1999; 
Esterre et al., 2000; Baird et al., 2002). These secondary infections 
elicit acute dermatolymphangioadenitis (ADLA), often referred to as 
acute attacks (Addiss and Brady, 2007). These episodes are 
common and likely play a role in the progression of lymphedema 
(Addiss and Brady, 2007). ADLA causes painful adenolymphangitis 
and cellulitis and is associated with swelling of the limbs, redness 
and warmth of the affected area and pain (Figure 1.4). During acute 
attacks, individuals often experience fever, headache, and general 
malaise (Olszewski et al., 1997; Dreyer et al., 1999). These 
symptoms can be managed by the use of analgesics and 
antipyretics to relieve pain and to reduce fever. Additionally, the use 
of first-line antibiotics is recommended (Shenoy, 2008; Mand et al., 
2012). Frequency of acute attacks can be reduced by maintaining 
good hygiene that can be achieved by basic home care (Shenoy et al., 1995; Suma et al., 
2002; Addiss et al., 2010; Jullien et al., 2011).  
1.2.4 Tropical pulmonary eosinophilia 
A small proportion of individuals experience hypersensitivity to filarial infection that results in 
a syndrome known as tropical pulmonary eosinophilia (TPE). The syndrome typically affects 
adult men (20 to 40 years old) living in Asian LF-endemic countries (Ottesen and Nutman, 
1992; Ong and Doyle, 1998). TPE is characterised most commonly by hypereosinophilia 
(>3000/ml) and high levels of immunoglobulin (Ig) E in the blood (Neva and Ottesen, 1978; 
Ottesen et al., 1979; Hussain et al., 1981). Individuals with TPE generally do not have MF in 
the peripheral blood, but elevated antifilarial antibodies are often detectable (Ottesen and 
Nutman, 1992). Common symptoms include non-productive cough, shortness of breath, and 
Figure 1.4 Acute 
dermatolymphangioadenitis 
(ADLA) 
1. Introduction 
___________________________________________________________________________ 
8 
  
 
wheezing – clinical presentation that can be confused with asthma (Neva and Ottesen, 1978; 
Ottesen and Nutman, 1992; Ong and Doyle, 1998). Persons with TPE can also experience 
low-grade fever, weight loss and general malaise (Neva and Ottesen, 1978). TPE symptoms 
can last from a few days to a few weeks after which they can spontaneously resolve without 
treatment (Ottesen and Nutman, 1992). However, treatment with antifilarial drugs is 
recommended (Pinkston et al., 1987; Ottesen and Nutman, 1992).  
1.3 Diagnosis 
1.3.1 Adult worm 
Definitive diagnosis of infection depends on identification of adult worms or MF. However, the 
ability to detect adult worms in the lymphatics of infected individuals is difficult and is not 
typically done. Although biopsies can be performed on suspicion of infection, they are 
impractical for routine use. Non-invasive techniques such as ultrasonography provide an 
alternative to biopsy and can be used to visualize adult worm nests in the lymphatics (Amaral 
et al., 1994; Dreyer et al., 1994; Noroes et al., 1996b; Fox et al., 2005). Active worms in 
these nests exhibit very distinct patterns of movement referred to as the “filarial dance sign” 
(Amaral et al., 1994). Additionally, subclinical lymphatic damage, dilatation of lymphatic 
vessels, can also be assessed by ultrasound (Suresh et al., 1997; Faris et al., 1998). While 
ultrasound examinations are relatively simple, they require specialized equipment and trained 
personnel and are not feasible to use on a regular basis in most LF-endemic settings.  
1.3.2 Microfilariae 
In contrast to the infrequent use of methods to identify adult worms, techniques used to 
detect MF have routinely been used to diagnosis filarial infection. MF in the peripheral blood 
can be observed by microscopically examining blood smears (20 µl to 60 µl whole blood) 
stained with Giemsa or hematoxylin and identifying distinct morphologic features to 
determine the species of filarial worm (Sasa, 1976). Giemsa stained images of the three 
species that cause LF are shown in Figure 1.5. Although blood smears are relatively simple 
and inexpensive to make, accurate diagnosis depends on skilled, experienced microscopists 
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correctly identifying MF. For increased sensitivity, larger volumes of blood (approximately 1 
ml) can be collected for concentration techniques such as the Knott's technique (Rawlins et 
al., 1994; Oliveira et al., 2014) or membrane filtration (McMahon et al., 1979; Moulia-Pelat et 
al., 1992; Rawlins et al., 1994). More recently, polymerase chain reaction (PCR) assays have 
been developed to detect parasite DNA and are the most sensitive of all available techniques 
(Lizotte et al., 1994; Zhong et al., 1996; Rao et al., 2006a; 2006b). However, molecular 
methods are not commonly used as they are expensive and require sophisticated laboratory 
infrastructure. Regardless of the technique used, the number of MF or the amount of DNA 
detected provides a measure of intensity of infection and can serve as a useful indication of 
adult worm burden in an infected individual. However, in most parts of the world, tests to 
detect MF are limited by the nocturnal periodicity of the parasites. In these areas, accuracy of 
diagnosis by any of these techniques is dependent on both the volume of blood collected and 
the collection of blood at the appropriate time (22:00 to 02:00 hours). Furthermore, detection 
of MF is relatively insensitive when parasite density is low and few MF are circulating in the 
peripheral blood (Gass et al., 2012). Thus, the chance of missing MF increases when there 
are few viable adult worms producing MF.  
1.3.3 Circulating filarial antigen 
When definitive diagnosis of the parasite is not possible or practical, the presence of 
circulating filarial antigen (CFA) can serve as a proxy for W. bancrofti infection. Currently, 
W. bancrofti B. malayi B. timori 
source: www.dpd.cdc.gov/dpdx 
Figure 1.5 Giemsa stained images of microfilariae of the three species of filarial worms that cause 
lymphatic filariasis 
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there are no diagnostic tests available for the detection of CFA of Brugia spp. CFA tests 
recognise parasite antigen that is highly expressed in the cuticle and reproductive organs of 
adult worms and is released in relatively large quantities by living worms (Weil and Liftis, 
1987). Consequently, CFA is commonly detectable in microfilaremic individuals (Weil and 
Liftis, 1987; Lammie et al., 1994; Weil et al., 1997). Additionally, CFA is often present in 
infected individuals who are amicrofilaremic and asymptomatic (Weil et al., 1988; 1996). 
Thus, results from these tests provide a more sensitive measure of infection compared to 
those used to identify MF. An added advantage is that CFA is detectable in peripheral blood 
at any time of day (Weil et al., 1986). As a result, the same restrictions for timely blood 
collection required for MF do not exist. CFA levels often decrease after treatment, but 
antigenaemia can persist after MF have been cleared from the blood (Eberhard et al., 1997; 
Ismail et al., 2001; El Setouhy et al., 2004; Simonsen et al., 2005; Helmy et al., 2006). While 
CFA tests afford advantages over parasitologic methods, positive results do not necessarily 
indicate the presence of viable adult worms capable of producing MF as worms past their 
reproductive lifespan can still produce detectable levels of CFA. Additionally, a viable female 
worm may be present in the absence of any male worms, making it impossible for MF to be 
produced.  
Quantitative measures of CFA assessed by enzyme-linked immunosorbent assay 
(ELISA) can provide an indication of adult worm infection intensity (Weil et al., 1987; More 
and Copeman, 1990). While the ability to estimate levels of CFA can be useful to monitor 
infection, ELISAs cannot be performed without adequate laboratory infrastructure. Detection 
of CFA was simplified with the introduction of an immunochromatographic card test (ICT) 
(Weil et al., 1997). This rapid format, lateral flow, point-of-care (POC) test allowed for the 
detection of CFA from peripheral blood, serum or plasma outside the confines of a 
laboratory. As with the ELISA format, the ICT was found to be sensitive and highly specific 
for the detection of W. bancrofti adult worm antigen (Njenga and Wamae, 2001; 
Chandrasena et al., 2002; Pani et al., 2004). However, more recently, positive ICT results 
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have been reported among individuals infected with Loa loa but negative for W. bancrofti, 
thus making it difficult to discriminate between the two filarial infections (Wanji et al., 2015; 
Pion et al., 2016). Unlike the ELISA platform, the ICT can only provide a qualitative 
assessment of the presence or absence of CFA. While the ICT provides an alternative to 
laboratory-based assays, there are some limitations to its use. There is a narrow window in 
which the results can accurately be read and interpreted, and false positive results are 
common when the test is read after the recommended reading time. Additionally, the tests 
have a relatively short shelf life (approximately 3 months) when stored above 4°C. 
Furthermore, the relatively high cost of the tests make it prohibitive to use in under-resourced 
countries. In an effort to address these limitations, the ICT was reformatted, and the Filariasis 
Test Strip (FTS) was developed (Weil et al., 2013). In laboratory and field evaluations, the 
FTS was found to be slightly more sensitive than the ICT but overall very comparable (Weil 
et al., 2013; Yahathugoda et al., 2015; Chesnais et al., 2017). Currently, production of the 
ICT is being phased out, and is being replaced solely by the FTS.   
1.3.4 Antifilarial antibody 
Antifilarial antibody responses develop prior to CFA and MF, making them early markers of 
exposure and infection (Hamlin et al., 2012). Similar to CFA, antibody responses can be 
detected in both microfilaremic and amicrofilaremic individuals (Ottesen et al., 1982; Zhang 
et al., 1999; el Serougi et al., 2000) providing advantages over parasitologic methods. 
Although nearly all individuals who live in LF-endemic areas develop antifilarial antibody 
responses within the first few years of life (Witt and Ottesen, 2001), mechanisms of 
protective immunity are poorly understood. Early immunodiagnostic techniques included 
complement fixation, haemagglutination, and indirect fluorescent antibody to assess 
antibodies against MF and adult worms (Ridley, 1956; Kagan, 1963; Kagan et al., 1963; 
Yong, 1973). Over time, diagnostic techniques have shifted towards commonly used 
platforms such as ELISA to assess isotype-specific responses. Although all major 
immunoglobulin (Ig) classes have been targets for immunoassays, studies have shown that 
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IgG is produced in significant amounts in infected individuals (Hussain and Ottesen, 1985; 
Ottesen et al., 1985; Hitch et al., 1989). Furthermore, there is evidence that the IgG4 
subclasses may distinguish active infection from chronic exposure (Hussain et al., 1987; 
Kwan-Lim et al., 1990; Kurniawan et al., 1993; Rahmah et al., 1994). However, because 
antibody responses persist after MF have cleared, it is often difficult to determine if 
responses are a result of current infection or past exposure. Limited evidence suggests that 
antifilarial responses are not lifelong and that individuals will eventually serorevert after 
infection has cleared (Wamae et al., 1992; Weil et al., 2008; Moss et al., 2011).  
Early assays used native filarial parasite antigen, and although these assays were 
relatively sensitive, they suffered from poor specificity (Maizels et al., 1985; Muck et al., 
2003; Fischer et al., 2005). Specificity of antibody assays was improved with the 
development of recombinant antigens such as Bm14 (Chandrashekar et al., 1994), WbSXP 
(Dissanayake et al., 1992), and BmR1 (Rahmah et al., 2001). Although cross-reactivity was 
reduced compared to when crude antigens were used, it was not eliminated (Weil et al., 
2011). This made it challenging to use these assays in areas where multiple filarial parasites 
exist. Recently, Wb123 (Kubofcik et al., 2012), a highly specific recombinant antigen has 
been described as an early serologic marker for W. bancrofti infection, thus potentially 
eliminating some of the challenges encountered with previous recombinant and crude 
antigens.  
1.3.5 Molecular xenomonitoring 
Molecular xenomonitoring (MX), the use of molecular methods (e.g. PCR) to detect filarial 
DNA in mosquitoes, can provide an indirect measure of infection in the human population 
(Williams et al., 2002; Fischer et al., 2007; Weil and Ramzy, 2007). Prior to the introduction 
of molecular techniques, dissection and microscopic examination of vector mosquitoes was 
the standard method used to determine infection rates in mosquitoes. This method was time 
consuming, labor intensive, and impractical for large-scale assessments. Furthermore, the 
sensitivity for detecting parasites by dissection declined as infection prevalence declined 
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(Ramzy et al., 1997; Plichart et al., 2006; Chambers et al., 2009). With the introduction of 
MX, pools of mosquitoes could be examined with increased efficiency and sensitivity.  
Collecting and examining mosquitoes provides a non-invasive alternative to sampling 
human populations. However, MX depends on the availability skilled persons to collect the 
mosquitoes, the ability to adequately sample the vector population, and laboratory 
infrastructure to test the mosquitoes. Additionally, the presence of filarial DNA in mosquitoes 
does not necessarily indicate the presence of infective parasites. RNA assays (Laney et al., 
2008; 2010) to detect infective 3rd stage larvae (L3) larvae exist but not commonly used, as 
they require collection of mosquitoes into special media to preserve RNA. Importantly, the 
direct relationship between filarial DNA levels in vector mosquitoes and infection rates in 
humans is unclear. Hence, the value of MX may be limited to simply identifying areas where 
human infections exist.    
1.4 Treatment 
Currently, there are no drugs that specifically target adult worms. Diethylcarbamazine (DEC), 
developed in 1947 as a derivative of the antiparasitic drug, piperazine (Hewitt et al., 1947), is 
the preferred treatment. Although it has limited macrofilaricidal impact (1996a; Noroes et al., 
1997), it is very effective at killing MF (Sasa, 1976; Hawking, 1979; Ottesen, 1985). 
Historically, a standard 12-day course of DEC (6 mg/kg/day) was recommended, but studies 
have documented comparable efficacy of a single dose (6 mg/kg) in achieving sustained 
reduction of MF of up to one year (Kimura and Mataika, 1996; Meyrowitsch et al., 1996; 
Noroes et al., 1997). DEC is relatively well tolerated but side effects such as headache, 
fever, and general malaise are common (Ottesen, 1985; Horton et al., 2000). Additionally, 
treated individuals can experience localized reactions and pain, likely due to the rapid killing 
of parasites (Ottesen, 1985). 
Ivermectin, an avermectin derivative, was first introduced as a veterinary drug in the 
early 1980s and as a human drug later that same decade (Aziz et al., 1982; Campbell, 1982). 
Similar to DEC, a single dose (200 µg to 400 µg) is very effective at rapid clearing of MF for 
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periods of up to 12 months but has virtually no impact on adult worms (Cao et al., 1997; 
Brown et al., 2000). As an added benefit, ivermectin can be used to treat common intestinal 
worms and ectoparasites such as scabies and lice (Meinking et al., 1995; Bockarie et al., 
2000; Kircik et al., 2016; Hardy et al., 2017). Individuals treated with ivermectin can 
experience similar systemic reactions as those treated with DEC (Horton et al., 2000). 
Albendazole, a benzimidazole, was first introduced for human use in the early 1980s 
(Pene et al., 1982; Rossignol and Maisonneuve, 1983). At a standard dose of 400 mg, it is 
effective against several helminth infections including LF (Addiss et al., 1997; Ismail et al., 
1998; Beach et al., 1999; Horton, 2000). Unlike DEC and ivermectin, the killing of MF after a 
single dose of albendazole is slow and gradual over 6 to 12 months (Gyapong et al., 2005). 
Systemic reactions to treatment are similar to the other antifilarial drugs (Horton et al., 2000). 
1.5 Epidemiology 
Historically, LF has been documented clinically or parasitologically in 104 countries in the 
tropics and sub-tropics (Sasa, 1976). MF of W. bancrofti were first described by Wucherer in 
1866 in a urine sample from a patient in Bahia, Brazil suffering from urinary schistosomiasis 
(Sasa, 1976). Six years later, Lewis identified W. bancrofti MF in a peripheral blood sample 
from a patient in India (Sasa, 1976). The first adult W. bancrofti worm was isolated in 1876 
from a lymphatic abscess on the arm of a Chinese patient in Brisbane, Australia (Sasa, 
1976). MF of Brugia malayi were not described as distinctly different until Lichtenstein and 
Brug did so in 1927. MF of Brugia timori were not characterized until 1965 by David and 
Edeson in 1965 (Sasa, 1976). In 1947, prior to a clear distinction between W. bancrofti and 
Brugia spp., Stoll estimated 189 million people infected with W. bancrofti worldwide (Stoll, 
1947).    
Currently, primarily as an indirect result of economic development, change in 
environmental conditions, and in a few cases by intentional treatment and control efforts, the 
number of LF-endemic countries has been reduced to 72 (WHO, 2017c). Although LF is 
widespread across many regions, it is not homogenously distributed in the countries where it 
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is endemic. Distribution is focal (Michael et al., 1996; Boyd et al., 2010; Cano et al., 2014), 
and pockets of transmission become increasingly difficult to detect as prevalence declines. 
LF is strongly associated with poverty (Gyapong et al., 1996; Coreil et al., 1998; Ramaiah et 
al., 1998; Hotez, 2007) and transmission often occurs in environments where there is risk for 
multiple infectious diseases, compounding the impact LF can have on populations. Because 
there are multiple mosquito species capable of transmitting filarial parasites, LF exposure is 
not restricted to only rural or urban areas as suitable mosquito breeding environments exist 
in both settings. LF is one of the leading causes of disability worldwide and in 2016 was 
responsible for an estimated 1.19 million disability-adjusted life years (DALYs) (GBD, 2017).  
Transmission of LF is influenced by a variety of factors including the number of 
infected persons, the density of MF in the blood of infected persons, and the density of 
mosquito vectors. Infection is usually acquired in childhood. Children born to microfilaremic 
mothers are more likely to be infected than those born to uninfected mothers (Lammie et al., 
1991; 1998). However, MF infrequently cross the placental wall during pregnancy, 
suggesting infections are not acquired in utero, but instead that repeated exposure to the 
mother predisposes children to infection (Campello et al., 1993; Eberhard et al., 1993). In LF-
endemic countries, prevalence of infection increases with age (Das et al., 1990; Lammie et 
al., 1994; Meyrowitsch et al., 1995; Kazura et al., 1997) and there are many more infected 
individuals than cases of overt clinical disease, thus making clinical diagnosis a significant 
underestimation of the number of persons affected by LF. Since repeated exposure to filarial 
parasites is needed to establish infection (Hati et al., 1989; Rwegoshora et al., 2005), short-
term travel to endemic areas poses minimal risk for acquiring infection.  
Because of the time required for MF to mature into adult worms, the ability to detect 
markers of infection is limited by the time required for patent infection to appear. Antifilarial 
antibody responses are the earliest marker of infection and typically develop within the first 
few months after exposure (Hamlin et al., 2012). CFA develops 6 to 12 months after 
antibodies (Hamlin et al., 2012). As MF are only produced after adult worms have mated, it is 
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the most lagging indicator. MF typically are not present for at least 12 to 18 months after CFA 
(Hamlin et al., 2012).  
Although LF is widespread, several characteristics of the responsible filarial parasites 
make elimination feasible. The parasite does not multiply in the human host or the vector 
mosquito, and humans are the only definitive host for W. bancrofti (Sasa, 1976). Because 
sustained transmission is dependent on both humans and mosquitoes, there are multiple 
entry points for employing effective treatment and vector control strategies to disrupt the 
transmission cycle. Consequently, in 1993, an International Task Force for Disease 
Eradication (ITFDE) listed LF as one of six diseases that could feasibly be eradicated (CDC, 
1993).  
1.6 Global Programme to Eliminate Lymphatic Filariasis 
In 1997, at the 50th World Health Assembly (WHA), a resolution was passed to eliminate LF 
as a public health problem by 2020 (WHA resolution 50.29) (WHO, 1997). Shortly thereafter, 
in 2000, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) was organised to 
assist countries in achieving this goal (Ottesen, 2000). To reach established elimination 
targets, LF programmes set out to treat individuals in endemic areas through annual 
community-wide mass drug administration (MDA) for at least 5 years. At the start of GPELF, 
an estimated 120 million individuals were infected, and approximately 1.4 billion people were 
at risk for filarial infection (WHO, 2000). Since then, mainly through MDA programmes, the 
number of people at risk of infection has been reduced to 856.4 million (WHO, 2017c). By the 
end of 2016, MDA had been implemented in 63 of 72 LF-endemic countries, with a 
cumulative 6.7 billion treatments delivered since the launch of GPELF (WHO, 2017c).  
The global LF elimination strategy has two main aims. First, to interrupt transmission 
through MDA; and second, to alleviate suffering caused by the disease through morbidity 
management and disability prevention (MMDP). WHO has established guiding principles to 
achieve these aims (WHO, 2011a, 2017d), and thus, all LF elimination programmes follow 
the basic programmatic steps. 
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1.6.1 Mapping and baseline 
To address the first aim of GPELF, transmission interruption, programmes first conduct 
mapping to determine if intervention is necessary. At the start of GPELF, to take advantage 
of momentum surrounding the potential for elimination, there was a bias towards starting 
MDA. Treatment was sometimes initiated based on historic evidence alone or the presence 
of clinical disease (i.e. lymphedema and hydrocele). When parasitological assessments were 
conducted, district-wide treatment decisions were usually based on testing a convenience 
sample of 50 to 100 individuals. MDA was triggered when >1% of the tested individuals were 
positive for MF or CFA (WHO, 2011a). Currently, more rigorous, population-based 
assessments are recommended for mapping (Gass et al., 2017). After mapping, prior to 
initiating MDA, some programmes have chosen to conduct baseline assessments of MF or 
CFA. Although these surveys involve testing 300-500 people, they are frequently based on 
testing a convenience sample of the population and may not be a true representation of the 
entire area where MDA is implemented.   
1.6.2 Treatment regimen 
Recommended MDA treatment regimens depend on the local context. At the start of GPELF, 
co-administration of either DEC (6 mg/kg) plus albendazole (400 mg) (DA) or ivermectin (200 
µg/kg) plus albendazole (400 mg) (IA) was recommended (WHO, 2001). Dual combination 
therapy was found to be safe and more effective at clearing MF than monotherapy with any 
of the three drugs (Horton et al., 2000; Gyapong et al., 2005). DA, the preferred combination, 
was recommended in all areas where LF and onchocerciasis were not co-endemic. 
Consequently, DA was used in most countries outside of Africa. Because of the risk of 
serious side effects induced by DEC when administered to individuals infected with 
Onchocerca volvulus (Bird et al., 1980; Aziz, 1986), the recommended drug combination in 
areas of co-endemicity was IA. This made IA the default MDA regimen in most of Africa. In 
select areas in Central and West Africa, in addition to O. volvulus and W. bancrofti, L. loa is 
present. Because there can be significant risk in treating loiasis with either DEC or ivermectin 
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(Carme et al., 1991; Gardon et al., 1997), monotherapy with albendazole is recommended for 
LF MDA (Pion et al., 2017; WHO, 2017d). Rapid scale up and implementation of MDA was 
possible in large part because of generous donations of albendazole from GlaxoSmithKline 
(then Smith Kline Beecham) and ivermectin from Merck and Company (Ottesen, 2000). 
Since then an additional donor of DEC, Easai Co., Ltd., has joined the effort of supporting the 
global need for MDA medicines (Naito, 2012).  
Since all of the medicines have limited impact on adult worms, at least five annual 
rounds of dual combination MDA are administered during the reproductive lifespan of adult 
worms. The effectiveness of MDA depends on epidemiological coverage; an effective round 
is defined as more than 65% of the total population taking the medicines (WHO, 2017d). 
MDA is not recommended for pregnant women in the first trimester or severely ill persons. 
Because it is logistically challenging to weigh individuals during MDA, age or height are often 
used as proxies to determine dosing. DEC is not given to children under 2 years of age, and 
ivermectin is not recommended for individuals under 90 cm.  
Recently, studies have been conducted to evaluate the safety and efficacy of triple 
drug combination of ivermectin, DEC, and albendazole (IDA). IDA was found to be extremely 
effective at clearing MF in infected patients and suppressing MF for up to two years after a 
single dose (Thomsen et al., 2016). As a result, in November 2017, WHO endorsed IDA for 
programmatic use (WHO, 2017d). Currently, WHO recommends IDA in areas eligible for DA 
MDA that have implemented fewer than four rounds MDA or have evidence of persistent 
transmission even after five rounds of MDA.  
1.6.3 Monitoring and evaluation   
In addition to ensuring high treatment coverage, assessments are needed to effectively 
monitor the impact of MDA. Large-scale surveys are not always feasible and cannot be done 
frequently. Instead, during the MDA implementation period, treatment impact is periodically 
monitored through sentinel and/or spot-check sites to provide information on trends of 
infection (WHO, 2011a, 2017d). Sentinel sites are established before the first round of MDA 
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and are recommended to remain constant throughout the duration of the programme. Sites 
are selected based on populations known to be or suspected to be at high risk. Ideally, 
sentinel sites have stable populations of at least 500 people so that a minimum of 300 
individuals ≥5 years of age can be tested for MF or CFA during each survey. The general 
recommendation is to have a minimum of one sentinel site per 1 million population, but more 
sites are encouraged if resources allow. Because sentinel site populations are closely 
monitored, they often become more likely to adhere to programme activities. Results from 
these sites, therefore, may not be representative of the population over time. Spot-check 
sites have the same characteristics as sentinel sites other than the site locations are not 
fixed. Spot-check sites are selected in order to counter potential bias introduced by repeated 
assessments sentinel sites.  
Ideally, sentinel and spot-check site surveys should be conducted as frequently as 
possible. Mid-term surveys, after the 3rd round of MDA, are useful to determine if the 
programme is on track or if programmatic activities need to be altered in any way. However, 
mid-term surveys are optional and are not routinely conducted. Currently, an assessment 
after the 5th round of effective MDA, known as a pre-transmission assessment survey (pre-
TAS) is required as part of the criteria to determine eligibility for stopping MDA. Prevalence of 
CFA in W. bancrofti areas or antifilarial antibody in Brugia spp. areas must be <2% or MF 
prevalence <1% in sentinel and spot-check sites to qualify for the TAS (WHO, 2011a).  
1.6.4 Transmission assessment survey 
After multiple rounds of MDA, national LF elimination programmes must be able to determine 
whether transmission is likely no longer sustainable even in the absence of treatment. In 
2011, WHO published guidance on conducting TAS, a statistically rigorous survey designed 
to help programme managers determine whether infection levels have been lowered below 
the threshold at which transmission is sustainable even in the absence of MDA (WHO, 
2011a). The results of a TAS provide evidence for deciding whether to stop or continue MDA. 
The established threshold below which it is believed that transmission will no longer be self-
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sustaining is <2% CFA prevalence in areas where Anopheles spp., Culex spp. and Mansonia 
spp. are the main vectors, and <1% CFA prevalence in areas where Aedes spp. is the main 
vector. In the absence of antigen detection tools suitable for Brugia spp., the same 
thresholds are applied for antifilarial antibody prevalence in Brugia areas.  
The target population for TAS is young children (6 to 7 years old) because any 
evidence of infection in this population is an indication of relatively recent infection. If the total 
number of positive children identified in an evaluation unit (EU) is at or below a critical cutoff 
value, the EU “passes” and MDA can be stopped.  If the number of positives exceeds the 
critical cutoff value, then the EU “fails” and MDA is continued. The TAS sample size and 
critical cutoff values are powered so that the EU has at least a 75% chance of passing if the 
true infection prevalence is half the threshold, and no more than a 5% chance of passing if 
the true prevalence is greater than or equal to the threshold (WHO, 2011a). After stopping 
MDA, TAS is repeated twice at 2- to 3-year intervals in order to confirm that transmission is 
still below the critical threshold.  
1.6.5 Morbidity management and disability prevention 
Although MMDP has been recommended since the inception of GPELF, progress toward 
providing adequate care has lagged behind the MDA arm. To meet the objectives of the 2nd 
aim of the global programme, programmes must ensure that all affected persons have 
access to a minimum package of care. These basic services including the ability to treat 
acute attacks, lymphedema management, and hydrocele surgery will help to reduce 
morbidity and prevent disability. However, integrating these activities into health systems has 
been challenging for programmes to do, and therefore, MMDP services have not scaled up 
as rapidly as needed. In many countries that have had successful MDA programs, MMDP 
services are still not available in all areas where they are required.   
1.6.6 Validation of elimination of lymphatic filariasis  
After all EUs in a country have successfully passed all required TAS, and access to MMDP 
services has been established where there is a need, the country has met the criteria 
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established by WHO for validation of elimination. In 2015, WHO formally endorsed a 
standardized process for formally acknowledging elimination of LF as a public health problem 
(WHO, 2017e). As part of this process, national programmes compile all relevant data into a 
dossier for review. To date, 11 countries (Cambodia, Cook Islands, Egypt, Maldives, Marshall 
Islands, Niue, Sri Lanka, Thailand, Togo, Tonga, and Vanuatu) have completed the current 
validation process and have been recognized by WHO for their achievements (Taleo et al., 
2017; WHO, 2017f; Khieu et al., 2018). Post-validation surveillance activities have not yet 
been standardised. A schematic of the major stages of an LF elimination programme are 
illustrated in Figure 1.6.    
 
Figure 1.6 LF elimination programme life cycle 
1.7 Surveillance and diagnostic needs 
As of 2016, almost 1,100 TAS have been implemented globally with an overall pass rate of 
>90% (WHO, 2017c). As a result, there are 500 million people living in areas that no longer 
require MDA. Although there has been significant progress since the start of GPELF, it is 
clear that the original target of elimination by 2020 will not be reached since an estimated 
856 million people in 52 countries are living in areas that still require MDA (WHO, 2017c). Of 
the countries where interventions are needed, 22 (42%) have not scaled up MDA to 100% 
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geographic coverage in all endemic implementation units (WHO, 2017c). Additionally, 
several countries have found that, despite completing the recommended number of treatment 
rounds, infection levels are still not below established thresholds for stopping MDA. 
Furthermore, some areas have passed TAS and stopped MDA despite undetected ongoing 
transmission (Lau et al., 2017; Rao et al., 2017).  
At this critical juncture of GPELF, it is imperative to identify strategies to accelerate 
progress toward global elimination and to protect the advances made to date. The recently 
WHO-endorsed triple drug regimen will likely contribute toward the acceleration of 
programmes. Although this new strategy holds promise, it is unclear if the current monitoring 
and evaluation (M&E) framework will be appropriate for monitoring the impact of IDA, and it 
will be important to identify the most appropriate sampling strategies and diagnostic tools to 
use in this context. 
1.7.1 Surveillance strategy gaps 
As MDA begins to scale down in countries, it is important to develop robust strategies to 
establish a surveillance baseline and to detect any possible recrudescence of infection as 
early as possible. However, beyond TAS, post-MDA surveillance has not been standardised. 
During the surveillance period, programmes often face significant resource limitations. 
Therefore, it is essential for surveillance approaches to be simple and efficient yet sensitive 
and timely. Because of the lag between infection and the appearance of clinical signs, it is 
not feasible to rely on clinical indicators for surveillance. As a result, by definition, all 
surveillance for LF must involve active detection of infection. To maximise both efficiency and 
sensitivity to detect informative signals, it is critical to understand the most appropriate 
population(s) to monitor and what signal(s) to measure. In some cases it may be more 
appropriate to monitor incident infections among young children. In other cases it may be 
more appropriate to monitor decreasing trends of infection among older individuals. The TAS 
design, although statistically robust, is not powered to detect changes in CFA prevalence 
over time. Therefore, the results of TAS conducted during the post-MDA surveillance period 
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fail to document trends of antigenaemia. Collecting additional evidence using alternative 
indicators may provide important information needed during the surveillance period.  
1.7.2 Deficiencies in diagnostic tools used for surveillance 
In the early stages of GPELF, detection of MF in peripheral blood was used routinely for 
mapping and to monitor the impact of MDA (Ottesen et al., 1997; Ottesen, 2006; Weil and 
Ramzy, 2007). Detection of MF in thick blood films served as an indication of viable adult 
worm infections and provided evidence needed to make programmatic decisions. However, 
logistical challenges were encountered because of the requirement for night blood 
collections. Additionally, it was increasingly difficult to detect MF in populations after multiple 
rounds of MDA (Gass et al., 2012). Many of the limitations experienced with MF detection 
were addressed with the introduction of the ICT. The detection of CFA served as a 
reasonable proxy for infection, and importantly, could be conducted with blood collected any 
time of the day, thus eliminating the need for night blood collections. Although the ICT, and 
now the FTS, provides advantages over the detection of MF, there are some limitations to 
the use of CFA tests, especially during the post-MDA surveillance period. Similar to the 
observed decline in MF prevalence after treatment, antigenaemia also begins to decline and 
becomes increasingly difficult to detect in populations (Gass et al., 2012). Evidence suggests 
that detection of antifilarial antibodies provides the earliest indicator of filarial exposure 
(Hamlin et al., 2012). Therefore, monitoring filarial exposure through the assessment of 
antibody responses may provide a useful tool for detecting potential recrudescence. Many of 
the currently available LF antibody tests have been shown to be sensitive measures of 
exposure and infection but may lack the specificity needed to make important programmatic 
decisions (Muck et al., 2003; Lammie et al., 2004; Weil et al., 2011). With the recent 
development and availability of Wb123, the ability to use a highly specific antibody detection 
test as a surveillance tool may be within reach.  
There is still a need to determine how best to use serologic responses during the 
post-MDA surveillance period in order to provide evidence for interruption of LF transmission. 
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To better understand the potential applicability of LF serology during the post-MDA 
surveillance period, antibody responses must first be characterised among populations that 
have received multiple rounds of treatment. Thereafter, it may be possible to identify the 
most appropriate surveillance strategy (e.g. population-based surveys, facility-based 
monitoring, etc.). Additionally, programmatic feasibility of diagnostic tool platforms should be 
considered. Currently, various platforms, including rapid tests, ELISA, and multiplex bead 
assays (MBAs) are used. Each of these platforms has advantages and disadvantages and 
therefore can have varying utility depending on the situation. Rapid tests provide a relatively 
simple platform that is not dependent on the constraints of laboratory infrastructure. 
However, these tests are often subject to inter-observer variability. For example, the Brugia 
RapidTM (Reszon Diagnostics; Selangor, Malaysia) appears to have very good sensitivity in 
areas where Brugia spp. is endemic (Dewi et al., 2015), but there have been challenges with 
test interpretation because of the difficulty in determining the presence or absence of test 
lines. ELISA generally provides increased sensitivity compared to rapid tests, but it can be 
challenging to determine appropriate cutoffs needed to interpret results. Recently, MBAs 
have been developed as highly sensitive methods for simultaneous detection of antibody 
responses to multiple antigens (Priest et al., 2010; Moss et al., 2011; Hamlin et al., 2012; 
Lammie et al., 2012; Priest et al., 2016; Arnold et al., 2017). MBAs potentially allow for 
integrated assessments of multiple diseases providing an efficient approach to gathering 
information on diseases of public health importance, but MBAs require specialised equipment 
and sophisticated laboratory infrastructure. As LF prevalence declines, it is essential to 
identify sensitive tools capable of providing information on transmission status in order to 
guide programme decision-making. 
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2 Goal and objectives 
2.1 Goal 
The overarching goal of this PhD thesis is to provide recommendations on best approaches 
for conducting surveillance for lymphatic filariasis (LF) elimination programmes. There are 
two interlinked objectives: 
 to determine the utility of serologic tools during the post-mass drug administration 
(MDA) surveillance period within communities that have received multiple rounds of 
LF MDA; and    
 To determine the utility of the transmission assessment survey and other activities 
during the post-MDA surveillance period as platforms for integrated disease 
surveillance. 
2.2 Specific objectives 
The specific aims of this PhD thesis are 
 to compare LF antigen and antifilarial antibody responses during the post-MDA 
surveillance period by establishing age-prevalence curves for these responses in 
communities that have received multiple rounds of treatment; 
 to determine the appropriate age group(s) to monitor during the post-MDA period; 
 to compare circulating filarial antigen and antibody diagnostic tools for use during the 
surveillance period in order to determine the most appropriate diagnostic tool(s) to 
use for LF surveillance; and 
 to assess the feasibility of using existing disease programme infrastructures as 
platforms for multi-disease surveillance. 
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3.1 Abstract 
Background:  Lymphatic filariasis (LF) is a debilitating disease associated with extensive 
disfigurement and is one of a diverse group of diseases referred to as neglected tropical 
diseases (NTDs) which mainly occur among the poorest populations. In line with global 
recommendations to eliminate LF, Kenya launched its LF elimination program in 2002 with 
the aim to implement annual mass drug administration (MDA) in order to interrupt LF 
transmission. However, the program faced financial and administrative challenges over the 
years such that sustained annual MDA was not possible. Recently, there has been renewed 
interest to eliminate LF and the program, through support from World Health Organization 
(WHO), restarted annual MDA in 2015. The objective of this study was to evaluate the 
current status of LF infection in the endemic coastal region of Kenya before MDA campaigns 
were restarted.  
Results:  Ten sentinel sites in Kwale, Kilifi, Tana River, Lamu, and Taita-Taveta counties in 
coastal Kenya were selected for participation in a cross-sectional survey of LF infection 
prevalence. At least 300 individuals in each sentinel village were sampled through random 
house-to-house visits. During the day, the point-of-care immunochromatographic test (ICT) 
was used to detect the presence of Wuchereria bancrofti circulating filarial antigen in finger 
prick blood samples collected from residents of the selected sentinel villages.  Those 
individuals who tested positive with the ICT test were requested to provide a night-time blood 
sample for microfilariae (MF) examination. The overall prevalence of filarial antigenaemia 
was 1.3% (95% CI: 0.9-1.8%). Ndau Island in Lamu County had the highest prevalence 
(6.3%, 95% CI: 4.1-9.7%), whereas sites in Kilifi and Kwale counties had prevalences <1.7%. 
Mean microfilarial density was also higher in Ndau Island (234 MF/ml) compared to sentinel 
sites in Kwale and Kilifi counties (<25 MF/ml). No LF infection was detected in Tana River 
and Taita-Taveta counties.  Overall, more than 88% of the study participants reported to 
have used a bed net the previous night.  
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Conclusions:  Prevalence of LF infection is generally very low in coastal Kenya, but there 
remain areas that require further rounds of MDA if the disease is to be eliminated as a public 
health problem in line with the ongoing global elimination efforts.  However, areas where 
there was no evidence of LF transmission should be considered for WHO-recommended 
transmission assessment surveys in view of stopping MDA. 
3.2 Background 
In 2000, the World Health Organization (WHO) launched the Global Programme to Eliminate 
Lymphatic Filariasis (GPELF) in response to World Health Assembly resolution WHA50.29, 
which urged Member States to initiate activities to eliminate lymphatic filariasis (LF), a goal 
subsequently targeted for 2020 (WHO, 2011a). The GPELF has two principal aims: (i) to 
interrupt LF transmission, and (ii) to manage morbidity and prevent disability. To interrupt 
transmission of LF infection, the GPELF recommends annual community-wide mass drug 
administration (MDA) of antifilarial tablets to entire at-risk populations aged two years and 
above for 4-6 years at adequate levels of coverage. Modeling studies have estimated 
adequate treatment coverage to be at least 65% of total population in endemic areas (Stolk 
et al., 2003; Michael et al., 2004).  
In Kenya, LF is confined to the coastal region where ecological factors are suitable for 
its transmission (Moraga et al., 2015). The Kenyan Ministry of Health (MoH) launched its LF 
elimination program in 2002 when MDA was conducted in the then Kilifi District. Unlike in 
many other African countries, onchocerciasis is not endemic in LF-endemic coastal Kenya. 
Therefore, the recommended antifilarial treatment for MDA is single-dose annual mass 
treatment with diethylcarbamazine (DEC, 6 mg/kg) plus albendazole (400 mg). In 2003, the 
program was scaled up to include Kwale and Malindi Districts. Another two rounds of MDA 
were conducted in these districts in March 2005 and December 2008 and a further round 
was conducted in December 2011, when MDA was extended to Tana River and Lamu 
counties. Such intermittent MDA is not consistent with GPELF recommendations to provide 
annual MDA for 4-6 years and its impact on transmission is unclear.  
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Monitoring and evaluation is recognized as an essential activity during 
implementation of any disease control program. The current WHO guidelines for 
epidemiological monitoring of LF recommend selection of at least one sentinel site per 1 
million people or implementation unit (IU) (WHO, 2011a). The selected villages should have 
at least 500 persons so as to enable sample collection of at least 300 specimens. Testing for 
circulating filarial antigen (CFA) using immunochromatographic test (ICT) and parasitological 
detection of microfilariae (MF) in blood have been the gold standard tests for monitoring the 
impact of LF elimination programs (WHO, 2011a).  
Kenya’s Ministry of Health NTD Unit successfully appealed to the World Health 
Organization Regional Office for Africa (WHO-AFRO) and other partners for support to re-
establish the MDA program starting in 2015. Subsequently, the WHO Country Office selected 
the Eastern and Southern Africa Centre of International Parasitic Control (ESACIPAC), which 
is part of the Kenya Medical Research Institute (KEMRI), to conduct a comprehensive 
epidemiological assessment of LF infection before re-starting the MDA campaign in the 
coastal region of Kenya. The present paper reports results from this assessment and 
provides critical evidence that can be used for making decisions on MDA in addition to 
providing a basis for future monitoring of the LF program in coastal Kenya.    
3.3 Materials and methods 
3.3.1 Study design and survey sites  
A cross-sectional survey was conducted in October 2015 in ten LF sentinel sites (villages) 
located across the coastal region in Taita-Taveta, Kwale, Kilifi, Tana River and Lamu 
counties. Five of the sites were those that were previously selected by the LF program – 
Ndau Island (Lamu), Kipini (Tana River), Masindeni and Jaribuni (Kilifi), and Makwenyeni 
(Kwale). Five new sentinels sites were selected in Tana-River (Mikinduni), Kilifi (Kinarani), 
Kwale (Mirihini and Mwadimu), and Taita-Taveta (Kimorigo) to represent implementation 
units (sub-counties) that were established after initial MDA implementation. The five earlier 
sentinel sites were selected according to estimated risk of LF as estimated from a previously 
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published report (Wijers, 1977). In the present study, health workers at the county level 
assisted in the selection of the 5 new sentinel sites. The new sites were purposively selected 
to participate in the survey based on the presence of cases of the diseases and/or 
environmental factors indicating that LF transmission is likely to occur as given in the WHO-
AFRO guidelines for mapping of lymphatic filariasis (WHO, 2014). 
3.3.2 Study population and sample size 
The target population consisted of residents of the ten selected sentinel villages. The 
residents of villages in Taita-Taveta, Kwale, Kilifi and Tana River live in dispersed 
homesteads within their respective villages often located in the countryside. However, the 
residents of Ndau Island live in a relatively compact village with households being very close 
together. Typically, villages in the Kenyan coastal region have population of 600-900 persons 
(Njenga et al., 2011a). Following WHO guidelines that at least 300 persons be tested in each 
sentinel site, the target sample population for the survey was 3000 study participants. The 
sampling assumed that the average household size in coastal Kenya consists of 5 members 
per family and 3 individuals would agree to voluntarily participate in the survey. Thus, an 
estimated 100 households were to be visited in each village. Residents of the sentinel 
villages were recruited into the study if aged 2 years or more and not severely ill.  
3.3.3 Survey strategy 
The LF survey was conducted using a house-to-house approach by four teams. Each team 
consisted of two laboratory technologists, two data collectors, a driver and a team leader. 
Additionally, the village chairman and a local volunteer in each selected village joined the 
survey team to assist with mobilization of community members. Individuals in each sentinel 
village were sampled through random house-to-house visits. Refusal to participate in the 
survey was encountered but the target sample was achieved in most sentinel sites.  
A survey questionnaire was programmed onto mobile smartphones (Samsung Galaxy 
Trend S7560) and used to collect data from consenting participants (or parent/guardian in 
case of children). The data collected using the mobile smartphones included information on 
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age, history of previous residence, use of deworming tablets, and long lasting insecticide-
treated net (LLIN) ownership and use. Data on blood collection and results of the ICT test 
were also recorded onto the questionnaire. Additionally, the smartphones were used to 
collect global positioning system (GPS) coordinates of each study household.  
3.3.4 Laboratory procedures 
Blood collection  
The middle finger of consenting individuals was cleaned using a cotton ball soaked in 70% 
isopropyl alcohol. After drying, the tip of the finger was pricked using a sterile lancet and 
blood immediately collected using capillary tubes for ICT test (100 µl) and preparation of dry 
blood spots (DBS) on TropBio filter paper (60 µl). Serological tests will be performed later 
and described elsewhere. Any individual who tested positive for filarial antigens by ICT test, if 
consenting, was also tested for MF. Details of each laboratory procedure are given below. 
Immunochromatographic test (ICT) 
Prior to survey initiation, quality control (QC) of the ICT test kits (BinaxNow® Filariasis, Alere 
Inc., USA) received for the survey was performed in KEMRI-ESACIPAC Regional NTD 
Reference Laboratory using well characterized serum samples. All the test kits assessed 
passed the QC analysis. In the field, 100 µl of the blood was used for the ICT test. After 
application of a whole blood sample to the ICT card, the results were read exactly at 10 
minutes as recommended by the manufacturer. An additional 60 µl of finger prick blood 
samples were collected from participants and applied onto TropBio filter paper (TropBio Pty 
Ltd, Townsville, Qld, Australia) for future serological studies. 
Microfilariae detection 
Individuals who tested positive by ICT test were invited for further testing for MF in night time 
blood samples collected between 20:00 hours and 24:00 hours. The counting chamber 
method was used for examination and enumeration of Wuchereria bancrofti microfilariae in 
the night blood specimens (McMahon et al., 1979). Briefly, 100 µl of blood was mixed with 
900 μL of 3% acetic acid and the samples transported to KEMRI-ESACIPAC regional NTD 
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reference laboratory in Nairobi where MF were examined and counted under a light 
microscope.  
3.3.5 Data management and analysis  
Participants’ responses were captured electronically into Open Data Kit 
(www.opendatakit.org/), which included in-built data quality checks to prevent data entry 
errors.  
Filarial infection was defined as a positive ICT result. Observed overall prevalence of 
filarial infection was calculated at sentinel site and county levels. 95% confidence intervals 
(CIs) were obtained by binomial logistic regression, taking into account clustering by 
households. Prevalence by sex and age group was calculated and 95% CIs determined 
using a Generalized Least Squares (GLS) random effects model that adjusts for household 
clustering. For purposes of this analysis, the following age groups were used: < 10, 10-17 
and ≥ 18 year olds. The overall and village level proportion estimates of reported LLIN use 
were estimated and 95% CIs were determined using Generalized Linear Latent and Mixed 
Models (GLLAMM) adjusted for clustering by households. Overall, cross-county analysis of 
the impact of LLIN use on participant infection status was analysed, first using univariable 
analysis allowing for factors associated with filarial infection (i.e. age group and gender) and 
described as odds ratios (OR), using mixed effects logistic regression at both household and 
county levels. For multivariable analysis, adjusted OR (aOR) were obtained by mutually 
adjusting all minimum generated variables using multivariable mixed effects logistic 
regression at 95% CI taking into account both household and county levels.  
The mean coordinates of all households sampled in each village were used to obtain 
geographic locations of the sentinel sites that were mapped using Arc GIS Desktop version 
10.2.2 software (Environmental Systems Research Institute, Inc., Redlands, CA). All 
statistical analyses were carried out using STATA version 14.0 (STATA Corporation, College 
Station, TX, US).  
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3.4 Results 
3.4.1 Sentinel site surveillance 
Ten sentinel sites (villages) were surveyed between 8th and 18th October 2015 in Kwale, Kilifi, 
Tana River, Lamu and Taita-Taveta counties in Coastal Kenya (Figure 3.1). A total of 2,996 
participants agreed to be registered for the survey, but 20 individuals (0.67%) either withdrew 
or did not provide a blood sample, hence final analysis was done for the remaining 2,976 
participants. Samples for CFA testing using ICT test and dry blood spots (DBS) for 
serological assays were obtained and prepared for 2,976 participants and 2,972 participants, 
respectively. The reported age of individuals ranged from 2 to 100 years, with a median of 18 
years (IQR = 31 years). Of the enrolled participants, 1,260 (42.3%) were male.  
Table 3.1 provides the projected population of the five counties (Statistics, 2009), 
demographic characteristics of the study participants, overall LF infection prevalence by ICT 
test in each county, and the adjusted odds ratios for the factors associated with the LF 
infection. Overall, 38 of 2,976 (1.3%; 95% CI: 0.9–1.8) individuals were found to be CFA 
positive using the ICT test. There was no significant difference in the prevalence of CFA 
positive individuals by sex (p=0.148). Age-group classification was arbitrarily assigned for 
younger children (<10 year olds), older children (10–17 year olds), and adults (≥18 year 
olds). The odds of CFA among persons aged 18 years and above was significantly higher 
than those among younger persons (OR = 3.12; 95% CI: 1.16–8.43; p=0.024). The overall 
prevalence of CFA positive persons in Kilifi and Kwale counties was 0.9% (95% CI: 0.4–1.8) 
and 1.1% (95% CI: 0.6–2.1), respectively, but there were villages where the prevalence was 
up to 1.7%. There was no evidence of LF infection in the sentinel sites in Tana River and 
Taita-Taveta counties. 
Table 3.2 and Figure 3.1 present the prevalence of CFA positive individuals by 
sentinel site. Ndau Island/village in Lamu County had the highest percentage of CFA positive 
persons, with 20 of 320 (6.3%; 95% CI: 4.1–9.7) individuals found to be antigen positive. 
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Infection in Ndau Island was also observed in young children with 6 of the 20 (30%) CFA 
positive individuals being children aged 10 years and below. 
Out of the 38 persons found to be positive for LF infection by ICT test, 33 (86.8%) 
provided a night-time blood sample for examination of MF. Assuming that all the individuals 
that were CFA negative by the ICT test were also negative for microfilaraemia, the 
prevalence of MF was highest in Ndau Island in Lamu County (1.9%; 95% CI: 0.9–4.1), but 
below 1% in three sentinel sites found to have CFA positive individuals in Kwale and Kilifi 
counties. The mean intensity of microfilaremia among MF positive persons in Ndau Island 
was also higher (234 MF/ml; 95% CI: 62–880) than in the other sentinel sites (Table 3.3). 
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Table 3.1 Demographic characteristics and filarial prevalence (%) by ICT test in 10 sentinel 
sites, coastal Kenya, October 2015 
Demographic 2015 
Population 
Sentinel n (%) CFA prevalence Multivariable logistic 
projections sites  (%) (95% CI) aOR (95% CI)a P-value 
County 
Kwale 792,698 
 
3 
 
877 (29.5) 
 
1.1 (0.6–2.1) 
 
– 
 
– 
Kilifi 1,307,185 3 911 (30.6) 0.9 (0.4–1.8) – – 
Tana River 292,885 2 593 (19.9) 0 – – 
Lamu 123,842 1 320 (10.8) 6.3 (4.1–9.7) – – 
Taita-Taveta 347,195 1 275 (9.2) 0 – – 
All counties 2,863,805 10 2,976 1.3 (0.9–1.8) – – 
Sex      
Male – 10 1,260 
(42.3) 
1.5 (0.9–2.4) 1.58 (0.85–
2.95) 
0.148 
Female – 10 1,716 
(57.7) 
1.1 (0.7–1.7) Reference  
Age group      
< 10 – 10 865 (29.1) 0.7 (0.3–1.7) Reference  
10–17 – 10 609 (20.5) 0.2 (0–1.2) 0.23 (0.03–
2.05) 
0.188 
≥ 18 – 10 1,502 
(50.5) 
2.1 (1.5–2.9) 3.12 (1.16–
8.43) 
0.024* 
LLIN use      
Yes – 10 2,647 
(88.9) 
1.1 (0.8–1.6) 0.40 (0.19–
0.86) 
0.019* 
No – 10 329 (11.1) 2.7 (1.4–5.2) Reference  
aAdjusted odds ratios (aOR) were obtained by mutually adjusting all minimum generated variables 
using multivariable mixed effects logistic regression at 95% CI taking into account households and 
county levels 
*P < 0.05 
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Table 3.2 Surveyed households and sentinel site level circulating filarial antigen (CFA) 
prevalence (%), coastal Kenya, October 2015 
County/village Households 
No. CFA 
positive/No. 
examined 
Prevalence 
(%) (95% CI) 
Kwale County    
   Makwenyeni 69 5/297 1.7 (0.7-3.9) 
   Mwadimu 67 5/290 1.7 (0.7-4.0) 
   Mirihini 52 0/290 0 
Kilifi County    
   Kinarani 94 1/307 0.3 (0-2.4) 
   Jarubuni 93 2/298 0.7 (0.2-2.6) 
   Masindeni 96 5/306 1.7 (0.7-3.9) 
Tana River County    
   Mikinduni 75 0/294 0 
   Kipini 83 0/299 0 
Lamu County    
   Ndau 105 20/320 6.3 (4.1-9.7) 
Taita-Taveta County    
   Kimorigo 94 0/275 0 
All villages 828 38/2976 1.3 (0.9-1.9) 
 
Table 3.3 Sentinel site microfilariae prevalence (%) and mean intensity (MF/ml), coastal 
Kenya, October 2015 
Village No. CFA 
positive/No. 
examined 
No. 
examined for 
MFa 
No. MF 
positive 
Mean intensityb 
(MF/ml) 
MF 
prevalencec 
    (95% CI) (95% CI) 
Kwale County      
Makwenyeni 5/297 5 1 22 (3–156) 0.3 (0–2.4) 
Mwadimu 5/290 4 1 10 (1–71) 0.3 (0–2.4) 
Mirihini 0/290 0 0 0 0 
Kilifi County      
Kinarani 1/307 0 0 0 0 
Jaribuni 2/298 1 0 0 0 
Masindeni 5/306 4 1 5 (1–35) 0.3 (0–2.4) 
Tana River County      
Mikinduni 0/294 0 0 0 0 
Kipini 0/299 0 0 0 0 
Lamu County      
Ndau 20/320 19 6 234 (62–880) 1.9 (0.9–
4.1) 
Taita Taveta County      
Kimorigo 0/275 0 0 0 0 
All villages 38/2,976 33 9 140 (39–502) 0.3 (0.2–
0.6) 
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3.4.2 Bed nets and deworming  
Table 3.4 summarizes bed net ownership and usage among the 10 sentinel villages. Overall, 
97.6% (95% CI: 96.6-98.5%) of the respondents reported owning at least one LLIN, with 
88.8% (95% CI: 87.0-90.7%) reporting to have slept under a bed net the previous night. 
However, bed net usage was observed to be lower in Mwadimu village (73.3%; 95% CI: 
63.8-82.7) in Kwale County and Ndau Island (75.0%; 95% CI: 67.9-82.1) in Lamu County. 
There was a significantly lower risk of LF infection among participants who reported bed net 
use compared to those who did not use a bed net (Table 3.1, OR = 0.40, 95% CI: 0.19-0.86, 
p = 0.019).  
Of 2,950 responses about deworming, 1,184 individuals (40%) reported receiving 
deworming drugs during the last six months prior to the study with 68.6% and 21.0% 
receiving the treatment at school and home, respectively.  
Table 3.4 Bed net ownership and usage by sentinel village, coastal Kenya, October 2015 
Village Proportion possessing at least 
one LLIN % 
LLIN usage, previous night % 
 (95% CI) (95% CI) 
Makwenyeni 99.7 (99.0–100) 89.2 (84.0–94.4) 
Mwadimu 95.1 (90.8–99.3) 73.3 (63.8–82.7) 
Mirihini 91.5 (84.2–98.7) 89.5 (82.0–96.9) 
Kinarani 97.4 (91.2–99.6) 89.6 (83.9–95.4) 
Jaribuni 99.5 (98.6–100) 92.7 (88.1–97.3) 
Masindeni 98.4 (93.0–99.1) 88.1 (82.8–93.5) 
Mikinduni 99.0 (95.8–100) 93.6 (89.5–97.7) 
Kipini 100 (98.6–100) 99.5 (98.5–100) 
Ndau 98.7 (96.7–100) 75.0 (67.9–82.1) 
Kimorigo 96.7 (94.2–99.3) 96.7 (94.4–99.0) 
All villages 97.6 (96.6–98.5) 88.8 (87.0–90.7) 
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3.5 Discussion 
The results of the current survey suggest that transmission of LF infection in Tana River and 
Taita-Taveta counties may be absent and could be used to request WHO-AFRO to support 
the Kenyan LF program to conduct transmission assessment surveys in these counties. 
Kenya’s LF elimination program was launched in 2002, but has however, seen inconsistent 
treatment delivery coupled with challenges that resulted in MDA campaigns not being 
conducted every year as recommended by the GPELF (Table 3.5). A renewed commitment 
to re-start the LF elimination program in Kenya attracted support from the WHO-AFRO 
Regional Office and other partners and an MDA campaign was conducted in October 2015. 
This study was undertaken to provide the status of LF infection in the Kenyan coastal region, 
which is required in order to inform decisions on MDA campaigns. Overall, ICT positivity in 
most sentinel sites ranged between 0 and 1.7%. However, the LF infection data in sentinel 
sites in Lamu, Kilifi and Kwale counties indicate that transmission is still ongoing in these 
counties, thus justifying additional rounds of MDA in the three counties. These data, 
therefore, could allow the program to focus the currently available resources in areas that 
have empirical evidence of LF infection.  
Table 3.5 MDA implementation in coastal Kenya showing overrall treatment coverage (%), 
2002-2015 
County 2002 2003 2005 2008 2011 2015 
Kalifi MDA MDA MDA MDA MDA MDA 
(Malindi)  MDA MDA MDA MDA MDA 
Kwale  MDA MDA MDA MDA MDA 
Tana River     MDA MDA 
Lamu     MDA MDA 
Taita-Taveta       
Program (drug) coverage 81.2 79.5 72.3 62.7 58.3 54.3 
 
The original IUs have been revised due to several changes in administrative structures. Malindi is currently a sub-county in Kilifi 
County. Source: WHO preventive chemotherapy database (WHO/PCT databank) 
http://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en/ Accessed 06/11/2016 
 
Ndau Island in Lamu County had a relatively higher infection rate (6.3%) 
compared to the sentinel sites on the mainland. The microfilarial density among MF 
positive persons was also relatively higher in Ndau Island compared to the other sentinel 
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sites. Additionally, about 30% of LF infections on this island was detected in children aged 
ten years and below. Therefore, Ndau Island appears to be a hotspot of LF transmission 
and could be an indication of a similar situation in the other neighboring islands. A previous 
study conducted in Ndau Island four years after a pilot MDA campaign found MF 
prevalence to be 13.7% (Wijers and Kaleli, 1984). A survey conducted by our team in 
2011,  prior to the first MDA in Lamu County under the LF elimination programme, found an 
MF prevalence of 11.6% (MoH, unpublished). The results of the current study, however, 
demonstrate that the MDA campaign conducted in 2011 may be associated with a reduced 
prevalence of LF infection in the Island. Nonetheless, further epidemiological studies in Ndau 
Island should be considered to identify factors responsible for continued transmission of LF 
infection. A study in Leogane, Haiti examined factors that could contribute to continued 
transmission of LF infection and found that MDA non-compliance was significantly associated 
with infection (Boyd et al., 2010).  
The current study found that most households possessed at least one bed net and 
the majority of people interviewed reported that they used the nets regularly. The high bed 
net possession was corroborated by observation of many new bed nets (some still 
unopened) during the current study because the national malaria control program had 
conducted a mass LLIN distribution a few weeks prior to the LF survey. Vector control is 
increasingly being recognized as a possible complementary strategy for LF elimination 
(Sunish et al., 2007; Bockarie et al., 2009; Ichimori et al., 2014). A previous study found that 
vector control in Africa had increased significantly since 2005, with a three-fold increase in 
LLIN ownership and IRS coverage (Kelly-Hope et al., 2013). A few countries where there has 
been high LLIN coverage have reported the possibility of LF elimination in the absence of a 
MDA program. For example, the Gambia has historical evidence of LF transmission 
(McGregor et al., 1952; McFadzean, 1954; Hawking, 1977), a long history of large scale bed 
net distribution (Snow et al., 1988; Cham et al., 1996), and recent reports suggest that LF is 
no longer a public health problem in the country (Rebollo et al., 2015). The current study 
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observed significantly lower LF prevalence and risk of infection among individuals who 
reported bed net use thus suggesting that LLINs may have played a complementary role in 
reducing LF infection in the endemic Kenyan coastal region. 
A study on the impact of permethrin-impregnated bed nets on LF vector mosquitoes 
in villages in Kwale County reported that LF is transmitted by both culicine and anopheline 
mosquitoes. Of the LF vector species collected before implementation of the intervention, 
33.6% were members of An. gambiae complex [with more than 98% being An. gambiae 
(sensu stricto)], 30% were An. funestus, and 36.4% were Culex quinquefasciatus (Bogh et 
al., 1998). A malaria entomologic study reported that the primary vectors of malaria along the 
coast of Kenya include An. funestus and An. gambiae complex: An. gambiae (s.s.), An. 
arabiaensis, and An. merus (Mbogo et al., 2003). The WHO promotes integrated vector 
management (IVM) to improve the cost effectiveness of vector-control operations, and to 
strengthen the capacity of programmes, partnerships and intersectoral collaboration in their 
efforts to control, eliminate or eradicate vector-borne diseases (WHO, 2008). In areas with 
overlapping geographical distribution of LF and malaria, particularly where both infections are 
transmitted by the same species of mosquito vectors, the IVM approach is recommended as 
useful and appropriate for jointly managing control activities for the two diseases (WHO, 
2011b). Although pyrethroid resistance has become widespread among anopheline and 
culicine mosquitoes (Corbel et al., 2007; N'Guessan et al., 2007; Oxborough et al., 2010), the 
sustained use of insecticide-treated  bed nets has been associated with significant decrease 
in number of culicine mosquitoes in houses (Lindblade et al., 2006), which should therefore 
contribute to a reduction in LF transmission. 
According to the 2010–2020 strategic plan of the GPELF, the strategic aim is to 
provide access to MDA and other measures to interrupt transmission in all endemic areas 
(WHO, 2010). The current study provided further evidence that LLINs against malaria can 
indeed have complementary impact against LF and thus significantly contribute towards the 
goal to interrupt transmission of infection. This finding could be used to strengthen the call to 
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adopt IVM approach which requires coordinated control of both malaria and lymphatic 
filariasis so that the two programs could benefit from each program’s activities, thus 
enhancing their overall impact on public health (WHO, 2008, 2011b). Therefore, the Kenyan 
LF and malaria programs should consider jointly undertaking mosquito vector control in the 
coastal region so as to enhance their overall impact on public health. This way, any residual 
LF transmission is likely to be completely eliminated. 
Albendazole is a broad spectrum anthelmintic and is also used to treat LF infection, 
although the evidence on its efficacy when used alone is conflicting; studies in India 
demonstrated significant effects on both MF and antigenaemia (Hoti et al., 2010), but a study 
in Ghana reported minimal efficacy (Dunyo et al., 2000). The current study found substantial 
use of deworming drugs, which could be due to the ongoing national school-based 
deworming program that provides annual albendazole for the treatment of soil-transmitted 
helminths (Mwandawiro et al., 2013). A recent study conducted in an informal settlement 
area in Nairobi revealed that there are many non-governmental organizations and religious 
organizations that also provide albendazole to school-age children in Kenya (Harris et al., 
2015). Nonetheless, the results of the current study are similar to those from previous work in 
a historically high LF endemic area in Malindi sub-County in Kilifi County, which reported 
sustained reduction in LF infection despite missing MDA rounds (Njenga et al., 2011a). 
Taken together, the data suggest that LLIN use and deworming may have contributed to 
reduce LF infection despite the irregular implementation of MDA. 
A number of tests are currently available for diagnosis of W. bancrofti infection but 
thick blood smear microscopy for detection of MF and ICT for testing for CFA were chosen 
for monitoring and evaluation of LF elimination programs (WHO, 2011a). Previous evaluation 
of the ICT test in the coastal Kenya setting, before start of MDA campaigns, found the 
diagnostic tool to be 100% sensitive and specific for LF (Njenga and Wamae, 2001). 
However, a study in Cameroon has reported loss of sensitivity of ICT test in low prevalence 
settings and raised concern regarding the use of this tool for monitoring and evaluation of LF 
3. Assessment of lymphatic filariasis in coastal Kenya 
__________________________________________________________________________ 
44 
  
 
elimination programs (Gounoue-Kamkumo et al., 2015). Additionally, results of studies 
carried out in Central Africa have shown cross-reactivity of ICT test with Loa loa and 
Onchocerca ochengi infections and raised some doubts to the reliability of LF mapping data 
particularly in areas of L. loa co-endemicity (Wanji et al., 2015; Wanji et al., 2016). Therefore, 
the use of ICT test as the gold standard diagnostic tool in this study may be considered as a 
limitation that may significantly impact on the conclusions. Nonetheless, there are studies 
suggesting that antifilarial antibody testing could provide a more sensitive and specific 
measure of exposure to W. bancrofti in carefully selected populations in endemic areas and 
thus, may also be valuable as a tool for monitoring and evaluation of LF elimination programs 
(Joseph et al., 2011; Hamlin et al., 2012). Therefore, it might be useful to conduct operational 
research using strategies that complement CFA testing with the sensitive and specific 
antibody detection diagnostic assays to provide further information on current LF 
transmission in these counties. 
3.6 Conclusion 
The current study suggests that LF transmission may be absent in Taita-Taveta and Tana 
River counties in coastal Kenya and therefore transmission assessment surveys (TAS) 
should be considered with a view to stopping MDA. By contrast, ongoing transmission in 
Kwale, Kilifi, and Lamu counties indicates the need for further MDA rounds in these counties.  
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4.1 Abstract  
Currently, impact of schistosomiasis control programs in Schistosoma mansoni endemic 
areas is monitored primarily by assessment of parasitologic indicators only. Our study was 
conducted to evaluate the use of antibody responses as a way to measure the impact of 
schistosomiasis control programs. A total of 3,612 serum samples collected at three time 
points from children 1-5 years of age were tested for antibody responses to two schistosome 
antigens (SEA and Sm25) by multiplex bead assay. The overall prevalence of antibody 
responses to SEA was high at baseline (50.0%). After one round of mass drug administration 
(MDA) there was minimal change in odds of SEA positivity (OR=1.02, CI=0.79-1.32, p=0.89). 
However, after two rounds of treatment, there was a slight decrease in odds of SEA positivity 
(OR=0.80, CI=0.63-1.02, p=0.08). In contrast to the SEA results, prevalence of antibody 
responses to Sm25 was lowest at baseline (14.1%) and higher in years 2 (19.8%) and 3 
(18.4%). After one round of MDA, odds of Sm25 positivity increased significantly (OR=1.51, 
CI=1.14-2.02, p=0.005) and remained significantly higher than baseline after two rounds of 
MDA (OR=1.37, CI=1.07-1.76, p=0.01). There was a significant decrease in the proportion of 
1-year olds with positive SEA responses from 33.1% in year 1 to 13.2% in year 3 and a 
corresponding decrease in the odds (OR=3.25, CI=1.75-6.08, p<0.001). These results 
provide preliminary evidence that schistosomaisis program impact can be monitored using 
serologic responses. 
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4.2 Introduction 
Schistosomiasis, caused by infection with Schistosoma spp., affects more than 200 million 
people worldwide (WHO, 2015a). Prevalence and intensity of infection with Schistosoma 
mansoni peak between 10 and 15 years of age and gradually decline with age. In children, 
chronic schistosomiasis is associated with anemia and malnutrition and can compromise 
growth and cognitive development (King and Dangerfield-Cha, 2008). Because of the 
influence school aged children (SAC) have on transmission of schistosomiasis, mass 
treatment of this age group with praziquantel (PZQ) has been the cornerstone of 
schistosomiasis control activities (WHO, 2011c). Until recently, disease burden and morbidity 
among pre-school age children (PSAC) has remained understudied. However, recent 
research has shown that first infection is often acquired at a very young age (Sousa-
Figueiredo et al., 2010; Stothard et al., 2011; Verani et al., 2011; Ekpo et al., 2012; Stothard 
et al., 2013), and there is growing evidence that the burden of disease among PSAC may 
warrant global attention.  Although schistosomiasis-associated morbidity among PSAC is still 
not well defined, documented effects include fecal occult bleeding (Betson et al., 2010; 
Betson et al., 2012), anemia (Green et al., 2011; Magalhaes and Clements, 2011) and 
ultrasound abnormalities (Davis et al., 2015); however, discriminating these symptoms from 
other potential infectious causes remains a challenge. Despite mounting evidence for the 
need, PSAC are not routinely screened or included in schistosomiasis mass treatment 
programs in large part due to the need for better diagnostic tools and the lack of a pediatric 
formulation of PZQ.   
Currently, program impact in S. mansoni endemic areas is monitored primarily by 
assessment of parasitologic indicators only. This is traditionally done by monitoring changes 
in prevalence and intensity of infection using the Kato-Katz stool examination method (WHO, 
1991), which has long been the primary diagnostic tool used for S. mansoni and soil-
transmitted helminth (STH) control programs. While this method allows for relatively simple 
assessment of prevalence and intensity of infection, there are known limitations with its use. 
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Logistical challenges are introduced with the short time needed to collect and process 
samples, and quality results are dependent on trained microscopists who can correctly 
identify eggs. Furthermore, as prevalence of S. mansoni and STH infection decreases, the 
sensitivity of the Kato-Katz often decreases in parallel (Nikolay et al., 2014; Mwinzi et al., 
2015). Recent development of a urine based point of care circulating cathodic antigen test 
(POC-CCA) for S. mansoni has addressed some of the limitations with the Kato-Katz. A 
number of studies have compared the POC-CCA to Kato-Katz and found that it is more 
sensitive than the traditional stool based test (Tchuem Tchuente et al., 2012; Colley et al., 
2013). However, there are still some questions about the specificity of the test, especially in 
low prevalence settings (Foo et al., 2015). While there has been significant emphasis placed 
on using stool and urine based diagnostic tools to monitor the impact of treatment programs, 
less emphasis has been placed on the utility of antibody detection tools as a way to measure 
impact. Reduced transmission of schistosomiasis can be assessed, in principle, by 
documenting a lower prevalence of infection-specific antibody. Although there may be 
limitations to using antibody responses among older age groups, documenting reduced 
infection incidence among cohorts of young children can be one of the most powerful 
measures of program impact. However, this measure has not been incorporated into most 
monitoring and evaluation strategies.  Newly-developed multiplex bead assays (MBA) to 
detect antibodies against multiple antigens could make it possible to monitor the effect of 
treatment on infections, and these assays could potentially be used as an additional measure 
of program impact (Lammie et al., 2012). Our study was conducted to evaluate the use of 
antibody responses as a way to measure the impact of schistosomiasis control programs. 
4.3 Methods 
4.3.1 Study site 
The study was conducted from 2012-2014 in Mbita sub-county, which borders Lake Victoria 
in western Kenya. The majority of residents are subsistence farmers, although fishing is the 
main commercial activity in villages near the lake. In addition to fishing, the lake is used for 
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other occupations such as car washing and sand harvesting, and daily activities such as 
washing clothes and bathing. High rates of S. mansoni infection and malaria have been 
documented in the area (Odiere et al., 2012; Minakawa et al., 2015). Prior to the start of the 
study, malaria interventions had been in place for several years, but no mass drug 
administration (MDA) for schistosomiasis had been conducted. A single round of MDA for 
STH infections had been conducted in 2009 for SAC by the Kenya National school-based 
deworming program.       
4.3.2 Study design 
The study was part of a multi-country project designed to evaluate the impact of integrated 
neglected tropical disease (NTD) control programs. In Mbita, SAC from schools within 5km of 
Lake Victoria were screened to identify communities with S. mansoni prevalence ≥25% 
(Odiere et al., 2012). Thirty villages that met the selection criteria were randomized into two 
study arms to compare different MDA strategies for schistosomiasis and STH programs. 
Fifteen villages were randomized to a community-wide treatment arm and the remaining 15 
villages were randomized to a school-based treatment arm. In each of the 30 study villages, 
we aimed to enroll 100 PSAC (1-5 years) and their mothers or guardians. Additionally, we 
aimed to enroll 100 individuals ≥ 6 years (with no upper age limit) to give us a total target 
sample size of 300 individuals per study village. In both study arms, parasitologic and 
serologic indicators were monitored at baseline (year 1) and annually following treatment. All 
monitoring was done in cross-sectional surveys in the selected villages.    
4.3.3 Ethical considerations 
The study was approved by the Scientific Steering and Ethics Review Committees of the 
Kenya Medical Research Institute (KEMRI, SSC No. 2185) and of the Institutional Review 
Board of the U.S. Centers for Disease Control and Prevention (protocol #6249) through a 
reliance agreement with KEMRI. The study was explained to potential participants and 
written informed consent was obtained from persons who agreed to participate. Parents or 
guardians provided consent for children <18 years of age. Additionally, children between 7-
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17 years were asked to provide verbal assent for their participation. All identifiable 
information was kept confidential and maintained by using a secure database with access 
restricted to essential study personnel.  
4.3.4 Data collection 
All study villages were visited between May and July of each study year. Community leaders 
were sensitized to the study details at least one week prior to the arrival of the field teams. 
On the day of sample collection, residents of the community were asked to come to a central 
location within the village. The study was explained, and potential participants were given an 
opportunity to ask questions. After obtaining informed consent, participants were assigned a 
unique identifier and asked to provide basic demographic information such as age and sex. 
Additionally, information about the length of residence within the study village and bednet 
usage was collected. A single global-positioning system coordinate per village was recorded 
at the site of data collection. All data were collected on smartphones (Motorola Milestone 
XT720, Motorola, Chicago, IL) through a modified version of the OpenDataKit application and 
uploaded to a secure SQL server.    
4.3.5 Stool and urine collection and diagnostic tests  
For each participant, an attempt was made to collect a single stool sample to be processed 
by the Kato-Katz method.  Two slides were prepared from each stool sample, read 
independently by trained microscopists and examined for the presence of S. mansoni and 
STH (Ascaris lumbricoides, Trichuris trichiura, hookworm) eggs. Arithmetic means of the 
results from the duplicate slides were calculated and expressed as eggs per gram (EPG) of 
stool. Results for S. mansoni were categorized as light (1-99 EPG), moderate (100-399 EPG) 
and heavy (≥400 EPG) intensity infections according to the current WHO thresholds.(WHO, 
2011c) A single urine sample was collected and tested by dipstick (URiSCAN, YD 
Diagnostics in year 1 and Hemastix, Siemens Healthcare Diagnostics in years 2 and 3) to 
assess hematuria as a proxy for S. haematobium infection. In year 2 and year 3, urine 
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samples positive for hematuria were filtered and examined for the presence of S. 
haematobium eggs.  
4.3.6 Blood collection and diagnostic tests 
Blood was collected via a single fingerstick. To assess anemia, hemoglobin levels were 
measured using a portable, battery operated hemoglobinomteter (HemoCue, Angelholm, 
Sweden) according to manufacturer’s specifications. Anemia was defined according to the 
Kenyan clinical guidelines: <10.0 g/dL for children <5 years old, <11.0 g/dL for children 5 to 8 
years old and <12.0 g/dL for individuals >9 years old; anemia was categorized as mild if 
hemoglobin was >8.0 g/dL, moderate if 5.0 to 8.0 g/dL and severe if <5.0 g/dL (Health, 2002) 
after adjusting for altitude (WHO, 2011d). Malaria infection status was determined by 
preparing thick blood films and using standard Giemsa staining techniques. Slides were 
examined by trained microscopists to determine malaria parasitemia, and positive infection 
was defined by the presence of one or more malaria parasites in 300 high-powered fields. 
Approximately 100µL of blood was collected into a serum capillary collection tube (Ram 
Scientific, Yonkers, NY) and transported back to the laboratory where serum samples were 
separated by centrifugation. Serum was stored at -20°C in the field laboratory in Homabay 
until transported monthly to the main KEMRI NTD laboratory located in Kisumu. In Kisumu, 
samples were stored at -80°C until sent to a KEMRI laboratory in Nairobi where samples 
were tested for antibody responses to a panel of antigens by multiplex bead assay (MBA) 
(described in the Multiplex bead assay section below).  
4.3.7 Treatment 
All eligible individuals in the community-wide treatment arm were offered annual treatment 
with single doses of PZQ (40mg/kg) and albendazole (ALB)(400 mg) approximately two 
months after data collection. In the school-based treatment arm, the current WHO-
recommended strategy to treat only SAC was followed (WHO, 2011c). In both study arms, 
because no current guidelines exist for the inclusion of PSAC in schistosomiasis control 
programs, only PSAC identified as positive for S. mansoni infection by Kato-Katz were 
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treated with crushed PZQ under the supervision of a medical professional. Coartem 
(artemether [20mg/dose] and lumefantrine [120 mg/dose]) was provided to individuals with 
malaria. Treatment with iron supplementation was provided for persons with mild and 
moderate anemia, and individuals with severe anemia were referred to the sub-county 
hospital according to the Kenya National Clinical Guidelines for Nutritional and Hematologic 
Conditions (Health, 2002).  
4.3.8 Multiplex bead assay 
An MBA was used in order to analyze antibody responses to multiple antigens at one time 
from a single serum sample (Lammie et al., 2012). The following schistosome antigens were 
included in the panel for our study: S. mansoni soluble egg antigen (SEA)(Carter and Colley, 
1978) and Sm25, an integral glycoprotein found in microsomal preparations of S. mansoni 
adult worms (GeneBank Accession M37004.1) (Tsang et al., 1983; Ali et al., 1991). The 
Sm25 gene was cloned into BD BaculoGold TM pAcSecG2T Baculovirus Transfer Vector 
(BD 554797, Fisher Scientific, Waltham, MA), and the expressed Sm25 recombinant proteins 
from Sf-9 insect cells were purified using glutathione agarose beads. SEA was coupled to 
SeroMap microsphere beads (Luminex Corp., Austin, TX) in PBS at pH 7.2 using 120 
micrograms protein for 12.5 x 106 beads, and Sm25 was coupled in PBS buffer at pH 7.2 
using 12 micrograms of protein / 12.5 x 106 beads as previously described (Moss et al., 
2011). Test sera were diluted 1:400 in PBS buffer (pH 7.2) containing 0.3% Tween-20, 
0.02% sodium azide, 0.5% casein, 0.5% polyvinyl alcohol (PVA), 0.8% polyvinylpyrrolidone 
(PVP), and 3 µg/ml E. coli extract. Duplicate samples were tested as previously described 
(Moss et al., 2011; Hamlin et al., 2012). Samples having a coefficient of variation of >15% 
between duplicate wells for >3 positive antibody responses were repeated. Cutoff values of 
713.5 median fluorescence intensity (MFI)-background (bg) units for SEA (sensitivity = 
97.5%, specificity = 100%) and 52.5 MFI - bg units for Sm25 (sensitivity = 93.5%, specificity 
= 97.3%) were calculated at CDC from receiver operator characteristic curves using sera 
from 46 stool positive S. mansoni patients, presumed negative sera from 65 adult US citizens 
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with no history of foreign travel, and presumed negative sera from 45 US children. Cutoffs 
were adjusted for instrument differences between CDC and KEMRI using a 2-fold serial 
dilution of a strong positive serum pool to generate a standard curve. The adjusted cutoffs for 
the KEMRI instrument were 965 MFI – bg units for SEA and 38 MFI – bg units for Sm25. 
Additional antigens for malaria, Strongyloides, Ascaris, Giardia, tetanus and diphtheria were 
included in the MBA. Results from the additional antigens will be described elsewhere. 
4.3.9 Data analysis 
Statistical analyses were performed in SAS software version 9.3 (SAS Institute Inc., Cary, 
NC) and used the 5% level of significance.  Frequencies and proportions were compared 
using either the Rao-Scott Chi-squared statistic (Rao JN, 1984), which incorporates a design 
correction into the analyses; logistic regression with variance estimates by a Taylor series 
expansion (DA, 1983) to account for cluster sampling; or in two analyses of S. mansoni 
classification, a standard Pearson Chi-squared because a design effect could not be 
estimated. For logistic regression, odds ratios (ORs) and 95% confidence intervals are 
reported. Unless otherwise stated, results in this paper are for PSAC only and analyses are 
restricted to children with MBA results only. 
4.4 Results 
A total of 4,611 PSAC were enrolled in the study between 2012 and 2014. Of those enrolled, 
serum samples were available from 3,612 (78.3%) children and were tested by MBA. Mean 
age of enrollment at baseline was 3.0 years, decreased slightly to 2.8 years in year 2 and 
remained at 2.8 years in year 3. In each year of the study, the youngest (one year old) and 
oldest age (five years old) groups were somewhat underrepresented. The distribution of 
PSAC in each age group is shown in Table 4.1. Malaria prevalence as determined by thick 
blood smear increased significantly from year 1 to year 2 (OR=1.80, CI=1.03-3.16, p=0.04) 
and remained elevated in year 3 (Table 4.2). Approximately one-third of all PSAC had 
anemia at baseline. Prevalence of anemia increased to 40.9% in year 2, resulting in 
increased odds of being anemic (OR=1.35, CI=1.08-1.68, p=0.01) with approximately 32% of 
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anemic children classified as having moderate to severe anemia (Table 4.2). Anemia was 
significantly associated with malaria (Rao-Scott χ2(1)=129.60, p<0.001) and older age (Rao-
Scott χ2(4)=109.09, p<0.001) but was not associated with S. mansoni infection determined by 
either Kato-Katz (Rao-Scott χ2(1)=0.40, p=0.53) or MBA (Rao-Scott χ2(1)=0.08, p=0.77). The 
proportion of children with hematuria was high at baseline (33.8%) but was significantly lower 
in years 2 (1.5%, OR=0.03, CI=0.02-0.06, p<0.001) and 3 (3.9%, OR=0.08, CI=0.04-0.15, 
p<0.001; Table 4.2). None of the filtered urine samples was positive for S. haematobium 
eggs.   
Table 4.1  Age and sex distribution of pre-school aged children enrolled and tested by 
multiplex bead assay in each study year. 
    Year  
    1 (baseline) 2 3 
Years (months) n (%) female (%) n % female (%)  n % female (%)  
1 (12-23) 154 14.0 79 51.3 181 15.4 92 50.8 235 17.6 124 52.8 
2 (24-35) 225 20.4 134 59.6 259 22.1 126 48.6 296 22.2 156 52.7 
3 (36-47) 274 24.8 142 51.8 284 24.2 163 57.4 332 24.9 165 49.7 
4 (48-59) 354 32.1 169 47.7 427 36.4 233 54.6 433 32.4 218 50.3 
5 (60-71) 96 8.7 46 47.9 23 2.0 13 56.5 39 2.9 24 61.5 
 
Table 4.2 Prevalence of malaria, anemia and hematuria among pre-school aged children in 
each study year. 
    Year 
    1 (baseline) 2 3 
    n positive % n positive % n positive % 
Malaria 727 91 12.5 1,160 238 20.5 1,306 268 20.5 
Anemia 1,096 371 33.9 1,170 478 40.9 1,323 517 39.1 
     mild   250 67.4   345 72.2  351 67.9 
    moderate   113 30.5   131 27.4  152 29.4 
     severe   8 2.2   2 0.4  14 2.7 
Hematuria 1,025 346 33.8 1,103 17 1.5 1,241 48 3.9 
  
At baseline, the overall prevalence of S. mansoni infection by Kato Katz was 28.0%, 
with 40.3% of infections classified as moderate or heavy intensity. S. mansoni infection 
significantly increased with age (Rao-Scott χ2(4)=58.69, p<0.001). After one round of MDA in 
the study villages, there was minimal change in odds of S. mansoni infection among PSAC 
(OR=0.93, CI=0.70-1.23, p=0.61), but there was a significant decrease in the percentage of 
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moderate and heavy intensity infections from 11.3% to 7.9% and the odds of moderate or 
heavy intensity infection (OR=0.67, CI=0.47-0.97, p=0.03). By year 3, after two rounds of 
treatment, overall prevalence was still >20% and nearly 30% of infections were classified as 
moderate or heavy intensity (Figure 4.1). In contrast to S. mansoni infection, very low rates of 
STH infection were observed. Prevalence of any STH infection was <3% in each study year 
(data not shown).   
Figure 4.1 Prevalence and intensity of Schistosoma mansoni infection measured by Kato 
Katz among pre-school aged children in each study year. 
 
The overall prevalence of PSAC with antibody responses to SEA was high at baseline 
(50.0%) (Figure 4.2). After one round of MDA there was minimal change in odds of SEA 
positivity (OR=1.02, CI=0.79-1.32, p=0.89). However, after two rounds of treatment, there 
was a slight decrease in odds of SEA positivity (OR=0.80, CI=0.63-1.02, p=0.08). In contrast 
to the SEA results, prevalence of PSAC with antibodies to Sm25 was lowest at baseline 
(14.1%) and higher in years 2 (19.8%) and 3 (18.4%) (Figure 4.2). After one round of MDA, 
odds of Sm25 positivity increased significantly (OR=1.51, CI=1.14-2.02, p=0.005) and 
remained significantly higher than baseline after two rounds of MDA (OR=1.37, CI=1.07-1.76, 
p=0.01). There was a significant association between dichotomized anti-SEA antibody 
response and intensity of infection measured by Kato-Katz (Pearson χ2(3)=230.22, p<0.001, 
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Figure 4.3a). Similarly, there was a significant association between dichotomized Sm25 
responses and intensity of infection (Pearson χ2(3)=129.43, p<0.001, Figure 4.3b).  
Figure 4.2 Prevalence of antibody responses to SEA and Sm25 by study year measured by 
multiplex bead assay. 
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Figure 4.3 Antibody responses to (A) soluble egg antigen (SEA) and (B) Sm25 were 
significantly associated (p<0.001) with intensity of infection measured by Kato-Katz. Boxes 
enclose 25th and 75th percentile. Lines inside the boxes represent median MFI values. 
 
 
Although all of the study villages were located relatively close (<5km) to Lake Victoria, 
a gradient of antibody responses to SEA was observed. Median SEA responses for the 
villages at baseline ranged from 4 to 32,685 MFI. The highest responses were observed on 
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the island of Rusinga in the northwest corner of the sub-county and there was a significant 
decrease in the odds of a positive SEA response with each additional kilometer away from 
the lake (OR=0.22, CI=0.08-0.62, p=0.004, Figure 4.4a) after controlling for study year. After 
each round of treatment, median SEA responses remained very high on Rusinga, but 
decreased in some villages on the mainland closest to the lake (Figure 4.4b and Figure 4.4c). 
In any study year, there were no differences in stool results or antibody responses between 
the two study treatment arms. 
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A 
Figure 4.4 (A) Year 1: significant decrease (p=0.004) in the odds of a positive soluble egg 
antigen (SEA) response was observed with each additional kilometer away from Lake 
Victoria. (B) Year 2: after one round of treatment, median SEA responses remained high on 
Rusinga Island, but decreased in some villages on the mainland closest to the lake. (C) Year 
3: after two rounds of treatment, median SEA responses remained high on Rusinga Island, 
but continued to decrease in some villages on the mainland closest to the lake.  
  
  
B 
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There was no significant change in prevalence of S. mansoni infection by age after two 
rounds of treatment as determined by stool examination (All χ2(2)<3.11, p>0.21), and 
prevalence was >20% every year for older PSAC (Figure 4.5). In contrast to the egg data, 
there was a decrease in the proportion of 1-year olds with positive SEA responses from 
33.1% in year 1 to 13.2% in year 3 (OR=3.25, CI=1.75-6.08, p<0.001). Furthermore, there 
was a significant reduction in the median SEA MFI values among 1-year olds after two 
rounds of MDA (p<0.05) (Figure 4.6).  The same reduction was not observed in any other 
age group.    
C 
4. Multiplex serologic assessment of schistosomiasis in western Kenya 
__________________________________________________________________________ 
61 
  
 
Figure 4.5 Schistosoma mansoni prevalence by age and study year measured by Kato-Katz. 
 
 
Figure 4.6 A significant reduction (p<0.05) in the median soluble egg antigen (SEA) MFI 
values among 1-year olds after two rounds of MDA was observed. Boxes enclose 25th and 
75th percentile. Lines inside the boxes represent median MFI values. 
 
0
10
20
30
40
50
60
70
1 2 3 4 5
%
 P
o
si
ti
ve
Age (years)
Year 1 Year 2 Year 3
4. Multiplex serologic assessment of schistosomiasis in western Kenya 
__________________________________________________________________________ 
62 
  
 
4.5 Discussion 
In our prospective, cluster randomized trial in Mbita sub-county, western Kenya, S. mansoni 
infection prevalence was high among a group of young children. Although our findings were 
consistent with previous reports of high rates of S. mansoni infection among SAC in this sub-
county (Odiere et al., 2012), this study provides unique data on PSAC. At baseline, using the 
relatively insensitive Kato-Katz method on a single stool sample, nearly 30% of PSAC were 
identified as infected with a parasite that is often considered to be of little public health 
importance in this age group. As expected, prevalence of S. mansoni infection as determined 
by stool examination increased with age. However, our results highlight that young children 
were being exposed to contaminated water early in life, in some cases up to three years or 
more before they would be eligible for inclusion in MDA programs. Our findings add to the 
growing body of evidence that children are at risk for schistosomiasis at a very early age.  
Despite a high rate of S. mansoni infection in our study population, there was a 
relatively low prevalence of STH infection in the same group. Although the environmental 
conditions in Mbita sub-county were conducive to STH transmission and despite the lack of 
improved water, sanitation and hygiene interventions, the prevalence of STH infection was 
much lower than expected. Prior to the study there was one MDA for STH in 2009 and there 
have been anecdotal reports of unprogrammed deworming with ALB for STH. These factors 
may have contributed to the low prevalence of STH observed in our study. 
 Schistosomiasis control program strategies have traditionally aimed to reduce 
prevalence of moderate and heavy intensity infections. More recently, additional strategies 
are being considered to interrupt transmission. Attaining program goals are therefore 
dependent on diagnostic tools that can adequately measure prevalence and intensity of 
infection. Although it is commonly believed that lower intensity infections do not have 
significant impact on morbidity due to the disease, there is growing recognition that even light 
intensity infections can have considerable impact on the health of children (King, 2015). In 
our study, after two rounds of MDA, traditional parasitologic methods showed little change in 
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prevalence of S. mansoni infection in PSAC. There was a significant decrease in heavy 
intensity infections after the first round of treatment in our study, but approximately 29% of 
infections were still classified as moderate or heavy intensity after two rounds of MDA. Our 
results support the growing concern that a single annual round of MDA in high prevalence 
areas may not be sufficient to achieve program goals (Secor, 2015).  
In our study, stool exams were less sensitive than serology. It is possible that 
prevalence of S. mansoni infection was underestimated by only performing a single stool 
exam, but other studies have shown that in high prevalence areas, multiple stool exams 
conducted on consecutive days performed no better than a single exam (Verani et al., 2011). 
In complex and resource-constrained program settings, it is not feasible to collect multiple 
stool samples over consecutive days. We aimed to provide information that could be 
compared to current programmatic approaches. Additionally, it is unlikely that antibody 
results were significantly influenced by S. haematobium infection. Despite high rates of 
hematuria at baseline, there was no visible blood in any urine sample. High rates of 
hematuria were not observed in years 2 and 3. The use of different brands of urine dipsticks 
in year 1 and year 2 may have impacted hematuria results, but the absence of S. 
haematobium eggs upon urine filtration supports the claim that antibody results were likely 
attributable to S. mansoni infections . Although there have been reports of few isolated foci of 
S. haematobium in areas adjacent to Mbita (Sang et al., 2014), none have been identified in 
our study area.  Furthermore, it is possible that cutoff values for the MBA were inaccurate, 
leading to incorrect prevalence estimates. The ability to define robust cutoffs for serological 
assays can be challenging and is often limited by the availability of well characterized panels 
of samples to determine appropriate cutoffs. Despite potential limitations, it is clear that a 
high proportion of children in our study were exposed to S. mansoni at an early age. Our 
results showed good correlation between antibody responses to SEA and Sm25 and intensity 
of infection measured by Kato-Katz. Additionally, we observed a significant association 
between antibody responses and distance to Lake Victoria. This inverse gradient relationship 
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has been observed with stool results (Handzel et al., 2003; Woodhall et al., 2013), but to our 
knowledge has not previously been documented by serology.  
While there are limitations to using serology to distinguish between present and past 
schistosome infections, longitudinal monitoring of antibody responses could provide useful 
information on possible changes in exposure and may provide an advantage over traditional 
parasitologic methods. In addition to parasitologic methods, schistosomiasis control 
programs often include morbidity markers such as anemia to assess program impact. 
However, these markers are often difficult to measure and are not unique to infection with 
Schistosoma spp. In our study, we observed high rates anemia that were associated with 
malaria and not S. mansoni infection. As control programs successfully implement 
interventions, reduced transmission of schistosomiasis will result in fewer infections and 
lower prevalence of infection-specific antibody in cohorts of young children. Malaria control 
programs have described the use of seroincidence among young children born after control 
measures have been put in place as a way to measure current and historical transmission 
within communities (Drakeley et al., 2005; Cook et al., 2010; Arnold et al., 2014). Recently, in 
an lymphatic filariasis program setting, antibody responses were used to distinguish areas 
where programs had been implemented and successful, suboptimally implemented and not 
implemented at all (Dewi et al., 2015). This type of information would be useful for 
understanding how effective control programs have been. The use of serologic markers has 
most often been used in the context of low prevalence settings or surveillance. However, our 
results showed a decline in antibody responses among young children in an area where 
transmission was clearly ongoing. Although further studies are needed to support this finding, 
these results provide preliminary evidence that program impact can be monitored using 
serologic responses.    
Despite the limitations of this study, we believe the ability to use serologic assays to 
monitor schistosomiasis control programs could potentially provide advantages over the 
current stool based approach. It is often easier to collect blood samples versus stool and an 
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additional advantage is the ability to directly observe the collection of fingerstick blood 
whereas the same opportunity does not exist for stool or urine collection. Furthermore, very 
small quantities of blood or dried bloodspots can be used in MBAs that can simultaneously 
test for a variety of diseases of public health importance at the same time. As there is often 
overlap of many of these diseases, this opens opportunities for integrated program 
monitoring, including vaccine coverage surveys.  As schistosomiasis programs consider the 
feasibility of transitioning from control to elimination, the ability to document reduced 
seroincidence strengthens the evidence of elimination of transmission.  
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5.1 Abstract 
Background: Current WHO recommendations for lymphatic filariasis (LF) surveillance 
advise programs to implement activities to monitor for new foci of transmission after stopping 
mass drug administration (MDA). A current need in the global effort to eliminate LF is to 
standardize diagnostic tools and surveillance activities beyond the recommended 
transmission assessment survey (TAS).  
Methodology: TAS was first conducted in American Samoa in 2011 (TAS 1) and a repeat 
TAS was carried out in 2015 (TAS 2). Circulating filarial antigen (CFA) and serologic results 
from both surveys were analyzed to determine whether interruption of LF transmission has 
been achieved in American Samoa.  
Principal findings: A total of 1,134 and 864 children (5-10 years old) were enrolled in TAS 1 
and TAS 2, respectively. Two CFA-positive children were identified in TAS 1, and one CFA-
positive child was identified in TAS 2. Results of both surveys were below the threshold for 
which MDA was warranted. Additionally, 1,112 and 836 dried blood spots from TAS 1 and 
TAS 2, respectively were tested for antibodies to Wb123, Bm14 and Bm33 by luciferase 
immunoprecipitation system (LIPS) assay and multiplex bead assay. In 2011, overall 
prevalence of responses to Wb123, Bm14, and Bm33 was 1.0%, 6.8% and 12.0%, 
respectively. In 2015, overall prevalence of positive Bm14 and Bm33 responses declined 
significantly to 3.0% (p<0.001) and 7.8% (p=0.013), respectively.  
Conclusions/significance: Although passing TAS 1 and TAS 2 and an overall decline in the 
prevalence of antibodies to Bm14 and Bm33 between these surveys suggests decreased 
exposure and infection among young children, there were persistent responses in some 
schools. Clustering and persistence of positive antibody responses in schools may be an 
indication of ongoing transmission. There is a need to better understand the limitations of 
current antibody tests, but our results suggest that serologic tools can have a role in guiding 
programmatic decision making.  
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5.2 Author summary 
Lymphatic filariasis (LF), endemic in 72 countries, is a debilitating mosquito-transmitted 
parasitic disease caused by filarial worms. The Global Program to Eliminate Lymphatic 
Filariasis (GPELF) aims to interrupt transmission through mass drug administration (MDA) 
and to reduce suffering caused by the disease. At the start of GPELF in 2000 it was 
estimated that approximately 1.4 billion people were at risk for infection. By the end of 2016, 
primarily through successful MDA programs, the global number of people requiring 
interventions was reduced to 856.4 million. Current recommendations by the World Health 
Organization for LF surveillance advise programs to implement activities to monitor for new 
foci of transmission after stopping MDA. A current need in the global effort to eliminate LF is 
to standardize diagnostic tools and surveillance activities beyond the recommended 
transmission assessment survey (TAS). Two TAS were conducted in American Samoa; first 
in 2011 (TAS 1) and repeated in 2015 (TAS 2). In our evaluation, circulating filarial antigen 
and serologic results from both surveys were analyzed to determine whether interruption of 
LF transmission has been achieved in American Samoa. Despite passing TAS 1 and TAS 2, 
clustering and persistence of positive antibody responses in schools may be an indication of 
ongoing transmission. Results from our evaluation suggest that serologic tools can have a 
role in guiding programmatic decision-making. 
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5.3 Introduction 
Lymphatic filariasis (LF), endemic in 72 countries, is a debilitating mosquito-transmitted 
parasitic disease caused by filarial worms (Wuchereria bancrofti and Brugia spp.) (Taylor et 
al., 2010). In 1997, at the 50th World Health Assembly (WHA), a resolution was passed to 
eliminate LF as a public health problem by 2020 (WHO, 1997). Shortly thereafter, in 1999, 
the Pacific Program for the Elimination of Lymphatic Filariasis (PacELF) was established to 
eliminate the disease in the Pacific Region through a strategy of annual rounds of mass drug 
administration (MDA) (Pacific, 2006). The following year, the Global Program to Eliminate 
Lymphatic Filariasis (GPELF) was established to assist all LF-endemic countries in achieving 
this elimination goal through the same MDA strategy. At the start of GPELF it was estimated 
that approximately 1.4 billion people were at risk for infection. By the end of 2016, MDA had 
been implemented in 66 of 72 LF-endemic countries, with a cumulative total of 6.7 billion 
treatments delivered since the start of GPELF (WHO, 2017c).  
After multiple rounds of MDA, LF elimination programs must be able to determine 
when it is appropriate to stop treatment. The World Health Organization (WHO)-
recommended transmission assessment survey (TAS) was designed as a decision-making 
tool to determine when transmission of LF is presumed to have reached a level low enough 
that it cannot be sustained even in the absence of MDA (WHO, 2011a). In areas where W. 
bancrofti is the principal LF pathogen, infection is assessed in the TAS by measuring 
circulating filarial antigen (CFA). Since its integration into national programs in 2011, TAS 
has successfully been implemented across LF endemic countries, and based on the results, 
MDA has been discontinued in multiple locations. The global number of people requiring 
MDA has been reduced from 1.4 billion in 2000 to 856.4 million in 2016 (WHO, 2017c). 
Effective M&E is not only necessary during the MDA period but important throughout 
the lifespan of the LF program, including after MDA has stopped. Current WHO 
recommendations for post-MDA surveillance include periodic surveys: repeating TAS twice at 
2- to 3-year intervals after stopping MDA. Beyond the TAS, post-MDA surveillance guidance 
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has not been standardized. Current WHO recommendations for surveillance advise 
programs to implement activities to monitor for new foci of transmission through the 
assessment of microfilaremia, antigenemia, or antibodies (WHO, 2011a). After effective 
MDA, microfilaremia and antigenemia begin to decline in populations and become 
increasingly difficult to detect (Gass et al., 2012). Detection of antifilarial antibodies appears 
to provide the earliest indicator of filarial exposure (Hamlin et al., 2012), and the absence of 
detectable antibody responses may provide evidence that transmission has been interrupted.  
Surveys conducted in 1999 indicated that 17% of residents in 18 villages in American 
Samoa were infected with W. bancrofti (Pacific, 2006). This established American Samoa as 
one of the areas with the highest filarial infection levels in the Pacific Region and the only 
U.S. territory endemic for LF. The American Samoa Department of Health (DOH) started 
MDA in 2000. Annual MDA coverage was low (<50%) prior to 2003. After reassessment and 
modification of the communication and distribution strategies, the program treated an 
estimated 70% and 65% of the population in 2003 and 2004, respectively (King et al., 2011). 
Results from surveys in four sentinel sites showed an overall decline in CFA levels from 13% 
in 2003 to 0.95% in 2006 (Liang et al., 2008). An island-wide survey was conducted in 2007, 
and CFA prevalence was 2.3%, with the majority of the antigenemia detected in adults 
(Coutts et al., 2017). Because LF was presumed to be at very low levels, minimal 
programmatic activities were conducted from 2008-2010.  
In accordance with WHO recommendations, TAS 1 was conducted in American 
Samoa in 2011 and was repeated in 2015 (TAS 2). The DOH opted to include antifilarial 
antibody testing in both surveys to complement antigen testing. In this paper we report CFA 
and serologic results from the two TAS that were conducted to determine whether or not 
interruption of LF transmission has been achieved in American Samoa.  
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5.4 Methods 
5.4.1 Ethics statement 
The surveys were approved by the DOH Institutional Review Board (IRB) and the U.S. 
Centers for Disease Control and Prevention (CDC) as program evaluation, non-research. In 
preparation for the TAS, survey details were described in a written document distributed to 
school officials and parents or guardians of potential participants. In accordance with DOH 
and Department of Education policies, parents or guardians provided written permission for 
participation of children. Additionally, children ≥7 years of age were asked to provide oral 
assent for their participation on the day of the survey. All data were collected electronically, 
and identifiable information was kept confidential and maintained by using a secure database 
with access restricted to essential survey personnel. 
5.4.2 Survey site and design  
American Samoa, a U.S. territory, is located in the South Pacific comprising of seven small 
islands and atolls. More than 90% of the total population live on the main island of Tutuila 
with the remainder of the residents dispersed on the adjacent island of Aunu’u and the outer 
Manu’a islands of Ta’u, Ofu and Olosega. Tutuila and Aunu’u comprised the evaluation unit 
for TAS. TAS 1 was carried out in February 2011 and TAS 2 was conducted in April 2015. 
Surveys were implemented according to WHO guidelines for conducting TAS in areas where 
Aedes spp. are the main LF vectors (WHO, 2011a). Because of high school enrollment rates 
(>95%), school-based surveys were conducted at both time points, and grades 1 and 2 were 
used as a proxy for the recommended age (6-7 years). Systematic sampling was 
recommended for both surveys, but due to low rates of consent, all children with signed 
consent forms were enrolled. The target sample sizes in 2011 and 2015 were 1,042 and 
1,014, respectively. The critical cutoff, the maximum number of observed positive results that 
is consistent with a threshold of < 1%, for both surveys was six antigen-positive children. 
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5.4.3 Blood collection and examination 
For both surveys approximately 160 µL of blood was collected via a single finger stick into an 
EDTA-coated blood collection tube (Ram Scientific, Yonkers, NY). One hundred microliters of 
blood was used for the detection of CFA by immunochromatographic card test (ICT) (Alere; 
Scarborough, ME). The cards were read at 10 min and marked as either positive or negative 
according to the manufacturer’s instructions. The remaining 60 µL of blood (10 µL per 
extension x 6 extensions) was spotted onto filter paper (Cellabs, Sydney, Australia), dried 
and stored at -20°C until shipped to National Institutes of Health (NIH) for antifilarial antibody 
testing by luciferase immunoprecipitation system (LIPS) assay (Kubofcik et al., 2012) or CDC 
for testing by multiplex bead assay (MBA) (Moss et al., 2011; Lammie et al., 2012; Priest et 
al., 2016) (described below).  
5.4.4 LIPS 
In TAS 1, IgG responses to Wb123 were determined by previously described LIPS assay 
(Kubofcik et al., 2012). One modification was made to accommodate the use of dried blood 
spots (DBS) instead of serum. DBS were eluted in 200 μl of PBS, and 40 μl of the eluted 
material was used for the assay. Cutoff values were calculated from receiver operator 
characteristic (ROC) curves using sera from W. bancrofti-infected patients and presumed 
negative sera from North Americans with no history of foreign travel. 
5.4.5 MBA 
Antifilarial antibody responses to Bm14 (Chandrashekar et al., 1994) and Bm33 
(Dissanayake et al., 1993) for samples collected during TAS 1 and responses to Wb123, 
Bm14 and Bm33 for samples collected during TAS 2 were determined by previously 
described MBA (Moss et al., 2011; Hamlin et al., 2012; Lammie et al., 2012; Priest et al., 
2016). Briefly, DBS were eluted to yield a sample dilution of 1:400 in PBS buffer (pH 7.2) 
containing 0.3% Tween-20, 0.02% sodium azide, 0.5% casein, 0.5% polyvinyl alcohol (PVA), 
0.8% polyvinylpyrrolidone (PVP), and 3 µg/ml Escherichia coli extract. E. coli extract was 
added to the buffer to absorb antibodies to any residual E. coli proteins that may not have 
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been eliminated in the antigen purification process. Samples having a coefficient of variation 
of >15% between duplicate wells for ≥2 positive LF antibody responses were repeated. The 
average of the median fluorescent intensity (MFI) values from the duplicate wells minus the 
background (bg) fluorescence from the buffer-only blank was reported as MFI-bg. Cutoff 
values were calculated from ROC curves using sera from W. bancrofti-infected patients and 
presumed negative sera from US citizens with no history of foreign travel. 
5.4.6 Treatment 
Parents or guardians of individuals who were ICT positive were notified of test results, and 
the children were offered a standard single dose of diethylcarbamazine (DEC) (6 mg/kg) and 
albendazole (400 mg).   
5.4.7 Statistical analysis 
Analyses were performed in R version 3.3.0 (Team, 2016) with the survey package (Lumley, 
2004) using a 5% level of significance. Because a high percentage of the American Samoa 
population of 1st and 2nd graders participated, samples from TAS 1 and TAS 2 were treated 
as clustered samples with a finite population correction. Differences in frequencies were 
evaluated with a Rao-Scott Χ2 statistic (Rao JN, 1984). Confidence intervals for proportions 
utilize the incomplete beta function (Korn EL, 1998). Changes in MFI were evaluated with the 
complex sampling version of Mood’s test for differences in medians (Lumley, 2013). 
5.5 Results 
5.5.1 TAS 1 
A total of 1,134 children from 25 of 26 public and private elementary schools were enrolled in 
TAS 1; 50.6% were male, and the mean age was 6.8 years (range 5-10 years). Because 
written informed parental consent was required for participation, systematic sampling of 
children could not be applied as intended. All children with signed consent forms from 
parents/guardians were enrolled in the survey. One small private school (St. Theresa) was 
not sampled because of school officials refusal to participate. Demographic information was 
not available for 57 students from Tafuna Elementary. For 197 (17.4%) children enrolled, no 
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blood sample was collected or the quantity of blood collected was insufficient for testing by 
ICT. Of the samples tested, 2/937 (0.2%, 95% upper confidence limit (CL) 0.8%) were 
antigen positive. Both positive children were from the same school, Lupelele Elementary. 
Demographic information and number of samples tested by ICT are summarized by school in 
Table 5.1.  
5.5.2 TAS 2 
By 2015, two elementary schools that had existed in 2011 were closed and six new schools 
had opened. A total of 864 children from all 30 public and private elementary schools were 
enrolled in TAS 2; 48.4% were male, and the mean age was 7.0 years. As with TAS 1, 
written parental consent was required for participation and all children with signed consent 
forms were enrolled in the survey. For 96 (11.1%) children enrolled, no blood sample was 
collected or the quantity of blood collected was insufficient for ICT testing. Of the samples 
tested, 1/768 (0.1%, 95% CL 0.3%) was positive. The antigen-positive child was from 
Lupelele Elementary, the same school where the two antigen-positive children were identified 
in TAS 1 four years earlier. Demographic information and number of samples tested by ICT 
for TAS 2 are given in Table 5.1, stratified by school.  
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Table 5.1 All public and private elementary schools in American Samoa included in TAS 1 and TAS 2. Age and sex distribution of children enrolled in TAS 1 and TAS 2 and number of samples tested for 
circulating filarial antigen by ICT are summarized by survey year. 
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5.5.3 Antibody responses 
In 2011, a total of 1,112 DBS were prepared for antibody testing. Overall prevalence of 
responses to Wb123, Bm14, and Bm33 was 1.0%, 6.8% and 12.0%, respectively. There was 
at least one Wb123 antibody-positive child in 6/25 (24.0%) schools. Distribution of responses 
to Bm14 and Bm33 responses was more widespread than responses to Wb123 with at least 
one antibody-positive child identified in 88.0% and 80.0% of schools, respectively. In 2015, a 
total of 836 DBS were collected for antibody testing. Overall prevalence of Bm14 and Bm33 
responses declined significantly to 3.0% (p<0.001) and 7.8% (p=0.013), respectively. The 
prevalence of Wb123 responses was 3.6% in TAS 2, but results were not directly compared 
to those from TAS 1 because of the different testing platform used. The distribution of Wb123 
responses was more widespread in TAS 2 than TAS 1 with at least one antibody-positive 
child identified in 12/30 (40.0%) schools. Distribution of Bm14 responses was more focal in 
2015 than in 2011 with at least one antibody-positive child identified in 12/30 (40.0%) 
schools; only one of these 12 schools did not have any Bm14-positive children in TAS 1. 
Distribution of positive Bm33 responses was the most widespread (56.7% of schools) of the 
three markers assessed, but was still more focally distributed in 2015 compared to 2011. 
Antibody responses are summarized by school in Figure 5.1 and Table 5.2. Change in MFI-
bg for Bm14 and Bm33 was compared for the 22 schools included in both surveys. There 
were significant declines in the median quantitative MBA responses for Bm14 and Bm33 in 
21/22 (95.5%) schools. Median MFI-bg values are summarized in Table 5.3, stratified by 
school.  
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Figure 5.1 Distribution of antibody responses to Bm14, Bm33, and Wb123 by school for TAS 
1 (2011) and TAS 2 (2015) in American Samoa. Responses to Wb123 in TAS 1 were 
assessed by luciferase immunoprecipitation system (LIPS) assay. All other responses were 
assessed by multiplex bead assay. 
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Table 5.2 Distribution of antibody responses to Wb123, Bm14, and Bm33 in all elementary schools located on the main island of Tutuila in American Samoa. Responses to Wb123 in TAS 1 were assessed 
by LIPS. All other responses were assessed by multiplex bead assay. 
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Table 5.3 Median fluorescence intensity minus background (MFI-bg) values by school for the 22 schools included in both TAS 1 (February 2011) and TAS 2 (April 2015) in American Samoa. Minimum and 
maximum MFI-bg values within each school are indicated in parentheses 
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All three ICT-positive children identified in the surveys had positive antibody 
responses to Wb123, Bm14 and Bm33. However, concordance of individual antibody 
responses for antigen-negative children was relatively poor at both time points. Only 21/161 
(13.0%) antibody-positive children in TAS 1 and 20/73 (27.4%) positive children in TAS 2 had 
positive responses to at least two markers. Similar discordance was also observed for 
samples tested where the antigen status was unknown. Test concordance for antigen 
negative children is summarized in Table 5.4. Test concordance for children whose antigen 
status was unknown is summarized in Table 5.5.  
Table 5.4 Antibody test concordance among antigen negative children in TAS 1 (February 
2011) and TAS 2 (April 2015) in American Samoa. 
      Concordance with positive index  
  Index 
total # 
positive/N 
(%) Wb123 Bm14 Bm33 
TAS 1 
Wb123 7/935 (0.75)   6/7 (85.7) 7/7 (100.0) 
Bm14 63/935 (6.7) 6/63 (9.5)   
20/63 
(31.7) 
Bm33 
118/935 
(12.6) 7/118 (5.9) 
20/118 
(16.9)   
           
TAS 2 
Wb123 26/743 (3.5)   11/26 (42.3) 
16/26 
(61.5) 
Bm14 22/743 (3.0) 
11/22 
(50.0)   
15/22 
(68.2) 
Bm33 56/743 (7.5) 
16/56 
(28.6) 15/56 (26.8)   
 
Table 5.5 Antibody test concordance among children with unknown antigen status in TAS 1 
(February 2011) and TAS 2 (April 2015) in American Samoa. 
      Concordance with positive index  
  Index 
total # 
positive/N 
(%) Wb123 Bm14 Bm33 
TAS 1 
Wb123 2/175 (1.1)   2/2 (100.0) 1/2 (50.0) 
Bm14 11/175 (6.3) 2/11 (18.2)   4/11 (36.4) 
Bm33 13/175 (7.4) 1/13 (7.7) 4/13 (30.8)   
            
TAS 2 
Wb123 3/92 (3.3)   0/3 (0.0) 2/3 (66.7) 
Bm14 2/92 (2.2) 0/2 (0.0)   1/2 (50.0) 
Bm33 8/92 (8.7) 2/8 (25.0) 1/8 (12.5)   
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5.6 Discussion 
The TAS is used to determine when transmission of LF is low enough that MDA can safely 
be stopped. The attraction of the TAS design is that it facilitates decision-making and has 
proven feasible to implement yet is standardized and incorporates a statistically rigorous 
design. After stopping MDA, WHO recommends repeating TAS twice at 2- to 3-year intervals 
and conducting additional surveillance activities to confirm that transmission has been 
interrupted. However, beyond the TAS, post-MDA surveillance guidance has not been 
standardized. A current need in the global effort to eliminate LF is reliable diagnostic tools 
that can be used to guide programmatic decisions, especially decisions made in the final 
stages of the program (Solomon et al., 2012). In principle, because of the greater sensitivity 
of detection of antibody responses compared to antigen testing, antibody testing could 
provide an earlier signal of recrudescence or decreased transmission over time. Antibody 
testing could be included in the TAS without any modification of the survey design. The 
inclusion of antifilarial antibody testing in both TAS 1 and TAS 2 conducted in American 
Samoa in 2011 and 2015, offered an opportunity to determine whether antibody testing 
would provide evidence that interruption of LF transmission had been achieved.  
Results of TAS 1 conducted in 2011 met criteria for stopping MDA, and results from 
TAS 2 carried out in 2015 were below the threshold for which MDA was recommended. The 
outcomes from these surveys indicated that LF transmission had been reduced below the 
threshold at which transmission was thought to be sustainable. Although there was a 
decrease in the absolute number of antigen-positive children identified from TAS 1 to TAS 2, 
it was not possible to determine if antigen prevalence had changed between the two surveys 
since TAS is not statistically powered to detect changes over time. This illustrates a key 
challenge in post-MDA monitoring – as transmission declines and programs near elimination 
endpoints, it becomes increasingly difficult to rely on microfilariae (mf) and antigen markers. 
Ideally, during the post-MDA surveillance period, trends could be measured to 
provide information on LF status in order to assist programs to take appropriate action as 
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necessary. Since measures of antibody responses are more sensitive than mf and antigen 
detection (Gass et al., 2012), it is conceivable that changes in antibody prevalence could be 
used in the context of TAS to complement antigen testing. Although antigen prevalence in 
TAS 1 was <1%, responses to Wb123, Bm14, and Bm33 were 1.0%, 6.8%, and 12.0%, 
respectively. Similarly, antigen prevalence was low in TAS 2, but antibody prevalence was 
greater than antigen prevalence by all three markers. While there are limitations to using 
antigen markers during the surveillance period, the ability to monitor LF transmission status 
may be facilitated by using more sensitive antibody markers. 
There were, however, differences among the three antibody markers. In TAS 1, the 
distribution of positive responses to Wb123 was relatively focal with antibody positive 
children in <25% of schools. In contrast, the distribution of positive Bm14 and Bm33 
responses was more widespread with at least one antibody-positive child identified in >80% 
of schools. The more widespread distribution of Wb123 responses seen in TAS 2 may have 
been in part a function of using a different assay platform in 2015. Responses to Bm14 in 
TAS 2 were also fairly widespread, but less common than in TAS 1. However, the schools 
with Bm14-positive children were not necessarily the same ones in which Wb123-positive 
children were identified. Distribution of positive Bm33 responses was the most widespread of 
the three antibody markers assessed in TAS 2, detected in children in more than half of the 
schools, but was still more focally distributed than in TAS 1. It is possible that the three 
antibody markers used were measuring different LF exposure or infection patterns, but it is 
unclear how results of antibodies to a single marker should be interpreted.   
There was good concordance of antibody responses among antigen-positive children. 
As expected, presence of CFA was associated with positive antibody responses to all three 
markers; Wb123, Bm14, and Bm33. However, among antigen-negative children, 
concordance of the antibody responses was poor, and a similar pattern was observed among 
children whose antigen status was unknown. These differences in antibody responses could 
be a reflection of the differences between antibody responses triggered by larval (Wb123) 
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and adult worm (Bm14 and Bm33) exposures, but further research is needed to characterize 
LF antibody responses, especially during the post-MDA surveillance period. 
In principle, as LF programs successfully implement MDA, reduced transmission of 
LF will result in lower prevalence of infection-specific antibody in young children and 
eventually an absence of detectable antibodies in the population. Overall, on the main island 
of American Samoa, there was a significant decline in antibody responses to Bm14 and 
Bm33 from 2011 to 2015 suggesting LF transmission was declining in the area. Furthermore, 
in every school included in both surveys, there was a significant decrease in the intensity of 
antibody responses from TAS 1 to TAS 2 providing additional support that LF exposure and 
infection had decreased during this period.  
Although the overall decline in Bm14 and Bm33 prevalence suggested lower 
exposure and infection among young children, the results should be interpreted with caution. 
Positive antibody responses to these antigens were relatively widespread across the island in 
2011. Even though responses to Bm14 and Bm33 were more focal in 2015, there were 
persistent responses in some schools. Furthermore, there was an apparent increase in 
Wb123 prevalence, but results of the two surveys could not be directly compared because of 
the different testing platforms used. Antibody responses in these schools could represent 
focal areas of persistent or recurrent LF transmission, residual seropositivity following 
interruption of transmission, or false-positive results. Bm14 and Bm33 are known to cross-
react with closely related filarial parasites (Lammie et al., 2004; Weil et al., 2011), but these 
parasites are not known to be in circulation in American Samoa. It is also possible that the 
cutoff values for the MBA were inaccurate. The ability to define robust cutoffs for serological 
assays can be challenging and is often limited by the availability of well characterized panels 
of samples to determine appropriate cutoffs. If the responses represent residual seropositivity 
after interruption of transmission, then seroprevalence will continue to decline, and future 
surveys can be conducted to confirm the downward trend. While there may have been issues 
with defining antibody assay parameters, the possibility that persistent antibody signals 
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represented true ongoing focal transmission cannot be excluded. Although the duration of 
antibody responses to Bm14 and Bm33 is unclear, presumably, positive signals among 
children in the target age range for TAS (6-7 years) indicate relatively recent exposure.  
All three CFA-positive children identified in TAS 1 and TAS 2 were from the same 
school (Lupelele Elementary), and there were antibody-positive children in this school at both 
time points. These results may have been an indication of LF status in the communities in 
which the children lived. Yet, since the primary vector, Aedes polynesiensis, is a day-biting 
mosquito, it is difficult to determine if LF exposure took place in the community or elsewhere. 
In areas of diurnal LF periodicity, there is a need to better understand the relationship 
between results from school-based surveys and community transmission. 
At present, it is unclear how to interpret persistent antibody responses in TAS 1 and 
TAS 2 in American Samoa. Although CFA results were below the threshold for which MDA 
was warranted, persistence of positive antibody signals is a potential cause for concern. In 
an island-wide vector study conducted in parallel to TAS 1, a large sample of mosquitoes 
was collected and tested for the presence of filarial DNA (Schmaedick et al., 2014). Results 
from the xenomonitoring survey indicated widespread, PCR-positive mosquitoes across the 
island. The presence of filarial DNA in mosquitoes raised suspicion that LF transmission was 
ongoing, but in the absence of established thresholds for programmatic action, no additional 
interventions were conducted. Additionally, in a serosurvey conducted just prior to TAS 1 
there was evidence of possible clustering of antigen-positive adults in some communities 
(Lau et al., 2014b). Although the potential impact of antigen-positive clusters on transmission 
is unclear, it is possible that infection levels are high enough in these areas to sustain 
transmission. Furthermore, results from a recent study in American Samoa demonstrated 
that PCR-positive pools of LF vector mosquitoes were statistically significant predictors of 
seropositivity for Wb123 but not for Bm14 (Lau et al., 2016), suggesting Wb123 could be an 
indicator of ongoing transmission. Although Wb123 prevalence was low in both TAS, it may 
have been an indication of recent larval exposures and the potential for ongoing 
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transmission. This also highlights the importance of understanding how to appropriately 
interpret responses to each of the antibody markers.   
It is unclear why there was an apparent disconnect between declining antibody 
prevalence in TAS and evidence of ongoing transmission in other survey results. It is 
possible that the school-based cluster survey approach was not sensitive enough to reflect 
LF status in communities. Although all primary schools were included in the TAS, children 
from multiple villages attended each school. The transmission status of individual 
communities may have been more accurately reflected if a certain proportion of children from 
each village was tested. There is a need to better understand the significance of spatial 
distribution of CFA and antibody signals.  Additionally, there may have been potential bias 
introduced in the way the TAS were conducted. The requirement for written informed consent 
resulted in lower than desired participation in surveys, and a true random sample of children 
could not be obtained. This highlights one of the challenges in areas where survey 
participation is dependent on intensive sensitization of communities. 
Currently, there is no clear guidance on how to investigate CFA- or antibody-positive 
children identified during TAS, but utilizing survey results may allow programs to identify 
areas where additional interventions may be needed. In American Samoa, there was an 
overall decline in antibody prevalence, but there were indications that raised concerns of 
ongoing transmission. All antigen-positive children were from the same school, but no 
specific follow up activities took place. Furthermore, there were schools in which there were 
persistent antibody signals from TAS 1 to TAS 2, which may have been an indication of focal 
transmission. There are challenges in utilizing cluster-based survey methodologies to assess 
focal diseases especially when prevalence is assumed to be low. There have been activities 
conducted in Sri Lanka to determine relationships among various indicators, including CFA, 
antifilarial antibody, and the presence of filarial DNA in Culex mosquitoes (Rao et al., 2014; 
2017). However, there is a pressing need to conduct similar activities in Aedes spp. and 
Anopheles spp. settings.  
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As GPELF continues to make progress, it is critical to identify strategies for effective 
monitoring and evaluation to determine if transmission has been interrupted. Making 
incorrect programmatic decisions can have major political and financial implications. Despite 
passing TAS 1 and TAS 2, clustering and persistence of positive antibody responses in 
schools may be an indication of ongoing transmission in American Samoa. Although there is 
a clear need to better understand the limitations of current antibody tests, our results suggest 
that serologic tools can have a role in guiding programmatic decision making. 
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6.1 Abstract 
A current need in the global effort to eliminate lymphatic filariasis (LF) is the availability of 
reliable diagnostic tools that can be used to guide programmatic decisions, especially 
decisions made in the final stages of the program. This study carried out in The Gambia 
aimed to assess antifilarial antibody levels among populations living in historically highly LF 
endemic areas, and to evaluate the use of serologic tools to confirm interruption of LF 
transmission. A total of 2,612 dried blood spots (DBS) collected from individuals aged 1 year 
and above from 15 villages was tested for antibodies to Wb123 by enzyme-linked 
immunosorbent assay (ELISA). A subset of DBS (n=599) was also tested for antibodies to 
Bm14 by ELISA. Overall, prevalence of Wb123 was low (1.5%, 95% confidence interval (CI) 
1.1-2.1%). In 7 of 15 villages (46.7%), there were no Wb123-positive individuals identified. 
Individuals with positive responses to Wb123 ranged in age from 3 to 100 years. Overall, 
Bm14 prevalence was also low (1.5%, 95% CI 0.7-2.8%). Bm14 positivity was significantly 
associated with older age (p<0.001). The low levels of antibody responses to Wb123 
observed in our study strongly suggest that sustainable LF transmission has likely ceased in 
The Gambia. Additionally, our results support the conclusion that serologic tools can have a 
role in guiding programmatic decision making and supporting surveillance. 
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6.2 Introduction 
Lymphatic filariasis (LF) is a mosquito-transmitted parasitic disease caused by three main 
species of filarial worms (Wuchereria bancrofti, Brugia malayi, and B. timori) (Taylor et al., 
2010). In 1997, at the 50th World Health Assembly (WHA), a resolution was passed to 
eliminate LF as a public health problem by 2020 (WHA resolution 50.29) (WHO, 1997). 
Shortly thereafter, in 2000, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) 
was organized to assist countries in achieving this goal (Ottesen, 2006). At the onset of 
GPELF, it was estimated that 120 million individuals were infected, and that approximately 
1.3 billion people throughout the tropics and subtropics were at risk for filarial infection 
(Ottesen, 2006). To reach established elimination targets, LF programs set out to treat 
individuals in endemic areas through annual community-wide mass drug administration 
(MDA) for at least 5 years. By the end of 2015, MDA had been implemented in 63 of 73 LF-
endemic countries, with a cumulative total of 6.2 billion treatments delivered since the launch 
of GPELF (WHO, 2016a). 
Typically, LF programs first conduct mapping surveys to identify areas to target for 
treatment, then carry out multiple rounds of MDA and finally conduct transmission 
assessment surveys (TAS) designed to determine if infection levels are low enough to stop 
MDA (WHO, 2011a). Although most LF endemic countries have successfully followed this 
approach, some countries have yet to scale up programmatic activities. While there is a clear 
need to implement MDA in some of these areas, others have a history of high microfilariae 
(mf) prevalence but recent surveys have failed to confirm the presence of infection and 
appropriate programmatic action is unclear. A current need in the global effort to eliminate LF 
is reliable diagnostic tools that can be used to guide programmatic decisions, especially 
decisions made in the final stages of the program. Additionally, validated tools are needed to 
confirm the absence of LF transmission in situations where the requirement for program 
implementation is unclear. 
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In the early stages of the global LF program, detection of mf in peripheral blood was 
used routinely to monitor the impact of MDA (Ottesen et al., 1997; 2006; Weil and Ramzy, 
2007). In most LF-endemic areas in the world where the parasite is nocturnally periodic, 
logistic challenges were encountered because of the requirement to collect blood at night 
between 22:00 and 02:00 hours. Furthermore, it became increasingly difficult to detect mf in 
populations after multiple rounds of MDA (Gass et al., 2012). Many of the limitations 
experienced with mf detection were addressed with the introduction of the 
immunochromatographic card test (ICT) to detect circulating filarial antigen (CFA) (Weil et al., 
1997). Importantly, the ICT could be conducted with blood collected any time of the day, 
eliminating the need for night blood collections. Based on results of a multi-country 
comparison, the ICT was the diagnostic tool recommended for TAS (Gass et al., 2012). 
Currently, the recently introduced Filariasis Test Strip (FTS) (Weil et al., 2013) is the official 
diagnostic tool recommended for TAS. As production of the ICT is being phased out, it is 
acceptable for LF programs to use either the ICT or FTS in the interim. 
Although tools to detect CFA have been and continue to be useful for the global LF 
program, there are some limitations to their use. Similar to the observed decline in mf 
prevalence after treatment, antigenemia also begins to decline and becomes increasingly 
difficult to detect in populations that have been subjected to multiple rounds of MDA (Gass et 
al., 2012). Additionally, as infection prevalence declines, the prevalence and magnitude of 
serologic responses shifts and operational sensitivity of the assays will decline compared to 
the lab-defined sensitivity. Recent evidence suggests that detection of antifilarial antibodies 
provides the earliest indicator of filarial exposure (Hamlin et al., 2012), and the absence of 
detectable antibody responses may provide evidence that transmission has been interrupted. 
As control programs move ahead, there will be fewer infection-specific antibody responses in 
populations, and increasingly, only residual antibody responses in older individuals will be 
observed. Many of the currently available LF antibody tests have been shown to be sensitive 
measures of exposure and infection but may lack the specificity needed to make important 
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programmatic decisions (Muck et al., 2003; Lammie et al., 2004; Weil et al., 2011). However, 
the identification of a highly specific recombinant antigen, Wb123 (Kubofcik et al., 2012), as 
an early serologic marker for filarial infection provides a new surveillance tool (Steel et al., 
2013) that may be useful to confirm interruption of LF transmission. 
In the 1950s, mf prevalence in The Gambia was reported to be approximately 50% 
(McFadzean, 1954), among the highest in the world. Surveys conducted in the 1970s 
showed that mf prevalence had declined significantly in the absence of any LF-specific 
interventions (Knight, 1980). In 2001, stored serum samples from individuals living in 
historically highly LF endemic areas were tested for the presence of CFA, a more sensitive 
diagnostic marker than mf (Gass et al., 2012), and results indicated an even further decline in 
LF prevalence compared to results from the 1970s (Rebollo et al., 2015). In 2003, the 
Gambian Ministry of Health and Social Welfare (MOHSW) carried out a national LF mapping 
survey with the intent of identifying areas in need of MDA. Interestingly, the results indicated 
MDA was not necessary (Rebollo et al., 2015). In 2013, the MOHSW conducted TAS and 
found no evidence of LF transmission among young children (Rebollo et al., 2015). Although 
The Gambia has not followed the traditional approach for LF elimination, it appears that 
current criteria used as the operational definition of elimination have been achieved. The 
absence of antigenemia among children was likely an indicator of interrupted transmission, 
but there was no information collected from older age groups. In the absence of LF-specific 
interventions, the Gambian MOHSW felt it was important to assess LF status among older 
age groups to complement the TAS results. The current study aimed to assess antifilarial 
antibody levels among communities living in historically highly LF endemic areas of The 
Gambia, and to use serologic tools to determine whether or not interruption of LF 
transmission has been achieved. 
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6.3 Methods 
6.3.1 Study site and design 
The study took place in February 2015 in The Gambia, a small African country with the 
Atlantic Ocean to the west and all of its land borders shared with Senegal. It is the smallest 
country on the mainland of the continent and has an estimated population of 1.9 million 
people. The country is divided into five divisions (Central River, Lower River, North Bank, 
Upper River, and Western) and one city (Banjul). Fifteen villages (Dampha Kunda, Jappineh, 
Jambanjelly, Jiboro Koto, Kafuta, Kamanka, Kembujeh, Keneba, Kololi, Latrikunda Sabiji, 
Mandinaring, Marakissa, Sare Opatah Jawa/Dar Silameh, Sikon Batabu Kantora, and 
Tambasansang) with the highest historic evidence of LF were purposely selected for this 
study. The villages were located in four of the five divisions and in Banjul. No villages in the 
Central River Division were included in the study since LF prevalence in this area was low in 
the 1970s, and no evidence of infection was found in recent surveys. Following World Health 
Organization (WHO) guidance for monitoring LF in sentinel sites,(WHO, 2011a) a 
convenience sample of approximately 300 individuals (≥1 year old) in each village was 
enrolled in the study. 
6.3.2 Ethical considerations 
The study was approved by the Gambia Government/MRC Joint Ethics Committee. The 
Institutional Review Board of the U.S. Centers for Disease Control and Prevention (CDC) 
determined CDC to be a non-engaged research partner. Study details were explained to 
potential participants and written informed consent was obtained from persons who agreed to 
participate. Parents or guardians provided permission for participation of children <18 years 
of age. Additionally, children aged between 7 and 17 years were asked to provide verbal 
assent for their participation. All identifiable information was kept confidential and maintained 
by using a secure database with access restricted to essential study personnel. 
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6.3.3 Data collection 
On the day of sample collection, residents of the community were asked to come to a central 
location within the village. Upon obtaining informed consent, participants were assigned a 
unique identifier and asked to provide basic demographic information such as age and sex. 
All data were collected on Android-platform smartphones (BLU; Miami, FL) using the LINKS 
application (Pavluck et al., 2014) and uploaded to a secure SQL server. 
6.3.4 Blood collection and antigen testing  
Approximately 100 µL of blood was collected via finger stick and used for the detection of 
CFA by ICT (Alere; Scarborough, ME). The cards were read at 10 min and marked as either 
positive or negative according to the manufacturer’s instructions. An additional 60 µL of blood 
(10 µL per extension x 6 extensions) was collected onto filter paper (Cellabs; Sydney, 
Australia), dried and stored for antifilarial antibody testing. The dried blood spots (DBS) were 
stored at -20oC until shipped to CDC for testing. 
6.3.5 Antibody testing by enzyme-linked immunosorbent assay (ELISA) 
DBS were tested with the Filaria DetectTM IgG4 ELISA (InBios; Seattle, WA), a direct enzyme 
immunoassay that detects IgG4 antibodies to the recombinant Wb123 antigen. This test was 
performed according to the protocol provided by the manufacturer with minor modifications. 
Briefly, one blood spot extension (10 µL whole blood) was eluted overnight in 250 µL of 
sample dilution buffer provided in the kit to yield an approximate 1:50 serum dilution. The 
following day, samples were tested in duplicate by adding 100 µL of eluate to each well. Kit-
provided positive and negative controls were also tested in duplicate at a 1:50 dilution. 
Additionally, two internal positive controls (H3, H19; not provided in the kit) available at CDC 
were tested in duplicate at a 1:1500 (H3) and 1:900 (H19) dilution on each plate. These 
internal controls were used to standardize results across plates. Plates were incubated at 
37°C for 30 min and then washed with kit-provided wash buffer. Mouse anti-human IgG4 
conjugated with horseradish peroxidase (HRP) was added to each well at a 1:100 dilution 
and incubated at 37°C for 30 min. After washing, 100 µL of tetramethylbenzidine (TMB) was 
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added to each well and plates were developed at room temperature in the dark for 9 min. 
Reactions were stopped by adding 50 µL of kit provided stop solution to each well, and plates 
were read at 450 nm. To compare optical density (OD) values between Wb123 ELISA plates, 
mean OD values for each sample were divided by the mean OD of the H3 positive control to 
normalize results. 
All available samples from two villages (Kololi and Tambansansang) were tested with 
a non-commercial ELISA (CDC; Atlanta, GA) for IgG4 antibodies against the recombinant 
Bm14 antigen (Chandrashekar et al., 1994). This assay has relatively high sensitivity (92%) 
and specificity (99%) and was determined to be an appropriate alternative to a commercially 
available Bm14 ELISA. Greiner Microlon High Binding plates (Greiner Bio-One; Monroe, NC) 
were coated with Bm14 at a concentration of 0.3 µg/mL in antigen sensitizing buffer (0.5 M 
Tris/HCl, pH 8.0 + 0.3 M KCl + 2 mM EDTA) and incubated overnight at 4°C. One blood spot 
extension was added to 250 µL of dilution buffer (PBS pH 7.2 + 0.3% Tween20 + 5% milk) 
and incubated overnight at 4°C. Positive control serum samples were diluted 1:50 in dilution 
buffer and used to construct a 9-point standard curve and to serve as two calibrator positive 
controls for each plate. All controls were held at 4°C overnight. The following day, diluted 
samples and controls were tested in duplicate by adding an aliquot of 100 µL to each well. 
Plates were incubated at room temperature on a shaker for 30 min. Mouse anti-human IgG4 
conjugated with HRP (cloneHP6025; Southern Biotech; Birmingham, AL) was diluted 1:2000 
and 100 µL was added to each well. Plates were incubated at room temperature with shaking 
for 30 min. TMB (100 µL) was added to each well and plates were developed at room 
temperature for 2 min. One hundred microliters of 1 M H2SO4 was added to each well to stop 
the reaction, and plates were immediately read at 450 nm. Plates were washed between 
each step with PBS + 0.3% Tween20. 
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6.3.6 Cutoff determination for ELISAs  
Cutoff values for Wb123 and Bm14 were calculated at CDC from receiver operator 
characteristic (ROC) curves using sera from W. bancrofti mf positive patients and presumed 
negative sera from adult US citizens with no history of foreign travel to LF-endemic countries. 
6.3.7 Statistical analysis  
Statistical analyses were performed in Stata version 14.1 (StataCorp LP; College Station, 
TX) and used the 5% level of significance. Chi-squared tests and logistic regression were 
used to identify associations between seropositivity and other factors. 
6.4 Results 
A total of 4,481 individuals (aged 1-100 years) from the 15 villages were enrolled in the 
study. Of those enrolled, a total of 2,612 (58.2%) DBS from all 15 villages were tested for 
antibodies to Wb123. There was no difference in age or sex between individuals not included 
for serologic testing and individuals with antibody results. Demographic information was not 
available for 161 (6.2%) samples with antibody results. Antibody prevalence for individuals 
with missing demographic data was not different than prevalence for those with available 
demographic information. There were no individuals who were antigen positive by ICT. 
Overall, prevalence of positive Wb123 responses was low (1.5%, 95% confidence interval 
(CI) 1.1-2.1%). In 7 of 15 villages (46.7%), there were no antibody positive individuals 
identified. Of the eight villages with at least one person with a positive Wb123 result, six 
(75%) were located in the Western Division (Figure 6.1). Individuals with positive responses 
to Wb123 ranged in age from 3 to 100 years. Wb123 results by community are summarized 
in Table 6.1. There was no statistically significant difference in Wb123 prevalence among 
study villages once adjusted for age, sex, and clustering by village. 
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Figure 6.1 Location of the 15 study villages in The Gambia and Wb123 antibody status in 
2015. 
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Table 6.1 Wb123 antibody prevalence by community in The Gambia in 2015. 
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All available samples from Kololi and Tambasansang were also tested by Bm14 
ELISA. Overall, Bm14 prevalence was low (1.5%, 95% CI 0.7-2.8%) in these two villages. In 
Kololi, there were two Wb123 positive individuals, but there were no positive Bm14 
responses in this community. In Tambasansang, there were 10 (3.4%) Wb123 positive 
individuals ranging in age from 4 to 65 years. Although a similar number of Bm14 positive 
persons was identified (9/292; 3.1%), all Bm14-positive individuals were over the age of 50 
years. Bm14 positivity was significantly associated with older age (p<0.001). The results of 
antibody testing and historic mf results are summarized in Table 6.2. 
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Table 6.2 Microfilariae prevalence in selected villages of The Gambia in the 1970s (Knight, 1980) and antifilarial responses to Wb123 and Bm14 in the same villages in 2015. 
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6.5 Discussion 
The results of TAS conducted in 2013 in The Gambia indicated there was no LF transmission 
among 6- and 7-year-old children and, in 2016, The Gambia was removed from WHO’s 
official list of LF endemic countries (WHO, 2016a). Although the absence of antigenemia 
among children in The Gambia was likely an indicator of interrupted transmission, there was 
no information collected from older age groups. Our study aimed to assess antifilarial 
antibody levels among populations living in historically highly LF endemic areas in The 
Gambia, and to evaluate the use of serologic tools to confirm the absence of LF 
transmission. 
Overall, no antigenemia was detected, and the prevalence of antibodies to Wb123 
was low in the 15 villages included in the survey conducted in 2015. Although there was clear 
evidence of LF transmission in the 1970s (Knight, 1980), results from the current survey 
suggest that little to no transmission of LF was occurring in these areas, consistent with the 
results of TAS implemented in the Gambia in 2013. The dramatic decline in LF prevalence 
over a 50-year period has been observed with increasingly sensitive diagnostic markers, and 
strongly suggests that sustainable LF transmission likely ceased in The Gambia during this 
period. The decrease in LF prevalence has been mainly attributed to a reduction in mosquito 
density due to changes in climate, improved standard of living, and the use of bednets for 
protection from mosquito bites since no LF-specific interventions have taken place (Knight, 
1980). The rapid scale-up of insecticide-treated nets (ITNs) used for malaria control since 
2000 has likely further contributed to the decline (Ceesay et al., 2008; Noor et al., 2009). 
Antibody responses are generally considered an early and sensitive indicator of 
transmission, and while there is incomplete information about the duration of antibody 
responses, they do appear to fall as transmission declines. In a study conducted in the Cook 
Islands, samples collected in the mid-1970s were analyzed for antibodies to Wb123 and 
compared to results from samples collected from the same island in 1992, five years after a 
single round of MDA against LF. Results indicated a significant decrease in Wb123 antibody 
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positivity, suggesting LF transmission had significantly decreased (Steel et al., 2012). 
Recently, in Indonesia, antibody responses were used to successfully distinguish areas 
where programs had been implemented and successful, sub-optimally implemented, and not 
implemented at all (Dewi et al., 2015). Although there is a need to gain more practical 
experience to operationalize the use of antibody assays, including determining the most 
appropriate diagnostic platform (e.g. rapid test, ELISA), our results have added information 
on the utility of serologic tools in an area where MDA was never conducted. 
Although seroprevalence was low, positive responses were not completely absent. 
Antibody responses could represent very focal areas of persistent or recurrent LF 
transmission, residual seropositivity following interruption of transmission, cross-reactivity, or 
false-positive results; the detected Wb123 responses may have different implications than 
the detected responses to Bm14. Approximately half of the villages had at least one positive 
Wb123 response. Six of eight villages with at least one antibody positive individual were 
located in the Western Division, where mf rates were in excess of 50% in the 1950s 
(McFadzean, 1954). However, the absence of positive antigen tests in these village makes it 
less likely that these results reflect focal transmission. 
If positive serology reflected persistence following interruption of transmission, an 
association with age would be expected (Mladonicky et al., 2009; Gass et al., 2012; Shawa 
et al., 2013). Antibodies to Bm14 can persist for years, but the expectation is that 
seroreversion will occur at some point (Ramzy et al., 2006; Moss et al., 2011). However, 
currently, there is insufficient data available on the rates of antibody decay to accurately 
predict when filarial infection cleared. An association between seropositivity and age was 
seen for the responses to Bm14, but not to Wb123; in Tambasansang, Bm14 positive 
individuals were all older than 50 years of age, and could have been exposed to infected 
mosquitoes before transmission had ceased in the country. 
The recombinant Bm14 antigen has also been reported as a highly sensitive marker 
for the assessment of filarial antibodies, but it is also known to cross react with closely 
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related filarial parasites (Lammie et al., 2004; Weil et al., 2011). Wb123, used on various 
diagnostic platforms including ELISAs, is reported to have high sensitivity and specificity for 
distinguishing W. bancrofti infection from closely related filarial infections (Kubofcik et al., 
2012). However, a possible explanation for the detected positive Wb123 responses is lower 
than expected Wb123 specificity. It is possible that the cutoff values for the ELISAs were 
inaccurate. The ability to define robust cutoffs for serological assays can be challenging and 
is often limited by the availability of well characterized panels of samples to determine 
appropriate cutoffs. 
As the GPELF continues to make progress, it is critical to identify strategies for 
reaching stated goals. Our results strongly suggest that LF transmission has likely ceased in 
The Gambia and that no programmatic intervention is required. Although there is a clear 
need to better understand the limitations of current antibody tests, to develop appropriate 
sampling strategies, and to determine optimal age groups to define antibody thresholds in 
order to provide robust evidence of the absence of transmission, our results also support the 
use of antibody tools to determine the status of LF transmission and suggest that serologic 
tools can have a role in guiding programmatic decision making. 
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7.1 Abstract 
The Global Programme to Eliminate Lymphatic Filariasis has made significant progress 
toward interrupting transmission of lymphatic filariasis (LF) through mass drug administration 
(MDA). Operational challenges in defining endpoints of elimination programs include the 
need to determine appropriate post-MDA surveillance strategies. As humans are the only 
reservoirs of LF parasites, one such strategy is molecular xenomonitoring (MX), the detection 
of filarial DNA in mosquitoes using molecular methods (PCR), to provide an indirect indicator 
of infected persons nearby. MX could potentially be used to evaluate program success, 
provide support for decisions to stop MDA, and conduct post-MDA surveillance. American 
Samoa has successfully completed MDA and passed WHO recommended transmission 
assessment surveys in 2011 and 2015, but recent studies using spatial analysis of antigen 
(Ag) and antibody (Ab) prevalence in adults (aged ≥ 18 years) and entomological surveys 
showed evidence of possible ongoing transmission. This study evaluated MX as a 
surveillance tool in American Samoa by linking village-level results of published human and 
mosquito studies. Of 32 villages, seropositive persons for Og4C3 Ag were identified in 11 
(34.4%), for Wb123 Ab in 18 (56.3%) and for Bm14 Ab in 27 (84.4%) of villages. Village-level 
seroprevalence ranged from 0–33%, 0–67% and 0–100% for Og4C3 Ag, Wb123 Ab and 
Bm14 Ab respectively. PCR-positive Aedes polynesiensis mosquitoes were found in 15 
(47%) villages, and their presence was significantly associated with seropositive persons for 
Og4C3 Ag (67% vs 6%, p<0.001) and Wb123 Ab (87% vs 29%, p = 0.001), but not Bm14 Ab. 
In villages with persons seropositive for Og4C3 Ag and Wb123 Ab, PCR- positive  
Ae. polynesiensis were found in 90.9% and 72.2% respectively. In villages without 
seropositive persons for Og4C3 Ag or Wb123 Ab, PCR-positive Ae. polynesiensis were also 
absent in 94.1% and 70.6% of villages respectively. Our study provides promising evidence 
to support the potential usefulness of MX in post-MDA surveillance in an Aedes transmission 
area in the Pacific Islands setting. 
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7.2 Author summary 
Lymphatic filariasis (LF) is caused by infection with filarial worms that are transmitted by 
mosquito bites. Globally, 36 million are disfigured and disabled by complications such as 
severe swelling of the legs (elephantiasis) or scrotum (hydrocele). The Global Programme to 
Eliminate LF (GPELF) aims to interrupt disease transmission through mass drug 
administration (MDA), and to control illness and suffering in affected persons. Significant 
progress has been made toward eliminating LF from many parts of the world, including the 
Pacific Islands. Current challenges of the GPELF include identification of any residual 
hotspots of ongoing transmission, and effective strategies for early identification of any 
resurgence of infections. As humans are the only reservoirs of LF parasites and mosquitoes 
have short flight ranges, one such strategy is to monitor LF infection in mosquitoes as an 
indicator of ongoing transmission nearby. Mosquito monitoring could potentially be used to 
evaluate program success, provide support for decisions to stop MDA, and conduct post-
MDA surveillance. Our study evaluated mosquito monitoring as a surveillance tool in 
American Samoa by linking village-level results of published studies of LF in humans and 
mosquitoes, and provides promising evidence to support the potential usefulness of mosquito 
monitoring in post-MDA surveillance the Pacific Islands. 
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7.3 Introduction 
Lymphatic filariasis (LF) is a parasitic infection caused by Wuchereria or Brugia species of 
helminth worms, and transmitted by mosquito vectors including Aedes, Anopheles, Culex 
and Mansonia species. Globally, an estimated 68 million people are currently affected, 
including 36 million microfilaraemic persons and 36 million who are disabled or disfigured 
with complica- tions such as severe lymphoedema, including elephantiasis and scrotal 
hydrocoeles (Ramaiah and Ottesen, 2014). The Global Programme to Eliminate LF (GPELF) 
aims to eliminate the disease as a public health problem by 2020 using two main strategies: 
i) to interrupt transmission through mass drug administration (MDA) and ii) to control 
morbidity and disability of affected persons. In the Pacific Islands, the Pacific Programme to 
Eliminate LF (PacELF) was formed in 1999 as part of GPELF to focus on 22 Pacific Island 
Countries and Territories (PICTs), which include >3000 islands and 8.6 million people 
(Ichimori and Crump, 2005). 
The sustained success of elimination programs requires cost-effective assessment 
and monitoring after successful completion of MDA to determine whether there are any 
residual foci of infection, and to detect potential resurgence in a timely manner. The WHO 
currently recommends post-MDA surveillance using transmission assessment surveys (TAS), 
which use critical cut-off values of numbers of antigen-positive children aged 6–7 years to 
determine whether transmission has been interrupted in defined evaluation units (WHO, 
2011a). In Brugia transmission areas, antibody positivity is used for TAS. Cut-off thresholds 
for passing TAS vary depending on population size of the target group and the local species 
of filarial parasites and mosquito vectors. For example, where W. bancrofti is endemic, the 
target cut-off value is estimated based on upper 95% confidence interval of <1% antigen 
prevalence if Aedes is the principal vector, or <2% antigen prevalence if Anopheles or Culex 
predominate. TAS typically involve school-based or community-based testing of 6–7 year old 
children. Community-based surveys are often logistically challenging, particularly in 
developing countries with limited financial and human resources. In some areas (e.g. most of 
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the Pacific Islands), difficult access to dispersed populations in remote islands provides 
additional challenges. Also, TAS typically use rapid antigen detection tests (Filarial 
Immunochromatographic Test (ICT) cards or Filarial Test Strips (Weil et al., 2013)), which 
might have reduced sensitivity after many rounds of MDA (Njenga et al., 2008; Gounoue-
Kamkumo et al., 2015). TAS has been widely used to inform important programmatic 
decisions including stopping or restarting MDA, but recent studies suggest that in some 
settings (including American Samoa), TAS might not be sufficiently sensitive for determining 
whether transmission has been interrupted (Lau et al., 2014a; Rao et al., 2014). 
As elimination programs reach the endgame phases and antigen prevalence drops to 
very low levels, increasingly sensitive tools and strategies will be required to efficiently detect 
any evidence of ongoing transmission or resurgence. The WHO and GPELF have identified a 
number of operational challenges and unanswered questions for elimination programs, 
including the significance of residual microfilaraemia and antigenaemia in communities where 
the target threshold level has been achieved through MDA, identification of residual high-
prevalence areas and strategies for managing them, and the need for development of cost-
effective strategies for post-MDA surveillance (WHO, 2016b). As humans are the only 
reservoir for W. bancrofti parasites, one such strategy is to monitor mosquitoes for evidence 
of LF larval stages (Bockarie, 2007; Mladonicky et al., 2009). Dissection and microscopic 
examination of mosquitoes is time consuming and labor-intensive, and cannot be routinely 
recommended for post-MDA surveillance for practical reasons. With recent technological 
advances, LF molecular xenomonitoring (MX), the use of molecular methods (PCR) to detect 
filarial DNA in mosquitoes, has been explored and promising results are emerging (Farid et 
al., 2007; Pedersen et al., 2009). PCR-positive mosquitoes provide an indirect indicator of 
the presence of infected humans and possible ongoing transmission (Williams et al., 2002; 
Goodman et al., 2003; Plichart et al., 2006; Bockarie, 2007). For example, considering that 
the flight ranges of Ae. polynesiensis mosquitoes are on the order of a hundred meters 
(Jachowski, 1954), detection of PCR-positive mosquitoes in areas where these are the main 
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vectors indicates that infected persons are or were recently nearby. Molecular methods are 
also more sensitive than manual dissection for detecting infections (Chambers et al., 2009). 
Studies have reported the ability of PCR to detect one microfilaria in pools of 50–100 
mosquitoes (Nicolas et al., 1996), and for at least 2 weeks after mosquitoes (both vector and 
non-vector) ingest microfilaria-positive blood (Fischer et al., 2007), which is close to the 
average life span of most mosquito species. 
Molecular xenomonitoring has been found to be a potentially useful indicator of 
human LF infections with different species of mosquito vectors in diverse settings including 
American Samoa (Mladonicky et al., 2009), French Polynesia (Plichart et al., 2006), Egypt 
(Farid et al., 2001; 2007), Sri Lanka (Rao et al., 2014), Sierra Leone (de Souza et al., 2015), 
and Ghana (Owusu et al., 2015). Molecular xenomonitoring is therefore potentially useful for 
evaluating the success of elimination programs, providing support for decisions to stop MDA, 
and conducting ongoing post-MDA surveillance (Weil and Ramzy, 2007). Compared to TAS, 
MX has the advantages of being non-invasive to humans, and potentially more cost-effective 
in some settings. However, MX requires entomological expertise for trapping and processing 
mosquitoes, and laboratories capable of conducting large scale molecular diagnostics. In 
addition, there are currently unanswered questions about sampling strategies, limited 
evidence to inform the translation of MX results into operational strategies, and no clear 
guidelines on the thresholds of DNA prevalence that should be used to indicate likely 
ongoing transmission. Cut-off points of 0.25%, 0.5%, and 1% have been suggested for Culex 
areas (Michael et al., 2006; Farid et al., 2007; Rao et al., 2014), and 0.085% for L3 and 
0.65% for any larval stage for Anopheles areas (Pedersen et al., 2009). There are currently 
no clear recommendations for Aedes areas, but a provisional threshold of <0.1% has been 
suggested (WHO, 2006b). The lower the estimated cut-off points, the larger the sample sizes 
of mosquitoes that will be required for MX. 
As part of the PacELF, American Samoa has made significant progress toward 
reducing LF infection rates. After seven rounds of MDA from 2000 to 2006, antigen 
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prevalence in humans dropped from 16.5% (N = 3018) in the 1999 baseline assessment to 
2.3% (N = 1881) in 2007 in a community cluster survey (DoPTS, 2013). American Samoa 
passed TAS in 2011–2012 and again in 2015, but recently published studies using spatial 
analysis of antigen prevalence in adults (Lau et al., 2014a) and molecular xenomonitoring 
(Schmaedick et al., 2014) showed evidence of possible ongoing transmission. By linking the 
results of the published human and mosquito studies, we aim to evaluate MX as a 
surveillance tool in the post-MDA setting in American Samoa, an Aedes transmission area in 
the Pacific Islands. 
7.4 Methods 
7.4.1 Study location and setting 
American Samoa is a US Territory in the South Pacific, consisting of a group of small tropical 
islands with a total population of 56,000 (Commerce, 2012) living in 67 villages. Over 90% of 
the population live in small villages on the main island of Tutuila, and the remainder on the 
adjacent island of Aunu’u and the remote Manu’a group of islands (Ta’u, Ofu, and Olosega). 
W. bancrofti is the only species of human filarial worm known to be present in American 
Samoa. The main vector is the highly efficient day-biting Ae. polynesiensis, and other vectors 
include Ae. samoanus (night-biting), Ae. tutuilae (night-biting), and Ae. upolensis (day-biting) 
(Ramalingam and Belkin, 1964; Ramalingam, 1968; Samarawickrema et al., 1987). 
7.4.2 Human infection data 
Data were obtained from a published study on the seroprevalence and spatial epidemiology 
of lymphatic filariasis in American Samoa (Lau et al., 2014a). The study used samples from a 
serum bank collected from May to August 2010 for a leptospirosis study; the study design 
has been published previously (Lau et al., 2012a; 2012b). Briefly, the study included 807 
adults (aged 18 to 87 years, 52.4% males) from 659 households in 55 villages on all five 
inhabited islands of American Samoa. Sampling was designed to provide a representative 
sample of the adult population in American Samoa, in both age and geographic distribution. 
Using these 2010 samples, a seroprevalence study was conducted in 2013 (Lau et al., 
7. Molecular xenomonitoring in American Samoa 
__________________________________________________________________________ 
112 
  
 
2014a), and found that 3.2% were seropositive for Og4C3 Ag, and 8.1% and 17.9% were 
seropositive for Wb123 Ab and Bm14 Ab, respectively (Lau et al., 2014a). The study also 
found significant spatial clustering of Ag-positive persons; average cluster size was 1,498m 
in diameter for those with Og4C3 Ag >32 units, and the proportion of the variation explained 
by geographic proximity was 62%. Higher infection rates were found in males and recent 
migrants to American Samoa. Antigen (Og4C3) positivity indicates the presence of adult 
worm antigen but does not provide information on the viability, e.g. the worm could be alive 
or dead, or there could be a single sex worm infection or sterile worm infection. The presence 
of Og4C3 Ag represents current or recent infection. The presence of antibodies represents 
current or past infection, possibly many years in the past. 
For our study, human data were summarized by village and the following variables were 
generated: 
 Total number of people sampled from each village 
 Village-level seroprevalence (point estimates and 95% CI) for Og4C3 Ag, Wb123 Ab 
and Bm14 Ab, 
 Seropositive village for Og4C3 Ag, Wb123 Ab, and Bm14 Ab (defined as villages with 
at least one seropositive person) 
A village-level summary of the human serological data is provided in Table S 7.1. 
7.4.3 Molecular xenomonitoring data 
Schmaedick et al conducted a MX study in American Samoa from February to June 2011, 
approximately 9 months after the above human serum specimens described above were 
collected. Detailed descriptions of the study and its findings have been published 
(Schmaedick et al., 2014), and a village-level summary is provided in Table S 7.1. Briefly, 
mosquitoes were collected from 34 randomly selected villages on the island of Tutuila, the 
only village on Aunu’u, all five villages on the Manu’a Islands, and the village of Ili’ili (on 
Tutuila) where two ICT-positive children were identified during the 2011 TAS. Up to 10 traps 
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were placed in each village for 24 to 48 hours, and mosquitoes were removed from traps 
twice daily. The study collected a total of 22,014 female mosquitoes of Aedes and Culex 
genera that were sorted into 2,629 pools of 20 mosquitoes (range 1 to 20) for PCR testing. 
Real-time PCR was conducted using primers designed to amplify a fragment of W. bancrofti 
(Rao et al., 2006a). A positive PCR result indicates the presence of filarial worm DNA, but 
does not provide any information on whether the worms are alive or transmissible. Each pool 
included only one mosquito species, except for the Ae. (Finlaya) group of species (Ae. 
oceanicus, Ae. samoanus, and Ae. tutuilae) which were combined for PCR testing because 
of morphological similarities. The MX study calculated maximum likelihood point estimates of 
the prevalence of PCR-positive Ae. polynesiensis for each village or village group using 
PoolScreen software (version 2.0.3), which takes into account the average number of 
mosquitoes per pool and the proportion of pools that were PCR-positive. Point estimates of 
village-level prevalence of PCR-positive Ae. polynesiensis ranged from 0% to 2.8% for 
villages on Tutuila and Aunu’u, and was 0% for all villages in the Manu’a islands. The 
findings indicated widespread presence of filarial DNA in the mosquito population, suggesting 
persistent low-level transmission of LF on Tutuila and Aunu’u. 
For our study, mosquito data were summarized for each village for i) Ae. 
polynesiensis, and ii) other mosquito species (all species apart from Ae. polynesiensis), and 
iii) any mosquito species. Entomological data available by village included number of traps 
used; number of females and pools of each mosquito species; number of PCR-positive pools 
of each species; and estimated prevalence of PCR-positive Ae. polynesiensis (using 
PoolScreen software). 
7.4.4 Ethical considerations 
This study used de-identified data from the two previously published studies described above 
(Lau et al., 2014a; Schmaedick et al., 2014). The human study only included adults, and 
written informed consent was obtained from each participant. The American Samoa 
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Institutional Review Board (IRB) provided approval for the use of the human serum bank for 
lymphatic filariasis research. 
7.4.5 Data analysis 
In the MX study, some small adjacent villages were combined into groups of two to four 
villages for trapping and analyses, and human data were grouped accordingly to match the 
entomological data. Human data were not available for three of the villages included in the 
MX study. For this study, analyses were limited to the villages or village groups where both 
human data and MX data were available for 32 locations: 23 individual villages on Tutuila, 3 
village groups (of two villages each) on Tutuila, the only village on Aunu’u, and all five 
villages on the Manu’a Islands. The 32 villages and village groups will be referred to as 
“villages” from here for ease of reference. 
Chi-squared tests and logistic regression were used to identify associations between 
seropositive humans and PCR-positive mosquito pools, and answer the following operational 
questions: 
 Is the presence of PCR-positive pools of Ae. polynesiensis in a village a useful 
indicator of a seropositive village? If so, how accurate are PCR-positive pools for 
predicting seropositive villages for Og4C3 Ag, Wb123 Ab, and Bm14 Ab? 
 Is the presence of PCR-positive pools of Ae. polynesiensis a better indicator of 
seropositive villages than PCR-positive pools of other mosquito species, or PCR-
positive pools of any mosquito species? In other words, do the time, effort, and 
expertise required to separate mosquitoes into species-specific pools improve the 
accuracy of the predictions? 
 Is the estimated prevalence of PCR-positive Ae. polynesiensis (calculated by 
PoolScreen) a better indicator of the above measures? In other words, is it necessary 
to estimate prevalence using PoolScreen, or does the presence/absence of PCR-
positive pools provide equally accurate predictions? 
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7.5 Results 
Serological results from 376 persons residing in 32 villages were included in the analyses. 
The average number of persons per village was 13.9 (range 2–73) for Tutuila and Aunu’u, 
and 14.0 (range 11–16) for the Manu’a Islands. 
Table 7.1 provides a summary of the number of seropositive persons and village-level 
seroprevalence for each serological marker in humans, and the entomological data used in 
this study. Of the 32 villages included in this study, 11 (34.4%) had residents who were 
seropositive for Og4C3 Ag, 18 (56.3%) for Wb123 Ab, and 27 (84.4%) for Bm14 Ab. On 
Tutuila and Aunu’u, village-level seroprevalence ranged from 0% to 33.3% for Og4C3 Ag, 0% 
to 66.7% for Wb123 Ab, and 0% to 100% for Bm14 Ab. In the Manu’a Islands, no individuals 
were seropositive for Og4C3 Ag, and village-level seroprevalence ranged from 0% to 18.8% 
for Wb123 Ab, and 13.3% to 27.3% for Bm14 Ab. On Tutuila and Aunu’u, the MX study 
identified PCR-positive pools of Ae. polynesiensis in 15 (55.6%) of the 27 villages included in 
this study, of other mosquito species in 7 (25.9%) villages, and of mosquitoes of any species 
in 17 (63.0%) of the villages. In the five villages on the Manu’a Islands, no PCR-positive 
pools of mosquitoes were identified during the MX study. 
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Table 7.1 Summary of human and entomological data from the 32 villages included in this study. 
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7.5.1 Association between PCR-positive mosquito pools and seropositive villages 
Associations between the presence of PCR-positive pools of mosquitoes and seropositive 
villages and are shown in Table 7.2, with analyses stratified for i) Ae. polynesiensis only, ii) 
for all other mosquito species and iii) for mosquitoes of any species. Chi-squared tests of 
association showed that PCR-positive pools of Ae. polynesiensis (p < 0.001) and PCR-
positive pools of any species (p = 0.002), but not pools of other species, were significantly 
associated with seropositive villages for Og4C3 Ag and Wb123 Ab, but not Bm14 Ab. 
Figure 7.1 shows that the presence of at least one PCR-positive pool of Ae. 
polynesiensis or of any species was associated with a significantly higher probability of 
identifying a village with inhabitants seropositive for Og4C3 Ag (p < 0.001 and p = 0.002) and 
Wb123 Ab (p = 0.001 and p = 0.002). In the 15 villages with at least one PCR-positive pool of 
Ae. polynesiensis, 10 (67%) were seropositive for Og4C3 Ag and 13 (87%) were seropositive 
for Wb123 Ab, compared to 6% and 29% of villages respectively, where PCR-positive pools 
were not identified. Similarly, in the 17 villages where at least one PCR-positive pool of any 
species were identified, 11 (59%) had inhabitants who were seropositive for Og4C3 Ag and 
14 (82%) with persons seropositive for Wb123 Ab, compared to 7% and 27% of villages 
respectively, with no PCR-positive pools. The presence of PCR-positive pools was not 
significantly associated with seropositivity for Bm14 Ab. PCR-positive pools of other mosquito 
species were not significantly associated with seropositive villages for any of the serological 
markers. 
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Table 7.2 Association between PCR-positive pools of mosquitoes and seropositive villages 
for Og4C3 Ag, Wb123 Ab, and Bm14 Ab. 
Antigen/antibody 
status of villages# 
Number of 
villages (% 
of total) 
Villages with 
PCR- positive 
pools of Ae. 
polynesiensis 
Villages with 
PCR-positive 
pools of 
other species 
Villages with 
PCR- positive 
pools of any 
species 
  N (%) p value* N (%) p value* N (%) p value* 
Total villages 32 (100%) 15 
(100%) 
 7 
(100%) 
 17 
(100%) 
 
Seropositive for 
Og4C3 Ag 
11 (34.4%) 10 
(66.7) 
<0.001 4 (57.1) 0.151 10 
(58.8) 
0.002 
Seronegative for 
Og4C3 Ag 
21 (65.6%) 5 (33.3) 3 (42.9) 7 (41.2) 
Seropositive for 
Wb123 Ab 
18 (56.3%) 13 
(86.7) 
0.001 6 (85.7) 0.075 14 
(82.4) 
0.002 
Seronegative for 
Wb123 Ab 
14 (48.8%) 2 (13.3) 1 (14.3) 3 (17.6) 
Seropositive for 
Bm14 Ab 
27 (84.4%) 13 
(86.7) 
0.737 6 (85.7) 0.912 14 
(82.4) 
0.737 
Seronegative for 
Bm14 Ab 
5 (15.6%) 2 (13.3) 1 (14.3) 3 (17.6) 
# A seropositive village is defined as a village with at least one seropositive person for the antigen or 
antibody. A seronegative village is defined as a village with no seropositive persons. 
*Chi-squared tests comparison of villages with presence/absence of PCR-positive mosquito pools and 
presence/absence of seropositive persons. Statistically significant results highlighted in bold. 
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Figure 7.1 Probabilities of identifying seropositive villages for Og4C3 Ag, Wb123 Ab and 
Bm14 Ab based on the presence of PCR-positive pools of a) Ae. polynesiensis, b) any 
mosquito species, and c) other mosquito species. 
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7.5.2 Predicting the location of seropositive villages by using the presence of PCR-
positive pools of mosquitoes 
Table 7.3 provides a summary of the accuracy of PCR-positive mosquito pools for predicting 
seropositive villages for each antigen and antibody. PCR-positive pools of Ae. polynesiensis 
provide a sensitivity of 90.9% and specificity of 76.2% for identifying villages with seropositive 
persons for Og4C3 Ag, with a high negative predictive value of 94.1% (i.e. absence of PCR-
positive pools was a good indicator of the absence of seropositive persons). PCR-positive 
pools of any mosquito species provide the same sensitivity (90.9%) but a lower specificity 
(66.7%), and a negative predictive value of 93.9%. 
For Wb123 Ab, PCR-positive pools of Ae. polynesiensis provide a sensitivity of 72.2% 
and specificity of 85.7%, while PCR-positive pools of any mosquito species provide a 
sensitivity of 77.8% and specificity of 78.6% for identifying seropositive villages. For Bm14 
Ab, PCR-positive pools of Ae. polynesiensis and any species had poor sensitivities (48.1% 
and 51.9%) and specificities (60.0% and 40.0%) for predicting seropositive villages. 
PCR-positive pools of Ae. polynesiensis or any mosquito species were statistically significant 
predictors of villages with residents seropositive for Og4C3 Ag (odds ratios of 32.0 and 20.0) 
and Wb123 Ab (odds ratios of 15.6 and 12.8), but not for Bm14 Ab. The correlation between 
PCR-positive pools of Ae. polynesiensis and seropositive villages for Og4C3 Ag and Wb123 
Ab are shown for each village in Tutuila and Aunu’u in Figure 7.2, and the Manu’a Islands in 
Figure 7.3. 
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Table 7.3 PCR-positive pools of mosquitoes as predictors of villages with inhabitants 
seropositive for Og4C3 Ag, Wb123 Ab, and Bm14 Ab. 
 Any PCR- 
positive 
pools 
Sensitivity Specificity Positive 
predictive 
value 
Negative 
predictive 
value 
Odds 
ratio* 
(95% 
CI) 
p 
value* 
a) 
Seropositive 
villages for 
Og4C3 Ag 
Ae. 
polynesiensis 
90.9% 76.2% 66.7% 94.1% 32.0 
(3.2– 
315.3) 
0.003 
Other 
mosquito 
species 
36.4% 85.7% 57.1% 72.0% 3.43 
(0.6– 
19.4) 
0.163 
Any mosquito 
species 
90.9% 66.7% 58.8% 93.3% 20.0 
(2.1– 
189.2) 
0.009 
b) 
Seropositive 
villages for 
Wb123 Ab 
Ae. 
polynesiensis 
72.2% 85.7% 86.7% 70.6% 15.6 
(2.5– 
96.1) 
0.003 
Other 
mosquito 
species 
33.3% 92.9% 85.7% 52.0% 6.5 
(0.7– 
62.1) 
0.104 
Any mosquito 
species 
77.8% 78.6% 82.4% 73.3% 12.8 
(2.4– 
69.7) 
0.003 
c) 
Seropositive 
villages for 
Bm14 Ab 
Ae. 
polynesiensis 
48.1% 60.0% 86.7% 17.6% 1.4 
(0.2– 
9.7) 
0.738 
Other 
mosquito 
species 
22.2% 80.8% 85.7% 16.0% 1.1 
(0.1– 
12.2) 
0.912 
Any mosquito 
species 
51.9% 40.0% 82.4% 13.3% 0.7 
(0.1– 
5.0) 
0.738 
*Odds ratio of seropositive village if PCR-positive mosquitoes were identified (logistic regression), and 
associated p value (statistically significant results highlighted in bold). 
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Figure 7.2 Associations between PCR-positive pools of Ae. polynesiensis and seropositive 
villages for Og4C3 Ag and Wb123 Ab on Tutuila and Aunu’u. 
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Figure 7.3 Association between PCR-positive pools of Ae. polynesiensis and seropositive 
villages for Og4C3 Ag and Wb123 Ab on the Manu’a Islands. 
 
 
7.5.3 Predicting the location of seropositive villages by using the estimated 
prevalence of PCR-positive Ae. polynesiensis 
In the MX study, the estimated prevalence of PCR-positive Ae. polynesiensis ranged from 
0% (95% CI 0–0.1%) to 2.8% (0.5–7.9%) on Tutuila and Aunu’u, and was 0% for all villages 
in the Manu’a islands. Table 7.4 shows that a higher estimated prevalence of PCR-positive 
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Ae. polynesiensis (as a continuous variable) was associated with increased odds of a 
seropositive village for Og4C3 Ag and Wb123 Ab, but the findings were not statistically 
significant with this sample size and the level of precision inherent in PoolScreen predictions 
based on pooled mosquito samples. 
Table 7.4 Association between estimated prevalence of PCR-positive Ae. polynesiensis 
(using PoolScreen) and seropositive villages for Og4C3 Ag, Wb123 Ab, and Bm14 Ab. 
Seropositive villages for Odds ratio* 95% CI p value 
Og4C3 1.76 0.51–6.03 0.367 
Wb123 1.85 0.46–7.34 0.384 
Bm14 0.42 0.11–1.64 0.211 
* Odds ratio on logistic regression, per 1% increase in estimated prevalence of PCR-positive Ae. 
polynesiensis (calculated using PoolScreen). 
 
7.6 Discussion 
Our results show that MX is a potentially useful tool for post-MDA surveillance of lymphatic 
filariasis in American Samoa. The presence of PCR-positive pools of Ae. polynesiensis was 
found to be a good predictor of villages with persons seropositive for Og4C3 Ag and Wb123 
Ab, but not Bm14 Ab. Bm14 Ab can persist for many years or decades after initial infection 
but does not necessarily persist for life, and antibody levels can also decline or be cleared 
after MDA (Helmy et al., 2006; Weil et al., 2008). Wb123 Ab can also persist for many years 
after initial infection, and declines after MDA (Steel et al., 2012). Currently, there is 
insufficient data on the relative rates of antibody decay or clearance, but it is thought that 
Wb123 Ab responses decay more rapidly than Bm14 Ab. Biologically, Wb123 Ab responses 
might increase earlier because they are against a larval antigen and therefore also more 
likely to be associated with mosquito exposure. In our study, the lack of association between 
PCR-positive pools of mosquitoes and Bm14 Ab was therefore not unexpected, but the 
association with Wb123 Ab could be related to earlier appearance or faster disappearance of 
Wb123 Ab than Bm14 Ab during and after active infections, respectively (Hamlin et al., 2012; 
Kubofcik et al., 2012; Steel et al., 2013). 
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In American Samoa, where ~75% of mosquitoes collected in the entomology study 
(using BG Sentinel traps) were Ae. polynesiensis, the presence of PCR-positive pools of 
either Ae. polynesiensis alone or any mosquito species provided similar predictive accuracy 
of identifying villages with residents seropositive for Og4C3 Ag or Wb123 Ab. Our study 
shows that in this setting, separation of mosquito species for MX did not improve the 
predictive accuracy for identifying villages with seropositive inhabitants. However, it is 
important to point out that our results would have been different if we had used traps with a 
different level of selectivity for Ae. polynesisensis. MX studies in locations with other vector 
species and employing different traps may require sorting of mosquito species to achieve 
optimal results. 
The presence of PCR-positive pools of Ae. polynesiensis or mosquitoes of any 
species had high sensitivity and high negative predictive value (both >90%) for correctly 
identifying villages with antigen-positive persons. These are both important for post-MDA 
surveillance because tests should have a high probability of identifying residual foci of 
transmission (when prevalence is very low) and low probability of missing these foci. In this 
study, the estimated prevalence of PCR-positive Ae. polynesiensis (using PoolScreen) was 
no more useful than the presence/absence of PCR-positive pools, but the sampling design 
(small number of persons in some villages) might have limited the ability to detect significant 
associations. 
Previous studies in three sentinel villages in American Samoa showed that MX could 
be a useful tool in post-MDA surveillance (Chambers et al., 2009; Mladonicky et al., 2009); 
our larger study of 32 villages corroborates those conclusions. Our findings also suggest that 
in American Samoa, it is appropriate to conduct post-MDA surveillance at the village level. 
This is biologically plausible considering that the main vector, Ae. polynesiensis, has a 
relatively short flight range of about 100 meters (Jachowski, 1954), and village residents are 
generally quite mobile within their own village, e.g. visiting homes of family and friends, 
sharing outdoor spaces, attending school and church, and shopping at local stores. Further 
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interventions (e.g. further targeted MDA or a test and treat approach) could also be 
conducted at the village or even sub-village level. 
The results should be considered in light of the study’s limitations. The study was 
based on serological data from humans; microfilaria results were not available because the 
study was conducted using a pre-existing serum bank. Human serological data and 
entomological data were sourced from previously published studies, and there was a time lag 
of approximately nine months between the human and entomology studies. Sampling of the 
human seroprevalence study was designed to maximize spatial dispersion for the purposes 
of predictive risk mapping for the original leptospirosis study (Lau et al., 2014a), resulting in 
small numbers of subjects in some villages and wide confidence intervals for the village-level 
LF seroprevalence estimates. The serum bank only included samples from adults (aged ≥ 18 
years); a study that focused on or only included children might produce different results 
regarding the usefulness of serological markers, e.g. there could be significant associations 
between PCR-positive mosquitoes and Bm14 Ab in children. Ae. polynesiensis, the primary 
vector in American Samoa, is a day-biting mosquito; our human data were summarized by 
village of residence, and it is possible that PCR-positive mosquitoes acquired infections from 
residents of other villages who visited during day time. 
Despite the study’s limitations, we were able to identify statistically significant 
associations between MX data and human seroprevalence data at the village level. Further 
studies specifically designed to assess the usefulness of MX in the post-MDA setting might 
produce results with even stronger associations. With higher resolution data, it is also 
potentially possible to determine thresholds for the prevalence of PCR-positive Ae. 
polynesiensis at which further interventions (e.g. repeating MDA or more intensive 
surveillance) are recommended. In American Samoa, LF transmission is dominated by Ae. 
polynesiensis; studies in other countries with a different mix of vector mosquitoes will be 
needed to determine whether separation of mosquitoes by species is necessary for MX. 
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This exploratory study provides promising evidence to support the potential 
usefulness of MX in post-MDA surveillance in an Aedes transmission area in a Pacific Island 
setting to predict sub-national areas where LF transmission may still be occurring. Although 
American Samoa has successfully completed MDA and passed two TAS of 6–7 year old 
children, there is evidence of ongoing low-level transmission of LF. Our findings 
demonstrated that in this setting, MX was useful for localizing residual areas of focal 
transmission and could potentially be used to inform the need for additional elimination 
activities. Our study also highlights that assessment of antigen prevalence in adults in post-
MDA surveillance could complement TAS and provide valuable information for informing 
programmatic decisions in the endgame. 
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Table S 7.1 Village-level human serological data for Og4C3, Wb123 and Bm14 
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8.1 Abstract 
Background: Since 2001, Haiti’s National Program for the Elimination of Lymphatic Filariasis 
(NPELF) has worked to reduce the transmission of lymphatic filariasis (LF) through annual 
mass drug administration (MDA) with diethylcarbamazine and albendazole. The NPELF 
reached full national coverage with MDA for LF in 2012, and by 2014, a total of 14 evaluation 
units (48 communes) had met WHO eligibility criteria to conduct LF transmission assessment 
surveys (TAS) to determine whether prevalence had been reduced to below a threshold, 
such that transmission is assumed to be no longer sustainable. Haiti is also endemic for 
malaria and many communities suffer a high burden of soil-transmitted helminths (STH). 
Heeding the call from WHO for integration of neglected tropical diseases (NTD) activities, 
Haiti’s NPELF worked with the national malaria control program (NMCP) and with partners to 
develop an integrated TAS (LF-STH-malaria) to include assessments for malaria and STH. 
Methodology/principle findings: The aim of this study was to evaluate the feasibility of 
using TAS surveys for LF as a platform to collect information about STH and malaria. 
Between November 2014 and June 2015, TAS were conducted in 14 evaluation units (EUs) 
including 1 TAS (LF-only), 1 TAS- STH-malaria, and 12 TAS-malaria, with a total of 16,655 
children tested for LF, 14,795 tested for malaria, and 298 tested for STH. In all, 12 of the 14 
EUs passed the LF TAS, allowing the program to stop MDA for LF in 44 communes. The EU 
where children were also tested for STH will require annual school-based treatment with 
albendazole to maintain reduced STH levels. Finally, only 12 of 14,795 children tested 
positive for malaria by RDT in 38 communes. 
Conclusions/significance: Haiti’s 2014–2015 Integrated TAS surveys provide evidence of 
the feasibility of using the LF TAS as a platform for integration of assessments for STH and 
or malaria. 
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8.2 Author summary 
Lymphatic filariasis and malaria are mosquito-borne parasitic infections that are endemic in 
Haiti. Soil-transmitted helminths are also present in Haiti, infecting large numbers of people 
every year. Since 2001, Haiti’s National Program for the Elimination of Lymphatic Filariasis 
(NPELF) has worked to reduce the transmission of LF through annual mass drug 
administration with the aim of reducing LF prevalence in the population below a threshold, 
such that transmission is assumed to be no longer sustainable. By treating the entire 
population of Haiti with a combination of drugs, the elimination program has made 
tremendous progress towards eliminating the disease. By 2014, Haiti’s NPELF had met the 
World Health Organization eligibility criteria to conduct LF transmission assessment surveys 
(TAS) and decided to use the LF TAS as a platform to collect information about STH and 
malaria. The WHO has called for the integration of program activities in the field, and the 
TAS is a platform that allows for such integration. In Haiti the integrated TAS reduced the 
burden of repeated surveys on communities by minimizing site visits and benefited all three 
disease programs by sharing the responsibilities of field data collection. 
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8.3 Introduction 
Globally, lymphatic filariasis (LF), soil transmitted helminths (STH) and malaria are frequently 
co-endemic, presenting opportunities for integration of programs targeting their control and 
elimination. The WHO Global Program to Eliminate LF (GPELF) was launched in 2000 with a 
commitment to the elimination of LF as a public health problem by 2020 through mass drug 
administration (MDA) (WHO, 2012a). By 2013, more than 4.4 billion treatments of 
diethylcarbamazine or ivermectin plus albendazole (DEC+ALB or IVM+ALB) had been 
distributed in 56 countries, achieving an estimated 46% reduction in the population at risk of 
LF from 1.46 billion to 789 million people (WHO, 2012a, 2013; Hooper et al., 2014). In 2012, 
an estimated 1.5 billion people were infected with STH globally (WHO, 2012b). In 2014, an 
estimated 269 million pre-school-aged (PSAC) and 576.6 million school-aged children (SAC) 
were living in areas endemic for STH, which WHO recommends be addressed with periodic 
administration of ALB or mebendazole (MBZ) preventive chemotherapy (PC) (WHO, 2012b). 
Globally, the WHO target is to treat at least 75% of children living in STH endemic countries 
with PC by 2020 (WHO, 2015b). Approximately 3.2 billion people live in areas where they are 
at risk for malaria transmission (WHO, 2015c). The WHO global technical strategy for malaria 
(2016–2030) aims to ensure universal access to malaria prevention, diagnosis and 
treatment, to accelerate efforts towards elimination and attainment of malaria-free status, and 
to transform malaria surveillance into a core intervention (WHO, 2015d). Occurring in the 
tropical and subtropical zones, LF and malaria are both transmitted by mosquito vectors, and 
in certain areas, by the same species. 
The island of Hispaniola is the only remaining Caribbean island that is endemic for 
both malaria and LF (Raccurt, 2004), with Haiti bearing the greater burden of both diseases. 
In 2001, Haiti’s National LF elimination program (NPELF) determined that nearly all 
communes were endemic for LF (Beau de Rochars et al., 2004) and began administration of 
MDA (DEC + ALB) in select areas. Full national treatment coverage (140 communes) was 
achieved by 2012 (Lemoine et al., 2016). In 2014, Haiti was one of the 25 countries in the 
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Americas where PC was needed for STH, and one of seven in the region that achieved the ≥ 
75% national coverage target (WHO, 2015b). Haiti’s malaria prevalence is low (0.4% in 
2011) (Lucchi et al., 2014), though 17,662 confirmed cases were reported in 2014 (WHO, 
2015c). Documented asymptomatic parasitemia (Lindblade et al., 2013; Elbadry et al., 2015) 
highlights the need for surveillance strategies to identify remaining high transmission foci. To 
attain elimination of LF and malaria in Haiti, and control of STH, the three disease programs 
sought to identify remaining foci of disease transmission by integration of surveillance 
activities. 
In 2011, the World Health Organization (WHO) recommended the Transmission 
Assessment Survey (TAS), a standardized and statistically rigorous survey for measuring LF 
prevalence (WHO, 2011a). WHO recommends that LF elimination programs conduct the 
TAS in areas that have: 1) received 5 or more effective annual rounds of MDA; and 2) where 
spot-check and sentinel site surveys indicate microfilaria (mf) prevalence is less than 1% or 
antigenemia prevalence is less than 2%. The WHO has called for integration of neglected 
tropical diseases (NTD) activities, and in 2015, released a protocol to integrate LF-TAS with 
an assessment for STH (WHO, 2015e). LF-TAS have successfully been integrated with STH 
assessments in various countries (Chu et al., 2014; Gunawardena et al., 2014; Drabo et al., 
2016). Results from these integrated surveys can be used to determine the frequency of 
school-based STH treatment needed after community-wide LF MDA stops. Haiti’s NPELF, 
National Malaria Control Program (NMCP) and partners saw an opportunity to synergize 
efforts for the LF and STH surveys in order to collect community-level information on malaria, 
as an integrated TAS for all three diseases (‘TAS-STH-malaria’). The decision for the LF and 
malaria programs to work together was facilitated by the fact that the both programs are led 
by the same director, and are housed within the same office at the Ministry of Public Health 
and Population (MSPP). To our knowledge, this was the first time the LF TAS was used as a 
platform for also assessing both STH and malaria. The aim of this study was to evaluate the 
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feasibility of using TAS surveys for LF as a platform to collect information about STH and 
malaria. 
8.4 Methods 
8.4.1 Ethics statement 
Transmission assessment surveys were conducted according to study protocols approved by 
institutional review board (IRB) of the United States Centers for Disease Control and 
Prevention and the Ethics Committee of the Haitian Ministry of Public Health and Population 
(MSPP). Following ministry policy, MSPP and IMA World Health staff recruited designated 
schools to participate in the survey and contacted the schools’ headmasters in advance to 
advise them of the purpose of the survey and to request that they notify parents. Children 
provided verbal assent at the time of the survey. 
8.4.2 Study site 
At the time of the surveys, Haiti’s 10 departments were divided into 140 communes. 
Communes with the lowest baseline LF antigen prevalence based on the 2001 national 
survey were combined to form evaluation units (EUs); these EUs ranged from three or more 
communes to an entire department (maximum of 10 communes, Sud Est) (Table 8.1). 
Communes with greatest LF antigen prevalence at baseline were evaluated individually (n = 
8 EUs). Altogether, surveys were conducted in 14 EUs, composed of 47 communes in 6 
departments, where TAS eligibility requirements had been met (Figure 8.1). Between 
November 2014 and June 2015, TAS (LF-only) (EU 1), TAS-STH-malaria (EU 2) and TAS-
malaria (EUs 3–14) were conducted. Due to the ambitious TAS schedule for 2014–2015, 
MSPP approved piloting of the three disease protocol (TAS-STH-Malaria) in one EU for 
2015. 
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Table 8.1 Evaluation Units. 
EU 
# 
TAS type Department Number of 
communes in 
Department 
Number of 
Communes per EU 
Baseline LF antigen 
Prevalence (2001) 
1 LF Sud Est 10 10 0–4.9% 
2 LF + malaria 
+ STH 
Nippes 11 10 A 0–4.9% 
3 LF + malaria Centre 12 1 
B 0–4.9% 
4 LF + malaria Nord Est 13 2 
C 5–9.9% 
5 LF + malaria Nord Est 13 1 
D 10–45% 
6 LF + malaria Nord Est 13 9 
E 0–4.9% 
7 LF + malaria Nord Ouest 10 1 
F 7.0% 
8 LF + malaria Nord Ouest 10 7 
G 2.9% 
9 LF + malaria Nord 19 1
H 14.0% 
10 LF + malaria Nord 19 1 
I 30.0% 
11 LF + malaria Nord 19 1 
J 37.4% 
12 LF + malaria Nord 19 1 
K 45.0% 
13 LF + malaria Nord 19 1 
L 28.0% 
14 LF + malaria Nord 19 1
M 19.0% 
A = Anse à Veau, Arnaud, Asile, Fonds des Nègres, Grand Boucan, Miragoaˆne, Paillant, Petit Trou des Nippes, 
Petite Rivière des Nippes, Plaisance du Sud 
B = Saut d’Eau 
C = Saint Suzanne, Trou du Nord, Terrier Rouge 
D = Caracol 
E = Carice, Capotille, Ferrier, Fort Liberte´, Ounaminthe, Mombin Crouchu, Mont Organise, Perches, Vallieres 
F = Chansolme 
G = Jean Rabel, Bombardopolis, Baie-de-Henne, Mole Saint Nicolas, Saint Louis du Nord, Bassin Bleu, Anse à 
Foleur 
H = Dondon 
I = Plaisance 
J = Limonade 
K = Plaine du Nord 
L = Cap Haitien 
M = Limbe 
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Figure 8.1 Integrated Transmission Assessment Surveys. Haiti 2014–2015. 
 
8.4.3 Study design 
The TAS is a school- or community-based survey which employs a sampling strategy 
(cluster, systematic or census) determined by the total number of children in the target age 
group (six and seven years old), number of clusters (schools or census enumeration areas), 
primary school enrollment rate, and vector and parasite species in predetermined EUs (Table 
8.2). The TAS uses a critical cutoff for antigen prevalence in children, below which 
transmission is assumed to be no longer sustainable, even in the absence of MDA. When the 
number of LF positive cases among six and seven year olds is at or below the established 
threshold, the EU ‘passes’ the TAS and LF programs can decide to stop MDA. Surveys were 
designed using Survey Sample Builder (SSB) (Health) with survey design for STH and 
malaria assessments the same as for TAS. 
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Table 8.2 Transmission Assessment Survey Design by Evaluation Unit. 
EU 
number 
# 
TAS- type Number 
of 
Schools 
in EU 
Number 
of 
Targeted 
Schools 
Estimated 
number of 
Children 
Aged 6 & 7 
Years in 
the EU 
Target 
Sample 
Size 
Critical 
Cutoff of 
LF 
positives 
Survey Design Sampling by 
Age or 
Grade 
Assumed 
Absentee 
Rate 
C = Cluster; 
S = Systematic 
(Sampling 
Fraction, 
Interval) 
1 TAS 721 36 35,357 1,556 18 C (1.0, 1.0) Grade 10% 
2 TAS-STH- 
malaria 
367 43 14,813 1,548 18 C (1.0, 1.0) Grade 10% 
3 TAS- 
malaria 
67 38 2,442 1,228 14 C (1.0, 1.0) Age 10% 
4 TAS- 
malaria 
120 30 6,821 1,524 18 C (1.0, 1.0) Age 10% 
5 TAS- 
malaria 
17 17 707 365 4 S (0.57, 1.74) Age 10% 
6 TAS- 
malaria 
333 31 18,977 1,552 18 C (1.0, 1.0) Age 10% 
7 TAS- 
malaria 
25 25 1,597 530 6 S (0.39, 2.56) Age 15% 
8 TAS- 
malaria 
441 39 20,883 1,552 18 C (1.0, 1.0) Age 15% 
9 TAS- 
malaria 
26 29 754 365 4 S (0.57, 1.76) Age 15% 
10 TAS- 
malaria 
34 34 1,679 594 7 S (0.42, 2.4) Age 15% 
11 TAS- 
malaria 
42 42 1,336 780 9 C (0.96, 1.04) Age 15% 
12 TAS- 
malaria 
48 31 1,634 891 11 C (1.0, 1.0) Age 15% 
13 TAS- 
malaria 
199 39 9,299 1,532 18 C (1.0, 1.0) Age 15% 
14 TAS- 
malaria 
74 30 4,038 1,380 16 C (1.0, 1.0) Age 15% 
 
8.4.4 Survey teams 
The LF-only TAS teams were composed of a total of four people: (i) facilitator (responsible 
for identifying and organizing eligible children); (ii) enroller (responsible for enrollment); (iii) 
laboratory technician; and (iv) reader (responsible for reading laboratory test and recording 
result). 
Some of the TAS-malaria teams had an additional laboratory technician, for a total of 
5 team members. The TAS-STH-malaria teams had two additional individuals to collect and 
process the stool specimens and to perform Kato Katz, for a total of six or seven team 
members. Team members received intensive training prior to the surveys. 
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8.4.5 Population and school data 
The target population for all three survey parts was children aged six and seven years. This 
age group is selected based on the assumption that this age group of children would have 
been born just before or during the annual MDA campaigns for LF, and therefore, they 
should not have been exposed to bites of mosquitoes carrying infective larvae. 
Standard projection methods were used to estimate the population in the 14 EUs 
using data from Haiti’s most recent national census (2003). 
Since comprehensive lists of school enrollment were not available from the Ministry of 
Education (MOE), trained community-level workers visited schools within the EU and survey 
areas to generate lists of all schools with the number and ages of children enrolled. The 
numbers of children (of the targeted ages) enrolled in school were compared with the 
projected population of children in the target age group for each EU to estimate percent 
school enrollment rates and to inform survey design. 
8.4.6 Sampling 
Based on school enrollment rates, all 14 EUs were eligible to conduct school-based TAS 
(WHO, 2011a). The Haitian Ministry of Education indicated that 1st and 2nd grade students 
served as a reasonable proxy for six and seven year old children, therefore, selection criteria 
were set a priori to be conducted amongst 1st and 2nd grade students across the 14 EUs. 
At each school, eligible children were selected to receive an LF test according to the 
sample interval prescribed by SSB (Table 8.2). In the EUs where TAS-malaria was 
conducted (2–14), all children selected for LF testing were also tested for malaria. In the 1 
EU in which LF-malaria- STH TAS was conducted, an additional sampling interval was 
defined by SSB for selecting a subset of children to be tested for STH. 
8.4.7 Sample collection and field diagnostics (LF, STH and malaria) 
All diagnostic tests for the integrated TAS were carried out in the field. The diagnostic tests 
used for LF, STH and malaria were the BinaxNOW Filariasis immunochromatographic test 
(ICT) (Alere, Maine), Kato Katz (Vestergaard-Frandsen, Denmark), and First Response 
8. Integrated transmission assessment surveys in Haiti 
__________________________________________________________________________ 
139 
  
 
Malaria Histidine-Rich Protein II (HRP2) (II3FRC30) (Premier Medical Corporation, New 
Jersey) rapid diagnostic test (RDT), respectively. Dried blood spots (DBS) were collected on 
calibrated filter paper (Cellabs, Australia) for subsequent serological testing. 
From each enrolled child, technicians collected approximately 175 μL of blood from a 
single finger stick. Immediately following blood collection, 100 μL of blood was applied to the 
ICT and results were read at 10 minutes according to manufacturer instructions. Five μL of 
blood and 2 drops (60 μL) buffer were applied to the RDT and read at 20 minutes, according 
to manufacturer instructions. Sixty μl of blood was applied to calibrated filter paper and dried 
individually. 
Serological assays are currently underway at CDC in Atlanta, GA, and results will be 
reported separately. 
8.4.8 Sample collection and field diagnostics (STH) 
Stool cups were distributed at the time of enrollment. Stool samples were immediately 
processed on site and two slides were prepared and examined from each sample. 
8.4.9 Data collection and analysis 
All enrollment information and diagnostic results were recorded directly into Blu® smart 
phones and uploaded to the cloud-based LINKS (Pavluck et al., 2014) server using software 
developed and supported by the NTD Support Center. 
At the conclusion of the survey at each school visit, teachers and administration were 
given the diagnostic results. 
Data were downloaded from the server in Microsoft Excel. They were cleaned, 
merged and analyzed using SAS 9.3 at CDC. 
8.4.10 Treatment 
Children in whom any of the three diseases were detected were provided treatment 
according to national guidelines, using medications provided by the survey team. Those 
found to have LF or STH were given DEC+ALB or ALB, respectively. Children found to have 
malaria were referred to the nearest health public facility to receive chloroquine and 
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primaquine treatment free of charge, in compliance with the MSPP’s antimalarial first-line 
drug recommendation for treating uncomplicated malaria. 
8.5 Results 
Haiti’s NPELF and partners completed 14 TAS surveys between November 2014 and June 
2015 (Figure 8.1 and Table 8.1). In all, 16,655 children were tested for LF, 14,795 for 
malaria, and 298 for STH (Table 8.3). 
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Table 8.3  Results: Transmission Assessment Survey. 
 
8. Integrated transmission assessment surveys in Haiti 
__________________________________________________________________________ 
142 
  
 
Haiti’s first TAS (LF only) was conducted in November 2014 in Sud Est department 
(EU 1). Teams visited 36 schools and found that zero (0%) of 1,494 children tested positive 
for LF by ICT. 
The second TAS (TAS-STH-malaria) was conducted in February 2015 in Nippes 
department (EU 2). Teams visited 45 schools and found that 3 (0.2%) of 1,662 children 
tested positive for LF by ICT, 0 (0%) of 1,667 tested positive for malaria by RDT, and 46 
(15.4%) of 298 children tested positive for STH (Kato Katz). 
In the first two EUs, school grades poorly approximated age, with children enrolled in 
first and second grades ranging in age from five to 18 years. Despite testing children as old 
as 18 years of age, who could be more likely to have contracted LF before the start of MDA 
campaigns, only 3 children tested positive for LF in EU 2. In subsequent EUs, only six and 
seven year old children (from any grade) were identified and eligible for testing. 
From February to June 2015, TAS-malaria surveys were carried out in Nord, Nord 
Est, Nord Ouest and Centre departments (EUs 3–14). In total, teams visited 379 schools and 
tested more than 13,000 children for LF and malaria. In all, nine EUs passed the TAS. One 
(EU 13) marginally passed TAS with 18 positive for LF, which met, but did not surpass the 
critical threshold for continuation of LF MDA. Two EUs (11 and 12) failed the TAS with 19 
and 15 children testing positive for LF antigen by ICT, surpassing their respective thresholds 
of 9 and 11, respectively. Twelve of 13,128 children tested had positive RDT results. 
8.5.1 Estimated survey costs 
Team members spent a total of 316 working days (working day = 1 person working for 1 day) 
in the field to accomplish the TAS in 14 EUs. The LF-only TAS, the TAS-malaria and the 
TAS-STH-malaria required an average of 22, 22.5, and 27 working days per EU, 
respectively. In terms of productivity, LF-only TAS, TAS-malaria and TAS-STH-malaria teams 
completed activities at the same rate of 1.6 schools/day, accomplished by the additional 
personnel for the integrated TAS surveys. The cost of the TAS-malaria evaluation was an 
estimated 15% higher than the cost for the LF-only evaluation. The cost of the TAS-STH-
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malaria evaluation was 49% higher than the cost for the LF-only evaluation. The additional 
costs resulted from resources required for additional personnel and their transportation. 
8.6 Discussion 
Integrated surveys have the potential to both optimize resource utilization (human and 
financial) and generate useful data across programs using a robust survey platform. The 
Integrated TAS-STH-malaria survey was found to be feasible and generated useful 
information for all three programs. 
Twelve of the 14 EUs passed the LF TAS, allowing the program to stop MDA for LF in 
12 EUs, or 45 communes. In 36 of the communes that were able to stop MDA, baseline LF 
prevalence was low; however, the NPELF also succeeded in reducing LF prevalence 
sufficiently to pass TAS in 8 communes where LF prevalence was moderate or high at the 
time of mapping in 2000–2001. This achievement underscores the quality of the MDA 
activities and the ability of the program to achieve adequate participation of the population. In 
the two EUs that failed TAS (EU 12, 13), MSPP and partners will continue MDA for an 
additional two rounds, before re-evaluating in sentinel and spot check sites. Though EU 13 
technically passed the TAS with 18 children positive out of 2,002 tested, the EU is 
surrounded by other areas of ongoing transmission, and thus MSPP and partners took the 
conservative decision to continue MDA there for an additional two rounds. 
According to the WHO TAS-STH manual, the 46 positive STH results from EU 2 
would categorize the area as having a prevalence range of 10% to <20% (WHO, 2015e). 
This represents a decrease in STH prevalence from the 2002 national survey, but leads to 
the programmatic recommendation to conduct annual, school-based treatment for STH in 
that EU to maintain reduced STH levels. 
In all, malaria was detected by RDT in only 12 of 14,795 children in 38 communes. 
The inclusion of malaria RDTs in the LF TAS confirms that malaria prevalence in Haiti is low, 
and provides additional evidence in support of the decision to continue current programs and 
the development of new strategies in surveillance toward malaria elimination. Although few 
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malaria RDT-positive individuals were identified amongst a limited population, antibody 
assays should provide a cumulative history of exposure and potentially define transmission 
foci for both diseases. 
The integrated TAS strategy has several advantages. Most importantly, the integrated 
TAS-STH-malaria enabled partners to make programmatic decisions for stopping LF MDA 
and for deworming frequency for STH. As the LF program nears elimination, new approaches 
to STH monitoring and control, including the integrated TAS which produces actionable 
results for STH, should be incorporated into work plans. 
Second, the integrated TAS establishes a potential framework for integrated 
surveillance and a more coordinated approach to community-based intervention strategies. 
By testing for multiple infections, we were able to generate actionable results for more than 
one program. The results also informed thinking about the testing needed to support malaria 
elimination. In a single, integrated and carefully planned survey, we are able to maximize 
returns on the investment of field activities while also reducing burden on both field teams 
and communities. These synergies are especially important for diseases in the elimination 
phase, since surveillance efforts will be resource intensive for increasingly rare conditions. 
Third, this activity fostered collaboration between ministries of education (MOE) and 
health (MSPP), and across disease programs within MSPP. The integrated TAS marks the 
first time in which field activities for the three disease programs were combined in such a 
manner in Haiti. The NPELF and partners conveyed the common goals of each public health 
activity to encourage school administrators to allow field teams to conduct integrated TAS in 
schools. The support of school administrators will be particularly important as STH control 
moves towards school-based deworming following the end of LF MDA. The LF, malaria and 
STH programs and field teams worked well together in this mutually beneficial and 
informative activity, thereby developing and strengthening the new working relationship. 
Fourth, the integrated survey represented an overall cost savings, compared with 
performing similar assessments independently. The addition of the malaria assessment to 
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the TAS (TAS-malaria) cost an estimated 15% more in Haiti than the LF-only TAS, due to the 
addition of a team member for processing and reading of malaria RDTs. As teams become 
more familiar with the workflow, it is anticipated an additional team member might not be 
necessary to perform the malaria RDT. The integrated TAS-STH-malaria costs an estimated 
49% more than the LF-only TAS, due to the addition of two team members for processing of 
stool by Kato Katz. Obtaining the same information through separate surveys conducted by 
each independent program would have incurred substantially more expense. The integrated 
survey platform creates options to include additional tests to expand the utility of the survey. 
Lastly, the integrated TAS represented less of an intrusion for the communities than 
would three independent surveys. By performing multiple diagnostic tests in one coordinated 
visit, the amount of time that children were kept from classes was minimized. The overall 
activity was less time consuming, in that the school administration was approached only once 
on behalf of the three programs, and consent was obtained for all diagnostics concurrently. 
The one visit proved to take only slightly longer than the TAS-only activity, and provided 
immediate results to communities and treatment for infected children. 
This study identified a few challenges to performing the TAS in Haiti. First, the age of 
the children enrolled in first and second grades varies greatly, so the program was unable to 
rely on grades as a proxy for age. Testing children older than seven years (i.e. born prior to 
the start of MDA), provides a more conservative estimate of LF transmission since it includes 
children were born before MDA began, however it fails to answer the question about the 
effect of MDA on recent transmission. For this reason, the decision was made to identify 
children by age in EUs 3–14, rather than continuing to use grade as a proxy for age in order 
to better keep with the TAS protocol guidelines. 
Second, the estimate of student enrollment frequently exceeded actual child 
attendance on the day of the surveys. More schools needed to be visited in order to reach 
the predetermined sample size, which posed additional logistical burden on the field teams. 
The TAS survey guidelines rely on accurate estimations of the number of children of the 
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target ages living in each EU as well as school enrollment rates, to ensure that survey design 
yields representative and appropriately distributed samples from across the targeted 
population. Prior to the survey, current school enrollment rates were not available from the 
MOE, so partners obtained school data directly from the schools in each EU. 
Third, field teams had to manage several logistical challenges including limited 
access to cold chain for storage of ICT cards before TAS and dried blood spots after TAS. 
Limited cellular service, accessibility and difficult terrain of some selected schools, and 
school holidays were a challenge for field teams impacting sample size. Finally, sensitization 
was not always sufficient, leading to refusals in some instances. 
There were also limitations associated with the malaria program. First, although testing 
more than 14,700 six and seven year old children confirmed the low prevalence of malaria in 
the surveyed areas, the rates of RDT positivity was low and consequently, the results of the 
malaria antibody testing planned for specimens collected during this study are likely to be 
more informative for programmatic decisions than the RDT results. Second, the integrated 
TAS survey design, including geographic distribution of EUs, was based on historical LF 
mapping data. Use of malaria distribution as the basis for the creating EUs would have likely 
influenced the choice of how to combine communes to form EUs. 
8.7 Conclusions 
The activities reported here from 14 TAS surveys provide evidence of the feasibility of using 
the LF TAS as a platform for integration of assessments for STH and or malaria. 
In 2014, Haiti’s LF elimination program achieved eligibility for administration of TAS in 
47 communes and after conducting TAS was able to stop MDA campaigns for 
approximately1,981,920 people in 44 communes. Intensified activities in the next five years, 
including progressive implementation of TAS, stopping MDA, and phasing in post-MDA 
surveillance, will be essential to achieving the country’s elimination goal by 2020 (Ichimori et 
al., 2014). With this in mind, the NPELF and partners plan to conduct TAS (including TAS-
STH-malaria and TAS-malaria) in 58 additional communes in 2016 and 39 additional 
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communes before the end of 2017. Integrating assessment of STH infections will enable 
program managers to determine the effectiveness of proposed school-based STH programs, 
while Integrating malaria into the TAS platform will provide additional national data on recent 
malaria history, which is important for targeting malaria elimination efforts and ensuring 
progress towards a malaria-free Haiti. Despite experiencing many challenges, including the 
2010 earthquake and cholera outbreak, integrated TAS results support the assertion that 
Haiti is on track to meeting the WHO’s 2020 LF global elimination targets. Although malaria 
elimination is admittedly a more ambitious goal, development of integrated surveillance 
strategies will help to achieve this goal. 
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9.1 Abstract 
Accurate, cost-effective measurement of the burden of co-endemic infections would enable 
public health managers to identify opportunities for implementation of integrated control 
programs. Dried blood spots (DBS) collected during a cross-sectional lymphatic filariasis 
sentinel site survey in the coastal Kenyan counties of Lamu, Tana River, Kilifi, Kwale, and 
Taita-Taveta were used for the integrated detection of serologic IgG antibodies against 
antigens from several parasitic infections (Wuchereria bancrofti, Schistosoma mansoni, 
Plasmodium spp., Ascaris lumbricoides, and Strongyloides stercoralis) as well as markers for 
immunity to vaccine-preventable diseases (measles, diphtheria, and tetanus) on a multiplex 
bead assay (MBA) platform. High heterogeneity was observed in antibody responses by 
pathogen and antigen across the sentinel sites. Antibody seroprevalence against Wb123, 
Bm14, and Bm33 recombinant filarial antigens were generally higher in Ndau Island 
(p<0.001), which also had the highest prevalence of filarial antigenemia compared to other 
communities. Antibody responses to the Plasmodium species antigens CSP and MSP-119 
were higher in Kilifi and Kwale counties, with Jaribuni community showing higher overall 
mean seroprevalence (p<0.001). Kimorigo community in Taita-Taveta County was the only 
area where antibody responses against Schistosoma mansoni Sm25 recombinant antigen 
were detected. Seroprevalence rates to Strongyloides antigen NIE ranged between 3% and 
26%, and there was high heterogeneity in immune responses against an Ascaris antigen 
among the study communities. Differences were observed between communities in terms of 
seroprevalence to vaccine-preventable diseases. Seroprotection to tetanus was lower in all 
three communities in Kwale County compared to the rest of the communities. This study has 
demonstrated that the MBA platform holds promise for rapid integrated monitoring of trends 
of infections of public health importance in endemic areas, and assessing the effectiveness 
of control and elimination programs.  
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9.2 Author summary 
Establishment of successful private-public partnerships in the recent past has led to an 
increase in resources available for control and elimination of malaria and Neglected Tropical 
Diseases (NTDs). Implementation of control and elimination programs and their subsequent 
monitoring and evaluation would be greatly facilitated by development of new tools and 
strategies for rapid identification of areas of transmission so that interventions could be 
prioritized to regions where they were most needed. Since development of antibody 
responses in a host depend on exposure to an infectious agent, assessment of such 
serologic markers provides a sensitive way to measure differences between populations in 
pathogen exposure. Our study applied a state-of-the-art multiplex bead assay platform to 
perform integrated measurement of antibody responses to multiple parasitic diseases and 
immunizing antigens for vaccine-preventable diseases (VPDs) in ten lymphatic filariasis 
sentinel sites across the Kenyan coastal region. A community-level analysis of age-specific 
and overall mean seroprevalence fit using a flexible model ensemble provided an improved 
understanding about the distributions of the various parasitic infections and seroprotection to 
VPDs. This study provides an important proof of concept for how we could dramatically 
increase the value of existing surveillance activities using small volumes of blood collected 
on filter paper and analyzed using a single multiplex laboratory assay and novel data 
analysis techniques.  
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9.3 Introduction 
Persons living in tropical and subtropical areas are often faced with enormous health 
challenges resulting from the co-endemicity of HIV/AIDS, tuberculosis, and malaria. In 
addition, several other infectious diseases found in sub-Saharan Africa including some 
Neglected Tropical Diseases (NTDs) are common, particularly among the poor (Molyneux et 
al., 2005; Brooker et al., 2006; Hotez et al., 2006a). Past studies in the region have identified 
subgroups who are polyparasitized with soil-transmitted helminth (STH) infections, filarial 
parasites, and malaria (Keiser et al., 2002; Raso et al., 2004; Hürlimann et al., 2014). 
Lymphatic filariasis (LF) caused by Wuchereria bancrofti  is principally confined to the coastal 
region of Kenya where ecological factors are suitable for its transmission (Moraga et al., 
2015), and LF co-occurs with other infectious diseases such as STH infections, 
schistosomiasis, lower respiratory infections, and malaria (Okiro et al., 2007; Njenga et al., 
2011b; Munywoki et al., 2013).  
In the past, lack of resources and competing health priorities in sub-Saharan Africa 
have led to insufficient commitments to control NTDs. More recently, implementation of 
successful public-private partnerships (PPPs) for health have availed resources for control 
and/or elimination of NTDs as public health problems. In 2000 the World Health Organization 
(WHO) Global Programme to Eliminate Lymphatic Filariasis (GPELF), launched in response 
to World Health Assembly resolution WHA50.29, urged Member States to initiate activities to 
eliminate LF as a public health problem, a goal subsequently targeted for 2020 (WHO, 
2011a). Community-wide mass drug administration (MDA) of antifilarial drugs for 4-6 years is 
recommended for LF elimination, and modeling studies have estimated adequate treatment 
coverage to be at least 65% of total population in endemic areas (Michael et al., 1996; Stolk 
et al., 2003). Substantial progress has been made towards elimination of LF, with Togo being 
the first country in sub-Saharan Africa to be recognized by WHO for eliminating the disease 
as a public health problem (Sodahlon et al., 2013; WHO, 2017f). The Kenyan Ministry of 
Health launched an LF elimination program in 2002, but the program did not sustain MDA 
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campaigns annually as per GPELF recommendations (Njenga et al., 2011a; Njenga et al., 
2017). In 2015, the Ministry of Health successfully appealed to World Health Organization 
Regional Office for Africa (WHO-AFRO) and other partners for support to re-establish annual 
MDA campaigns. Subsequently, the WHO Country Office selected the Eastern and Southern 
Africa Centre of International Parasitic Control (ESACIPAC), which is part of the Kenya 
Medical Research Institute (KEMRI), to conduct a comprehensive epidemiological 
assessment of LF infection before re-starting MDA.   
Antibody levels can provide valuable information about exposure to infections and 
can be helpful for characterizing pathogen transmission dynamics to help identify where 
interventions are needed the most. As some parasite antigens are known to elicit an 
immunoglobulin G (IgG) response that can be detected for a long period of time, serological 
analysis of young children provide an estimate of more recent exposure (Wipasa et al., 2010; 
Hamlin et al., 2012). A state-of-art multiplex bead assay (MBA) serological platform that 
enables simultaneous detection of antibodies against multiple antigens using a small volume 
of blood sample dried on filter paper [10 µL dried blood spots (DBS)] has been developed as 
a tool for integrated biomarker surveys (Priest et al., 2010; Moss et al., 2011; Lammie et al., 
2012). The MBA has successfully been used to simultaneously measure antibody responses 
to multiple parasitic diseases of public health importance as part of a vaccine-preventable 
disease serological survey in Cambodia (Priest et al., 2016). The platform has also been 
used to simultaneously assess IgG responses to a panel of malaria antigens (Arnold et al., 
2014; Rogier et al., 2017). In the current study, the MBA platform was used for multiplex 
serosurveillance of diseases of public health importance by testing for antibodies against LF 
and several other parasitic diseases (malaria, schistosomiasis, ascariasis, strongyloidiasis) 
as well as seroprevalence to selected vaccine-preventable diseases (measles, diphtheria, 
and tetanus).    
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9.4 Methods 
9.4.1 Study design and samples  
The DBS samples used in this study were collected during a cross-sectional LF survey 
conducted in October 2015 in ten sentinel sites located across the coastal region in Taita-
Taveta, Kwale, Kilifi, Tana River and Lamu counties as previously described (Njenga et al., 
2017). Briefly, 300 persons aged 2 years or more in each sentinel site were targeted for the 
LF survey as recommended in the WHO guidelines (WHO, 2011a). The characteristics of the 
study participants are described in Njenga et al. (Njenga et al., 2017). The middle finger of 
consenting individuals was cleaned using a cotton ball soaked in 70% isopropyl alcohol. After 
drying, the tip of the finger was pricked using a sterile lancet and blood was collected into 
capillary tubes for detection of circulating filarial antigen (CFA) by immunochromatographic 
card test (ICT) and onto filter paper for preparation of dried blood spots (6 spots of 10 µl 
each; Tropbio Pty Ltd, Queensland, Australia) which were used for the MBA.  
9.4.2 Ethics statement 
The study received ethical approval from Kenya Medical Research Institute (KEMRI) 
Scientific and Ethics Review Unit. In the study villages, chiefs and assistant chiefs arranged 
for community mobilization meetings during which the purpose of the survey and procedures 
to be followed were explained. Written informed consent was obtained from every individual 
who agreed to participate in this study; parents or legal guardians consented on behalf of 
children below 17 years. All of the community acquired samples were assayed in the KEMRI-
ESACIPAC laboratory in Nairobi, Kenya. 
9.4.3 Recombinant antigens and coupling to microsphere beads 
Recombinant Schistosoma mansoni glutathione-S-transferase (GST) protein was expressed 
from pGEX 4T-2 plasmid (GE Healthcare, Piscataway, NJ) and purified as previously 
described [26]. GST fusion proteins that included protein sequences from Brugia malayi 
[Bm33 (Moss et al., 2011); and Bm14 (Hamlin et al., 2012)], Strongyloides stercoralis [NIE 
(Rascoe et al., 2015)], and Plasmodium falciparum 3D7 strain [MSP119 (Won et al., 2017)] 
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were expressed and purified as previously described.  A W. bancrofti Wb123-GST fusion 
protein was a kind gift from T. Nutman (NIH, Bethesda, MD). These proteins were coupled to 
SeroMap beads (Luminex Corp., Austin TX) using the protein quantities and buffer conditions 
previously described (Priest et al., 2016). S. mansoni native soluble egg antigen (SEA) was a 
kind gift of E. Secor (CDC, Atlanta, GA), and recombinant S. mansoni Sm25 antigen was 
expressed using the Baculovirus system previously described (Won et al., 2017). Both 
proteins were coupled to SeroMap beads using the protein quantities and buffer conditions 
previously described. 
Tetanus toxoid (Massachusetts Biological Laboratories, Boston, MA), diphtheria 
toxoid from Corynebacterium diphtheriae (List Biological Laboratories, Campbell, CA), and 
recombinant measles nucleoprotein (MV-N, Meridian Life Sciences, Memphis, TN) (Hummel 
et al., 1992) were purchased from commercial sources. Tetanus toxoid was coupled to 
SeroMap beads as previously described (Scobie et al., 2016). Diphtheria toxoid was coupled 
in buffer containing 50 mM 2-(N-morpholinoethanesulfonic acid (MES) at pH 5.0 with 0.85% 
NaCl at a concentration of 60 μg of protein per 1.25 x 107 beads in 1 ml final volume. In order 
to decrease background reactivity, measles MV-N was purified by chromatography on a 
MonoQ HR 5/5 strong anion exchange column (GE Healthcare, Piscataway, NJ) prior to use. 
Protein (0.75 mg) was loaded onto the column at a flow rate of 1 ml/ min and washed with 4 
ml of 25 mM Tris buffer at pH 8.0. This was followed by a 10 ml linear gradient to 0.25 M 
NaCl in Tris buffer, then by a 5 ml linear gradient to 1 M NaCl in Tris buffer. The majority of 
antibody-reactive MV-N eluted in the high salt fractions between 0.4 and 0.7 M NaCl. These 
fractions were pooled, concentrated using a Centricon-30 centifugal filter device (Millipore 
Corporation, Bedford, MA), and exchanged into buffer containing 10 mM sodium phosphate 
with 0.85% NaCl at pH 7.2 (PBS). Approximately 115 mg of protein was recovered (BCA 
micro assay, Pierce, Rockford, IL).  MonoQ purified MV-N was coupled in buffer containing 
50 mM MES at pH 5.0 with 0.85% NaCl at a concentration of 6 μg of protein per 1.25 x 107 
beads in 1 ml final volume.   
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Purified native hemoglobin (Hb) from Ascaris suum worms was a kind gift from P. 
Geldhof (Ghent University, Belgium) (Vlaminck et al., 2012; 2016). This antigen was coupled 
to 1.25 x 107 SeroMap beads in PBS buffer (pH 7.2) at a concentration of 120 μg/ ml. 
Cloning of the P. malariae MSP119 coding sequence from China I parasite strain is 
described elsewhere (Priest et al., in preparation). This antigen was coupled to 1.25 x 107 
SeroMap beads in 50 mM MES buffer at pH 5.0 with 0.85% NaCl at a concentration of 30 μg/ 
ml. The glutaraldehyde protocol of Benitez et al. (Benitez et al., 2011) was used to cross-link 
a synthetic 20 amino acid peptide [(NANP)5-amide] corresponding to the carboxy-terminal 
repeat of the P. falciparum circumsporozoite protein (PfCSP) (Dame et al., 1984; Ballou et 
al., 1985) to purified GST protein. Bead coupling conditions for this antigen were identical to 
those described above for the P. malariae MSP119 protein.   
9.4.4 Multiplex bead assay 
One bloodspot from each person, corresponding to about 10 µl of whole blood, was eluted 
overnight at 4⁰C with 200 microliters of PBS containing 0.05% Tween-20 and 0.05% sodium 
azide (1:40 serum dilution assuming a 50% hematocrit). A further dilution of 50 microliters of 
eluate into 450 µl of PBS containing 0.5% casein, 0.3% Tween 20, 0.02% sodium azide, 
0.5% polyvinyl alcohol (PVA), and 0.8% polyvinylpyrrolidone (PVP) (designated as PBN1) 
with 3 micrograms/ml Escherichia coli extract was made for a final serum dilution of 1:400. 
Serum dilutions were centrifuged at maximum speed to pellet the E. coli extract particulates 
immediately before use. Bloodspot dilutions were assayed in duplicate with antigen-coupled 
microsphere beads using a BioPlex 200 system platform (Bio-Rad, Hercules, CA) as 
previously described (Moss et al., 2011; Priest et al., 2016; Rogier et al., 2017). The average 
of the median fluorescent intensity values from the duplicate wells minus the background 
fluorescence from the buffer-only blank was reported as the “median fluorescence intensity 
minus background” (MFI-bg). Samples having a coefficient of variation of >15% for ≥2 
positive responses between the duplicate wells were repeated.  
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9.4.5 Cutoff determinations  
WHO International Standard reference sera for tetanus (TE-3; 120 IU/ml) and diphtheria 
(10/262; 2 IU/ml) purchased from the National Institute for Biological Standards and Control 
(NIBSC) (Potters Bar, Hertfordshire, United Kingdom) were used to identify MFI-bg cutoff 
values corresponding to immunoprotection. A tetanus TE-3 value of 10 mIU/ml (Kristiansen 
et al., 1997; Borrow et al., 2006) corresponded to a tetanus toxoid MBA response of 118 
MFI-bg units. A diphtheria toxoid MBA response of 4393 MFI-bg units corresponded to the 
0.1 IU/ml threshold for complete protection (Scheifele and Ochnio, 2009), and an MBA 
response of 183 MFI-bg units corresponded to the 0.01 IU/ml threshold for partial protection. 
Others have shown good concordance between the ‘gold standard’ assays for tetanus and 
diphtheria and assays using the multiplex bead format (van Gageldonk et al., 2011; Scobie et 
al., 2016). Although a WHO reference standard is available for the quantitation of measles 
virus-neutralizing antibody responses using the whole virus Plaque Reduction Neutralization 
Test (PRNT) (NIBSC 97/648; 3 IU/ml), the standard has not been calibrated for use in ELISA 
format assays (Bentley et al., 2006), and our MBA only detects IgG antibodies to the measles 
MV-N protein. In independent work using the specific bead set from this study Coughlin et al. 
(in preparation) determined that an ROC-optimized MFI-bg cutoff value of 178 MFI-bg units 
provided good sensitivity and specificity compared to the ‘gold standard’ PRNT. 
MBA cutoff estimates for the S. stercoralis NIE assay and for the three LF antigens 
(Bm33, Bm14, and Wb123) were assigned using a panel of 94 presumed negative sera 
donated by anonymous adult US citizens with no history of foreign travel. Test values greater 
than the mean plus three standards deviations of the presumed negative sample values were 
considered to be positive. For the P. malariae and P. falciparum MSP119 assays, log 
transformed data were used for the mean plus three standard deviation calculation, and the 
panel used for the P. falciparum cutoff included only 65 of the original 94 US adult 
volunteers. A ROC curve using sera from 41 stool-confirmed, anonymous ascariasis patients, 
65 of the adult US citizen volunteers and sera from 45 anonymous US children was used to 
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identify the cutoff for the Ascaris Hb MBA. All of the parasitic disease cutoff values were 
adjusted to account for differences between the instrument used for cutoff determination at 
the CDC in Atlanta, GA, and the instrument used to assay the Kenyan sample set at KEMRI 
in Nairobi, Kenya. Two-fold serial dilutions of the same strong positive sera were assayed on 
both instruments to generate standard curves for cutoff value adjustment.   
S. mansoni SEA and Sm25 coupled beads were used in an earlier study, and the 
adjusted, ROC-assigned cutoff values have been reported elsewhere (965 and 38 MFI-bg 
units, respectively) (Won et al., 2017).   
We also estimated seropositivity cutoff points for malaria, LF, and helminth antibody 
responses using the mean plus three standard deviations of a seronegative distribution 
estimated from the study measurements using finite Gaussian mixture models with two 
components (Benaglia et al., 2009).  
9.4.6 Statistical analysis 
Mean antibody levels (MFI-bg) were analyzed on the log10 scale due to skewness in their 
distribution. We estimated age-dependent mean antibody levels and seroprevalence for each 
study community using cross-validated, ensemble machine learning, with a library that 
included the simple mean, linear models, locally weighted regression (loess), and smoothing 
splines with 2 to 10 degrees of freedom, selected using 10-fold cross-validation (Arnold et al., 
2017). We estimated age-adjusted geometric mean antibody levels and seroprevalence for 
each community using targeted maximum likelihood estimation with influence curve-based 
standard errors (Arnold et al., 2017). In cases where seroprevalence approached zero, we 
estimated exact binomial confidence intervals. Analyses were conducted using R version 
3.3.1, and full replication files (data, scripts) are available through the Open Science 
Framework (https://osf.io/taknp).  
9.5 Results 
Antibody measurements were obtained from 2,837 individuals (range 271 – 297 per 
community) (Figure S 9.1). Antibody distributions varied by pathogen and antigen, and 
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overall there was good concordance between seropositivity cutoff values for malaria, LF and 
helminth antibody responses derived through ROC curve analysis or mean plus 3 standard 
deviation calculations and those derived by Gaussian mixture model analysis (Figure 9.1). 
We therefore relied on cutoff values derived from the Gaussian mixture model antibody 
responses for comparability to future studies that may not have access to positive and 
negative control specimens. Age-dependent patterns and community-level estimates of 
mean antibody levels and seroprevalence were highly consistent (Figure S 9.2, Figure S 9.3, 
Figure S 9.4, Figure S 9.5, Figure S 9.6), so we report results based on mean antibody levels 
in supporting information.  
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Figure 9.1 Distribution of quantitative antibody levels measured in 10 communities in Kenya’s 
coastal region, 2015. Antibody response measured in multiplex using median fluorescence 
units minus background (MFI-bg) on a Bio-Rad Bio-Plex platform. Seroprotection cut points 
for measles, diphtheria, and tetanus estimated using standard curve from WHO reference 
standards. Seropositive cut points for other antigens estimated using negative control serum 
samples (solid) and finite Gaussian mixture models (dashed). There was no negative control 
cut point determined for the P. falciparum CSP antigen. Table S 9.1 includes cutoff values. 
The script that created the figure is here: https://osf.io/d9jrc.  
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9.5.1 Antifilarial antibody measurements  
Individuals who tested positive for LF infection by ICT had higher mean levels of antibody 
responses against the 3 recombinant filarial antigens (Figure S 9.7). Antibody 
seroprevalence against all 3 recombinant filarial antigens were significantly higher in Ndau 
Island compared to other communities and the difference in seroprevalence in Ndau 
compared to other communities was greater among  persons less than 30 years old (Figure 
9.2). Antifilarial antibody responses against Bm14 antigen continued to increase with age in 
all communities. For Wb123, seroprevalence gradually increased with age in Ndau and 
increased from around the age of 30 - 35 years in Mwadimu community. Compared to the 
other communities, Jaribuni had slightly elevated mean antibody responses against Wb123 
and Bm33 antigens (p<0.0001), but not for Bm14 antigen (p=0.08). Amongst the youngest 
children, quantitative antibody levels differentiated communities more clearly than 
seroprevalence owing to high variability in seroprevalence estimates from the small sample 
sizes in the youngest age strata (Figure S 9.8). Elevated antibody levels among young 
children in Ndau, and possibly Jaribuni, were consistent with ongoing LF transmission. 
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Figure 9.2 Lymphatic filariasis antibody age-dependent seroprevalence and overall means, 
stratified by community in Kenya’s coastal region, 2015. Community-level mean 
seroprevalence is age-adjusted and error bars represent 95% confidence intervals. Figure S 
9.2 is an extended version of this figure that also includes quantitative antibody levels. The 
script that created this figure is here: https://osf.io/5zkxw.    
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9.5.2 Antibody responses to other parasite antigens 
Antibody responses to the P. falciparum CSP and MSP-119 antigens and to the P. malariae  
MSP-119 antigen increased with age in communities in Kilifi and Kwale counties, with higher 
seroprevalence in Jaribuni community compared to other communities in Kilifi (p<0.0001, 
Figure 9.3). Mean antibody responses against P. malariae MSP-119 antigen also increased 
with age and were highest in Jaribuni (p<0.0001), but very low in Ndau Island and Kipini 
communities (p<0.0001 for difference with other communities).  
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Figure 9.3 Malarial antibody age-dependent seroprevalence and overall means, stratified by 
community in Kenya’s coastal region, 2015. Community-level mean seroprevalence is age-
adjusted and error bars represent 95% confidence intervals. Figure S 9.3 is an extended 
version of this figure that also includes quantitative antibody levels. The script that created 
this figure is here: http://osf.io/kzfd3.  
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Antibody responses against Schistosoma mansoni Sm25 recombinant antigen were 
primarily detected in Kimorigo community, and the seroprevalence increased gradually with 
age, reaching a peak at around 25 years of age (Figure 9.4). However, although antibody 
responses to S. mansoni SEA antigen also increased with age in Kimorigo community and 
mean seroprevalance was higher, there were some responses against this antigen in many 
other communities.  
 
Figure 9.4 Schistosomiasis antibody age-dependent seroprevalence and overall means, 
stratified by community in Kenya’s coastal region, 2015. Community-level mean 
seroprevalence is age-adjusted and error bars represent 95% confidence intervals. Figure S 
9.4 is an extended version of this figure that also includes quantitative antibody levels. The 
script that created this figure is here: https://osf.io/tpcg7.  
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Steady increases in S. stercoralis NIE seroprevalence with age were observed and 
community level mean seroprevalence ranged between 3% and 26% (Figure 9.5). There was 
heterogeneity in age-dependent Ascaris Hb seroprevalence patterns across communities, 
with seroprevalence increasing with age in some communities and decreasing with age in 
others (Figure 9.5).  
 
Figure 9.5 Age-dependent seroprevalence and overall means for antibodies to S. stercoralis 
and A. lumbricoides, stratified by community in Kenya’s coastal region, 2015. Community-
level mean seroprevalence is age-adjusted and error bars represent 95% confidence 
intervals. Figure S 9.5 is an extended version of this figure that also includes quantitative 
antibody levels. The script that created this figure is here: https://osf.io/j7uxz.  
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9.5.3 Immune responses to vaccine preventable diseases 
Immune response against measles MV-N antigen increased with age, but two communities in 
Kwale County (Mirihini and Mwadimu) had <90% seroprotection (Figure 9.6). Immune 
responses to diphtheria toxoid were relatively higher among children, but waned slightly 
around the ages of 30-40 years before increasing slightly. Generally, diphtheria 
seroprotection ranged between 22-44% across communities, and partial protection (defined 
as responses of 0.01-0.099 IU/ml) ranged between 70-88% across communities. Immune 
responses against tetanus toxoid decreased by age in all communities until around 15 years 
when the levels increased again. Tetanus seroprotection was lower in all 3 communities in 
Kwale County.  
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Figure 9.6 Age-dependent seroprotection and overall seroprotection for measles, diphtheria, 
and tetanus stratified by community in Kenya’s coastal region, 2015. Community-level 
seroprotection is age-adjusted and error bars represent 95% confidence intervals. For 
diphtheria, we included separate community level estimates of seroprotection (MFI > 4393 
corresponding to 0.1 IU/ml) and partial protection (MFI > 183 corresponding to 0.01 IU/ml). 
Figure S 9.6 is an extended version of this figure that also includes quantitative antibody 
levels. The script that created this figure is here: https://osf.io/qrkhm.   
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9.6 Discussion 
Many established national parasitic disease control and elimination programs conduct routine 
surveillance to monitor and evaluate the impact of their targeted interventions. Epidemiologic 
surveillance systems that enable integrated surveillance and monitoring of co-endemic 
diseases and public health interventions could provide cost-effective synergy to support 
public health programs (Lammie et al., 2012). Antibodies can provide valuable information 
about past exposure to pathogens, and can be helpful for characterizing transmission 
dynamics in an area to help prioritize where and what interventions are needed the most 
(Lau et al., 2014a; Priest et al., 2016).   
The LF survey in coastal region of Kenya, which provided the opportunity to collect 
information for this study, demonstrated that Ndau Island in Lamu County had the highest 
prevalence of CFA by ICT (Njenga et al., 2017). The antifilarial antibody measurements 
assessed by MBAs closely aligned with the CFA results. Ndau Island had the highest levels 
of antibody responses to all three recombinant antifilarial antigens, which confirms the 
observation that LF transmission is currently higher in Ndau Island compared to the other 
communities. Previous studies have demonstrated a spatial relationship between antibody-
positive individuals and infected persons (Joseph et al., 2011). The high seroprevalence 
rates in Ndau, especially among children, are consistent with the conclusion that 
transmission is ongoing and not yet halted by the MDA campaign.  
Antibody responses against Bm14 antigen continued to increase with age in all 
villages, which may have been an indication of cumulative exposure to W. bancrofti, and also 
likely reflects historic transmission. Generally, antibody responses against the three 
recombinant filarial antigens were higher among with CFA-positive individuals than in CFA-
negative persons although the difference was relatively smaller for Bm33 (see Figure S 9.7). 
Results from a recent study in American Samoa demonstrated that PCR-positive pools of LF 
vector mosquitoes were statistically significant predictors of seropositivity for Wb123 but not 
Bm14, suggesting Wb123 could be an indicator of ongoing transmission (Lau et al., 2016). 
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Longitudinal studies in areas of intense LF transmission have shown that children acquire 
infections early in life (Lammie et al., 1998; Witt and Ottesen, 2001). Additionally, previous 
studies have demonstrated that antibody response against infective stage filarial larvae 
antigen Wb123 is a specific measure of Wuchereria bancrofti infection, and reduction in both 
antibody prevalence and transmission is seen most clearly in young children (Kubofcik et al., 
2012; Steel et al., 2012). Quantitative antifilarial antibody responses among youngest 
children (2-5 yr, 6-10 yr) provided much higher resolution distinctions between communities 
compared with seroprevalence using the same antigens or the ICT test (Figure S 9.8) – a 
result consistent with a recent analysis across diverse pathogens in low transmission settings 
where seropositive individuals are rare (Arnold et al., 2017). The higher resolution of 
quantitative antibody responses compared with seroprevalence, particularly when measured 
in small sampling clusters, suggests that quantitative antibody levels could serve as an 
important and more sensitive indicator of recent exposure in sentinel populations of young 
children, and may be valuable tool for surveillance in the context of lymphatic filariasis 
elimination programs (Hamlin et al., 2012). Thus, combined measurement of these markers 
may be suitable for characterization of LF transmission settings particularly towards the end 
of the program when the infection prevalence is very low.  
There was high heterogeneity in malaria seroprevalence among the study 
communities with Kwale and Kilifi counties generally showing relatively higher malaria 
transmission compared to the other 3 counties. The community mean seroprevalence values 
suggested that both P. falciparum and P. malariae transmission were highest in Jaribuni 
community in Kilifi County. These differences may reflect environmental heterogeneity in 
malaria larval breeding sites. A previous study in Kilifi and Kwale counties identified the 
primary vectors of malaria along the coast of Kenya to include Anopheles funestus and three 
members of the An. gambiae complex: An. gambiae s.s., An. arabiensis, and An. merus 
(Mbogo et al., 2003). The study also showed that relatively high malaria parasite prevalence 
can occur at low and even non-detectable levels of entomological inoculation rates (EIR), 
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suggesting that measurement of EIR may be a relatively insensitive indicator of malaria 
transmission in some settings. Although malaria parasite prevalence and/or EIR have 
traditionally been used for reporting malaria transmission intensity (Pothin et al., 2016), 
serological markers have increasingly been recognized as useful indicators for estimating 
malaria transmission intensity, which is key for assessing the impact of control interventions 
(Drakeley et al., 2005; Cook et al., 2010; Wong et al., 2014; Dewasurendra et al., 2017). 
Because of the longevity of the specific antibody response, seroprevalence reflects 
cumulative exposure and thus is less affected by seasonality or unstable transmission (Badu 
et al., 2012).  
In Kenya, Schistosoma haematobium is highly endemic along the coast where human 
exposure occurs primarily at pond and stream snail habitats (Clennon et al., 2004; Njenga et 
al., 2011b; Njaanake et al., 2016). The absence of S. mansoni from most of the Kenyan 
coastal region is attributable to the absence of the Biomphalaria spp. intermediate-host snails 
(Brown et al., 1981). In Mikinduni Community, along the lower Tana River, crude antigen 
SEA antibody responses were observed, but S. mansoni-specific Sm25 responses were 
lacking. In contrast, Taveta area in Taita-Taveta County is known to be endemic for both S. 
haematobium and S. mansoni infections (Thiongo and Ouma, 1987; Gouvras et al., 2013), 
and this is reflected in the high SEA and Sm25 antibody responses we observed in Kimorigo, 
a community located on the banks of the shallow freshwater Lake Jipe. The absence of S. 
mansoni species-specific antibody responses to Sm25 recombinant antigen in all of the 
communities except Kimorigo confirms that S. mansoni infection is likely absent from the 
lower coastal areas. Thus, S. mansoni Sm25 recombinant antigen seems to be an excellent 
antigen for measuring antibody responses to S. mansoni infection (Tsang et al., 1983), and 
SEA antigen likely detects antibody responses caused by both Schistosoma species by 
virtue of cross-reactivity.  
Presence of responses to S. stercoralis NIE antigen is noteworthy because there has 
been little information on the geographic distribution of this helminth in Kenya due to 
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diagnostic limitations. Copromicroscopic diagnostic methods commonly used in soil-
transmitted helminthiasis prevalence studies are inadequate for S. stercoralis detection 
(Steinmann et al., 2007), and thus its distribution in many areas is unknown. Concentration 
methods, namely the Baermann technique and Koga agar plate culture, have better but still 
unsatisfactory sensitivity (Glinz et al., 2010). A study employing NIE serology in Argentina 
found no cross-reactivity between S. stercoralis and infections with A. lumbricoides, 
hookworms, or H. nana, and the presence of other helminths in the stool did not affect the S. 
stercoralis-specific antibody responses (Krolewiecki et al., 2010). A study comparing five 
serologic tests identified NIE- Luciferase Immunoprecipitation System to be the most 
accurate assay for the diagnosis of S. stercoralis infection (Bisoffi et al., 2014). Previous 
studies using the recombinant NIE have documented high seroprevalence of S. stercoralis 
infection in remote Australian Indigenous communities and suggest that collection of dried 
blood spots may be a useful approach for field diagnosis of S. stercoralis seroprevalence 
(Mounsey et al., 2014; Kearns et al., 2017). This study, therefore, provides evidence for 
possible low-level transmission of S. stercoralis in coastal Kenya as the seroprevalence 
varies from community to community. Community mean antibody responses to the Ascaris 
Hb native antigen and seroprevalence exhibited high heterogeneity among the study 
communities. A population-based study in Indonesia has shown that an assay for antibodies 
to Ascaris Hb is useful for assessing transmission of Ascaris infections, and community 
antibody rates decreased rapidly following MDA of anthelmintic drugs. The decrease was 
also found to reflect reduced egg excretion at the community level (Vlaminck et al., 2016). 
Vaccination is one of the most one of the most cost-effective public health 
interventions available, and the epidemiology and burden of vaccine-preventable diseases 
vary by country and by region partly because of differences in vaccine uptake (Brenzel et al., 
2006). This multiplex integrated serosurveillance study identified heterogeneity in serologic 
antibody levels against measles, diphtheria, and tetanus antigens. Our study demonstrates a 
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need for regularly monitoring serological responses to vaccination programs in resource-poor 
settings where coverage may be low.  
Some of the limitations of this study are somewhat similar to those highlighted 
previously (Priest et al., 2016). Serological studies are traditionally faced with the challenge 
of establishing diagnostic cutoff points especially when well-characterized positive and 
negative serum samples are not available. Finite Gaussian mixture models applied in this 
study led to cutoff values that were very similar to those derived through ROC curves or from 
mean plus 3 standard deviation calculations for malaria, LF and helminth antibody responses 
(Figure 9.1). This result is consistent with a recent, multi-country comparison of cutoff 
methodology for trachoma antibodies (Migchelsen et al., 2017), and supports the use of finite 
mixture models to identify seropositivity cutoffs in studies without access to panels of known 
positive and negative specimens. For pathogens where cutoff values fall in the centre of a 
unimodal distribution and it is more difficult to distinguish seropositive and seronegative 
groups (e.g., A. suum Hb in Figure 9.1), the use of community mean antibody levels avoids 
the requirement of choosing a cutoff, and observed antibody response patterns were very 
consistent with seroprevalence estimates across all of the antibodies tested in this study 
(Figure S 9.2, Figure S 9.3, Figure S 9.4, Figure S 9.5, Figure S 9.6). Another limitation of 
this study is potential for antibody cross-reactivity. Since the coastal area has a typical 
tropical climate, it is likely that a plethora of pathogens are coincident, some with potentially 
cross-reactive antigens. A previous study reported that cross-reactivity of the Ascaris Hb 
native antigen with hookworm and possibly S. stercoralis and Toxocara spp. limited its value 
in serology if one is interested in ascariasis alone (Vlaminck et al., 2016). Thus, further 
studies are required to identify sensitive and specific recombinant antigens that could be 
used with more confidence in serological assays.   
In spite of these limitations this study employed a single multiplex integrated 
serological assay and analysis methodology to measure antibody levels against several 
pathogens. There was no need to run separate assays for each pathogen, and we did not 
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need to develop different mathematical models for each pathogen in order to compare 
exposure across communities and counties. The study highlighted overlap in pathogen 
burden that would not necessarily have been detected through single-disease surveillance. 
For example, Ndau Island was found to have the highest LF seroprevalence, but it also had 
highest Ascaris seroprevalence, thus supporting integrated control of these two helminths. 
Interestingly, Ndau had almost no evidence for P. falciparum malaria transmission. On the 
other hand Jaribuni community was found to stand out in terms of malaria, LF, and 
Strongyloides. Multiplex, integrated surveillance has the potential to enable us to look across 
diseases for opportunities for integrated control, thus providing synergy to global public 
health initiatives.  
9.7 Conclusion  
This study highlighted the utility of the MBA platform for integrated serosurveillance of 
biomarkers of diseases of public health importance. The multiplex integrated serologic assay 
has the potential to become an invaluable tool for integrated monitoring of trends in 
endemicity of diseases of public health importance and the effectiveness of public health 
control programs.  
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9.9 Supplemental Figures 
 
Figure S 9.1 Community-level sample size and age distribution. The script that created this 
figure is here: https://osf.io/7jxmn.  
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Figure S 9.2 Lymphatic filariasis antibody age-dependent mean response and seroprevalence, stratified by community in Kenya’s coastal region, 2015. Community-level mean antibody response and 
seroprevalence are age-adjusted and error bars represent 95% confidence intervals. Antibody response measured in median fluorescence units minus background (MFI-bg) on a Bio-Rad Bio-Plex platform. 
The script that created this figure is here: https://osf.io/c79rw.  
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Figure S 9.3 Malarial antibody age-dependent mean response and seroprevalence, stratified by community in Kenya’s coastal region, 2015. Community-level mean antibody response and seroprevalence 
are age-adjusted and error bars represent 95% confidence intervals. Antibody response measured in median fluorescence units minus background (MFI-bg) on a Bio-Rad Bio-Plex platform. The script that 
created this figure is here: https://osf.io/nhrc2.  
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Figure S 9.4 Schistosomiasis antibody age-dependent mean response and seroprevalence, stratified by community in Kenya’s coastal region, 2015. Community-level mean antibody response and 
seroprevalence are age-adjusted and error bars represent 95% confidence intervals. Antibody response measured in median fluorescence units minus background (MFI-bg) on a Bio-Rad Bio-Plex platform. 
The script that created this figure is here: https://osf.io/z8v4n.  
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Figure S 9.5 Age-dependent mean response and seroprevalence antibodies to S. stercoralis and A. lumbricoides, stratified by community in Kenya’s coastal region, 2015. Community-level mean antibody 
response and seroprevalence are age-adjusted and error bars represent 95% confidence intervals. Antibody response measured in median fluorescence units minus background (MFI-bg) on a Bio-Rad Bio-
Plex platform. The script that created this figure is here: https://osf.io/spnvx.  
  
9. Multiplex serologic testing in coastal Kenya 
__________________________________________________________________________ 
181 
  
 
F
ig
u
re
 S
 9
.6
 A
g
e
-d
e
p
e
n
d
e
n
t 
m
e
a
n
 r
e
s
p
o
n
s
e
 a
n
d
 s
e
ro
p
ro
te
c
ti
o
n
 f
o
r 
m
e
a
s
le
s
, 
d
ip
h
th
e
ri
a
, 
a
n
d
 t
e
ta
n
u
s
 s
tr
a
ti
fi
e
d
 b
y
 c
o
m
m
u
n
it
y
 
in
 K
e
n
ya
’s
 c
o
a
s
ta
l 
re
g
io
n
, 
2
0
1
5
. 
C
o
m
m
u
n
it
y
-l
e
v
e
l 
m
e
a
n
 a
n
ti
b
o
d
y
 r
e
s
p
o
n
s
e
 a
n
d
 s
e
ro
p
ro
te
c
ti
o
n
 a
re
 a
g
e
-a
d
ju
s
te
d
 a
n
d
 e
rr
o
r 
b
a
rs
 r
e
p
re
s
e
n
t 
9
5
%
 c
o
n
fi
d
e
n
c
e
 i
n
te
rv
a
ls
. 
A
n
ti
b
o
d
y
 r
e
s
p
o
n
s
e
 m
e
a
s
u
re
d
 i
n
 m
e
d
ia
n
 f
lu
o
re
s
c
e
n
c
e
 u
n
it
s
 m
in
u
s
 b
a
c
k
g
ro
u
n
d
 
(M
F
I-
b
g
) 
o
n
 a
 B
io
-R
a
d
 B
io
-P
le
x
 p
la
tf
o
rm
. 
T
h
e
 s
c
ri
p
t 
th
a
t 
c
re
a
te
d
 t
h
is
 f
ig
u
re
 i
s
 h
e
re
: 
h
tt
p
s
:/
/o
s
f.
io
/u
y
5
b
f.
 
Figure S 9.6 Age-dependent mean response and seroprotection for measles, diphtheria, and tetanus stratified by community in Kenya’s coastal region, 2015. Community-level mean antibody response and 
seroprotection are age-adjusted and error bars represent 95% confidence intervals. Antibody response measured in median fluorescence units minus background (MFI-bg) on a Bio-Rad Bio-Plex platform. 
The script that created this figure is here: https://osf.io/uy5bf.  
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Figure S 9.7 Distribution of three lymphatic filariasis antibodies, stratified by rapid antigen 
immunochromatographic card test (ICT) results. Boxes mark the median and interquartile 
range of the distributions. Antibody response measured in median fluorescence units minus 
background (MFI-bg) on a Bio-Rad Bio-Plex platform. Mann-Whitney U-test p < 0.0001 for 
differences in antibody responses between ICT negative and positive individuals. The script 
that created this figure is here: https://osf.io/k9tms.  
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Figure S 9.8 Community-level estimates of lymphatic filariasis seroprevalence and geometric 
mean antibody levels among children ages 2-5 and 6-10 years old. Child blood samples were 
tested by immunochromatographic card test (ICT) and three antigens (Wb123, Bm14, Bm33) 
measured in median fluorescence units minus background (MFI-bg) on multiplex Bio-Rad 
Bio-Plex platform. The mean number of specimens tested per community within each age 
stratum was 47 (median=47; interquartile range=39, 58; range 12, 70). 
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10 Discussion 
Prior to the start of GPELF, LF had been documented in 104 countries (Table 10.1) (Sasa, 
1976). LF disappeared in more than 30 countries, primarily as an indirect result of economic 
development, change in environmental conditions, and in a few cases by intentional 
treatment and control efforts. At the inception of GPELF, the number of LF-endemic countries 
has been reduced to 81 and subsequently, 9 more countries were determined to have no 
evidence of transmission. There is little debate that considerable progress has been made 
during the GPELF era from 2000 to 2016. The number of people at risk for infection was 
reduced from 1.4 billion in 2000 to 856.4 million in 2016, primarily through MDA programs 
(WHO, 2017c).By 2016, 20 of 72 LF-endemic countries no longer required MDA. Additionally, 
30 of the remaining 52 countries had scaled up MDA to 100% geographic coverage of the 
areas in need (Table 10.2) (WHO, 2017c). Much of the success can be attributed to the 
commitment of national governments and donors, but it is important to recognise that these 
accomplishments were facilitated by the existence of a well-defined M&E framework. With 
clear guidelines, national programmes are better able to plan activities to reach established 
targets and to measure the impact of these efforts. While it is important to recognise the 
progress of these programmes, it is critical to identify challenges and obstacles that may 
impede reaching the ultimate goal of global LF elimination. The majority of countries and sub-
national areas that lag behind are those that were anticipated to be the most difficult from the 
start of GPELF. These include areas affected by civil strife which prevents consistent 
implementation of programme activities, complex epidemiological settings where programme 
activities may need to be modified, and areas with persistent transmission despite multiple 
rounds of MDA. The recently endorsed IDA MDA regimen (WHO, 2017d) is an example of a 
new strategy that will likely play an important role in accelerating the progress of 
programmes. Results from clinical trials demonstrated superiority of IDA in sustaining 
clearance of MF over a 24-month period compared to the standard two-drug regimens 
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(Thomsen et al., 2016). However, in a programmatic context, it is impractical to identify all 
MF-positive individuals in order to monitor clearance of parasites. Furthermore, surveys that 
are designed to measure changes in MF prevalence require large sample sizes that are not 
feasible in most programme settings. It is important to understand if alternative indicators can 
be used that offer more programmatic feasibility. At present, it is unclear if CFA or antibody 
responses can be used to monitor the impact of IDA, but studies should be undertaken to 
determine if the current M&E framework needs to be adapted for monitoring the impact of 
IDA.  
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Table 10.1 Countries with clinical or parasitologic evidence of LF prior to GPELF 
Americas Africa Europe Asia Pacific 
Barbados Algeria 
Bosnia and 
Herzegovina Bangladesh American Samoa 
Brazil Benin Croatia Cambodia Australia 
Colombia* Burkina Faso Hungary China Cook Islands 
Costa Rica Cameroon Italy India Fiji 
Cuba Cape Verde Macedonia Indonesia French Polynesia 
Dominica* Chad Montenegro Japan Guam 
French Guyana Comores Serbia South Korea Kiribati 
Guadeloupe DR Congo Slovenia Laos Marianas 
Guatemala* Egypt Turkey Malaysia Marshall Islands 
Guyana Ethiopia  Maldives Nauru 
Martinique Gambia  Myanmar New Caledonia 
Mexico* Guinea  Nepal Niue 
Montserrat* Guinea Bissau  Philippines Palau 
Puerto Rico Ivory Coast  Singapore Papua New Guinea 
St. Kitts Kenya  Sri Lanka Pitcairn  
St. Lucia* Liberia  Thailand Samoa 
Surinam Madagascar  Timor Leste Solomon Islands 
Trinidad* Malawi  Vietnam Tokelau 
United States Mali   Tonga 
Venezuela Mauritius   Tuvalu 
Virgin Islands Mozambique   Vanuatu 
 Niger   Wallis and Futuna 
 Nigeria    
 Reunion    
 
Sao Tome and 
Principe    
 Senegal    
 Seychelles    
 Sierra Leone    
 Sudan    
 Tanzania    
 Tunisia    
 Uganda    
 Zambia    
 Zimbabwe    
*by clinical signs only 
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Table 10.2 Status of LF-endemic countries in 2016 
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As MDA begins to scale down in countries where programmes have successfully met 
established targets, robust strategies are needed to establish a surveillance baseline and to 
detect any possible recrudescence of infection as early as possible. Since most LF infections 
are asymptomatic and because of the long delay between infection and the appearance of 
clinical signs, it is not possible to rely on clinical indicators for surveillance. Therefore, all 
surveillance for LF must involve active detection of infection. The TAS, currently the only 
recommended activity during the post-MDA surveillance period, is statistically robust but is 
not powered to detect changes in CFA prevalence over time. Therefore, the results of TAS 2 
and TAS 3 fail to document trends of antigenaemia. Collecting additional evidence using 
alternative indicators may provide important information that can be used to strengthen 
monitoring during the surveillance period.  
As prevalence declines, it is no longer practical to rely on parasitological indicators, 
and the necessity to adapt to the changing needs of the programme becomes increasingly 
important. During the surveillance period it is critical to balance limited resources with 
practical solutions without compromising the integrity of the programme. Although the 
detection of CFA serves as a reasonable proxy for infection, antigenaemia becomes 
increasingly difficult to detect in populations during the post-MDA period (Gass et al., 2012). 
Evidence suggests that detection of antifilarial antibodies provides the earliest indicator of 
filarial exposure (Hamlin et al., 2012). Therefore, monitoring filarial exposure through the 
assessment of antibody responses may provide a useful signal for detecting potential 
recrudescence.  
At present, there are opportunities to refine the M&E framework to adapt to the complex 
and changing needs of GPELF. As programmes continue to make progress towards 
elimination endpoints, there is an urgent need to identify sensitive diagnostic tools and robust 
strategies that can be used to guide programmatic decision making. To address the existing 
needs, the overarching goal of this PhD thesis was to provide recommendations on best 
approaches for conducting surveillance for LF elimination programmes. The studies 
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conducted as part of this thesis were designed to elucidate the two interlinked objectives of 
determining 1) the utility of serologic tools during the post-MDA surveillance period; and 2) 
the utility of the TAS and other activities during the post-MDA surveillance period as 
platforms for integrated disease surveillance. The activities included in this body of work were 
undertaken in an effort to provide meaningful contribution to GPELF. The studies were 
conducted in a way that aligned with the guiding principles of Swiss Tropical and Public 
Health Institute (Swiss TPH) to achieve significant improvements of human health and well-
being through research that sought solutions through innovation, validation, and application. 
Table 10.3 summarises the main findings and contributions of this PhD thesis within the 
context of the Swiss TPH guiding principles. While the specific outcomes and limitations have 
been discussed in the respective chapters, a more comprehensive view shall be discussed in 
this final chapter.  
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Table 10.3 Overview of the contributions of the studies implemented in this PhD thesis 
categorized by the guiding principles of Swiss Tropical and Public Health Institute 
Chapter Title Innovation Validation Application 
3 
Assessment of 
lymphatic filariasis prior 
to restarting mass drug 
administration 
campaigns in coastal 
Kenya 
Described the 
challenge of using 
parasitologic 
indicators to 
determine LF 
programme endpoints 
and identified the 
need to identify 
alternative indicators 
Documented the need 
to resume MDA in 
some areas   
4 
Multiplex serologic 
assessment of 
schistosomiasis in 
western Kenya: 
antibody responses in 
preschool aged children 
as a measure of 
reduced transmission 
Utilised a multiplex 
bead assay (MBA) to 
demonstrate that 
sensitive serologic 
tools can be used to 
more accurately 
monitor the impact of 
schistosomiasis 
interventions 
Comparison of 
standard parasitologic 
methods and MBA 
over a 3-year period in 
a programmatic 
setting; documented 
high prevalence of 
schistosomiasis in pre-
school aged children 
Parasite-specific 
antibodies among 
children declined, 
demonstrating antibody 
responses can be used 
to measure the impact of 
MDA 
5 
Comparison of antigen 
and antibody responses 
in repeat lymphatic 
filariasis transmission 
assessment surveys in 
American Samoa 
Utilised antibody tools 
to determine LF 
transmission status 
Comparison of 
circulating filarial 
antigen (CFA) and 
antibody responses  
Antibody results led to 
the concern that focal 
areas of transmission 
existed; the same 
concern was not raised 
when examining CFA 
results alone 
6 
Use of antibody tools to 
provide serologic 
evidence of elimination 
of lymphatic filariasis in 
The Gambia 
Absence of antibody 
responses strongly 
suggests antibody 
responses will no longer 
be detectable in 
populations after 
transmission has been 
interrupted; contributed 
to documenting the 
elimination of LF in the 
country 
7 
Lymphatic filariasis 
elimination in American 
Samoa: evaluation of 
molecular 
xenomonitoring as a 
surveillance tool in the 
endgame 
Analysed relationship 
between presence of 
filarial DNA in 
mosquitoes and 
antibody responses in 
humans   
Responses to Wb123 
related to filarial DNA in 
mosquitoes suggesting 
that Wb123 can be used 
as a marker of 
transmission for 
surveillance 
8 
Partnering for impact: 
integrated transmission 
assessment surveys for 
lymphatic filariasis, soil 
transmitted helminths 
and malaria in Haiti 
Integrated malaria 
assessment into TAS 
Feasible to add 
malaria testing into 
existing LF programme 
platform 
TAS can be considered 
as a platform for 
integrated surveillance; 
the malaria programme 
in Haiti continues to use 
TAS as a platform  
9 
Multiplex serologic 
testing within a cross-
sectional lymphatic 
filariasis sentinel site 
survey in coastal Kenya 
reveals community-level 
differences in IgG 
antibody responses to 
parasitic diseases and 
vaccines 
Utilised a single blood 
sample from a single 
survey to assess 
antibody responses to 
multiple antigens of 
public health 
importance 
Utilising a multiplex 
approach allows the 
generation of more 
comprehensive 
assessment of disease 
burden compared to 
results from single-
disease surveillance 
Integrated 
serosurveillance could 
greatly facilitate 
prioritizing areas where 
interventions are most 
needed 
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10.1 Establishing the need for serologic tools for lymphatic filariasis programmes 
10.1.1 Determining lymphatic filariasis status in areas of complex epidemiology   
The global LF elimination strategy is predicated on the assumption that if antifilarial 
medicines are delivered consistently over a defined period of time, transmission will be 
reduced to a level at which it is no longer sustainable even in the absence of MDA. A clear 
threat to LF elimination is the inability to accurately assess if intervention is warranted. While 
the WHO-recommended programmatic steps are straightforward, there are settings where 
the standard methods cannot be applied as designed. In areas where W. bancrofti and L. loa 
are co-endemic, standard practice is to treat with albendazole only (Pion et al., 2017; WHO, 
2017d). Because of the risk of severe adverse events, ivermectin is administered only after 
individuals are tested for L. loa infection and confirmed to be eligible for treatment. This 
requires collecting blood at the appropriate time (10:00 to 14:00 hours) (Sasa, 1976) to rule 
out high L. loa MF density. Test-and-treat programmes are resource-intense and are difficult 
to implement, but this approach is recommended in filarial-endemic areas where there is risk 
of L. loa infection. The inability to include ivermectin as part of the LF MDA package, will 
likely prolong the time needed to reduce transmission below the target thresholds. Currently, 
there is a need to clearly map and define the geographic expanse of loiasis and LF, 
especially the areas where they overlap. One challenge in confirming the presence of LF is 
the apparent lack of specificity of CFA tests when L. loa is present (Wanji et al., 2015; Pion et 
al., 2016). Consequently, there is a critical need to identify an alternative test that can be 
used. While detection of MF is an option, low sensitivity of the method coupled with logistical 
constraints as well as the challenge in distinguishing species of MF make it a poor choice for 
an alternative platform. In principle, species-specific serologic tests for W. bancrofti and L. 
loa could be used to rule in or rule out areas for treatment and reduce the areas where 
expensive test and treat programmes are needed. Recently, the development of a highly 
specific recombinant antigen, Wb123, has been shown to be an early marker for W. bancrofti 
infection and may provide the ability to use antibody detection for mapping in L. loa areas.  
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10.1.2 Assessing programme outcomes in areas with irregular programme delivery  
In areas where LF programme implementation is not complicated by L. loa, a different 
challenge is introduced when the MDA strategy recommended by WHO is not followed as 
intended. When there is inconsistent implementation of interventions, it is difficult to discern 
the underlying reasons for unsuccessful programme outcomes. In some cases, irregular 
programme activities may be contributing to the inability to reduce transmission below 
established thresholds. There is evidence that missing a single annual cycle of MDA can 
reverse progress made to that point (Won et al., 2009). However, perhaps an issue of greater 
concern is the uncertainty around the apparent absence of transmission when MDA has not 
been consistently carried out. Since there are recognised risks associated with missing 
rounds of MDA, ensuring that all epidemiological targets have been met in these settings is 
paramount. As illustrated in our sentinel site surveys in Kenya (chapter 3), despite irregular 
implementation of MDA, transmission appeared to be below target thresholds in some areas. 
It is possible that widespread use of long-lasting insecticidal nets (LLIN) distributed primarily 
for malaria control may have provided ancillary benefit beyond their intended use. In 
principle, use of LLINs can reduce exposure to infective mosquito bites (Bockarie et al., 
2002; Pedersen and Mukoko, 2002; Odermatt et al., 2008), thus contributing to the reduction 
and possible interruption of LF transmission.   
In the surveys carried out in chapter 3, the absence of CFA among adults in in Kenya 
suggests transmission had been interrupted, but concerns were raised knowing that the 
sensitivity of the ICT may be inadequate in low prevalence settings (Gass et al., 2012). This 
highlights the potential challenge of using traditional parasitologic methods to determine 
programme endpoints. In a programmatic setting in Sri Lanka, despite meeting WHO-
established CFA targets among children and stopping MDA, there was evidence of 
transmission among older individuals that was supported by the detection of filarial DNA in 
mosquitoes (Rao et al., 2014). In this setting, CFA prevalence among schoolchildren was 
well below the threshold (<2%) considered necessary for sustainable transmission. However, 
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antibody prevalence was >5% in some schools, and elevated antibody levels were found in 
communities where parasite DNA was detected in mosquitoes. In this case, the use of an 
antibody indicator instead of an antigen indicator may have led to a decision to conduct 
targeted treatment or MDA. The ability to use a serologic indicator may provide the 
necessary evidence to definitively document the presence or absence of transmission. In 
Kenya, where no antigen- or MF-positive individuals were identified in some sentinel sites, 
absence of infection-specific antibody responses in children would strengthen the conclusion 
that interventions were not warranted. As described in chapter 9, quantitative antibody levels 
among children were higher in areas where CFA-positive adults were identified, whereas 
assessing transmission status using CFA results in children was less clear because so few 
children under 10 years of age were antigen-positive. The next step in Kenya will be to 
implement TAS in the areas where transmission appears to have been interrupted. Since 
CFA prevalence is expected to be very low, consideration should be given to including 
antibody testing at that time to ensure MDA is not warranted.  
10.2 Demonstrating the utility of antibody tools for neglected tropical disease 
programmes  
10.2.1 Advantages of serology compared to traditional diagnostic methods  
Currently, of the NTDs amenable to preventive chemotherapy, only onchocerciasis 
elimination programmes routinely use a serologic indicator to assess programme 
performance (WHO, 2016c). The other PC NTD programmes, including LF, face similar 
challenges in relying on parasitological or clinical indicators that are often insensitive and 
inadequate for use during the late stages of programmes. As prevalence declines, tools with 
greater sensitivity and specificity are needed to detect residual infections and will allow more 
conclusive demonstration that transmission has been interrupted. Additionally, more robust 
tools will provide early signals of any recrudescence that may arise during the surveillance 
period. As a result, there is increasing effort to investigate the use of more sensitive serologic 
tools for programme decision-making. For example, trachoma elimination programmes 
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currently rely on the use of a clinical indicator to determine the need for MDA. This requires 
expertise in examining eyelids for follicular inflammation caused by infection with Chlamydia 
trachomatis (Solomon et al., 2004). As prevalence declines, it becomes increasingly difficult 
for graders to maintain the skills needed to accurately identify disease-related pathology. 
Furthermore, it is possible for clinical signs of trachoma to persist after infection has cleared 
(Martin et al., 2015; Macleod et al., 2016; Butcher et al., 2018). Reliance on a non-specific 
clinical indicator may unnecessarily initiate or prolong MDA in areas where it is not needed. 
However, there is evidence that measuring antibody responses may provide a more objective 
way to assess the need for treatment. In Tanzania, children with more intense ocular 
pathology had higher antibody responses than others, and 44% of children with no apparent 
ocular pathology had antibody responses to trachoma antigens (Goodhew et al., 2012). 
Additionally, antibody responses appear to decline after treatment (Goodhew et al., 2014), 
providing opportunities to evaluate changes in antibody responses to monitor the impact of 
MDA. 
Similar deficiencies and needs exist for schistosomiasis control programmes. 
Currently, programmes are monitored primarily by assessing parasitological indicators. 
However, as prevalence declines, there are similar declines in sensitivity of diagnostic 
methods that are routinely used (Bergquist et al., 2009; Nikolay et al., 2014; Mwinzi et al., 
2015; Utzinger et al., 2015) making it arduous to monitor the impact of MDA. In chapter 4, 
our findings in western Kenya provide another example of the potential to use serologic 
responses to guide programme activities. In this setting, significant changes in antibody 
prevalence were observed among the youngest children, and suggest that exposure from 
infection with Schistosoma mansoni had been reduced. Although the children enrolled in the 
study were too young to be eligible for routine MDA programmes, they served as an 
appropriate age group to monitor for incident infections. Our results documented that MDA 
led to reduced parasite-specific antibodies among children, demonstrating the value of using 
serologic tools for surveillance as programmes reduce infection prevalence. Additionally, the 
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relative ease of collecting finger stick blood samples compared to the difficulty of collecting 
stool samples provides another reason to further explore the use of antibody tools, especially 
when testing young children. In the examples of schistosomiasis control and trachoma 
elimination, similarities across the programmes illustrate the limitations of traditionally used 
indicators and provide support for the general principle that sensitive serologic tools can be 
used to more accurately monitor the impact of interventions.  
10.2.2 Using serology to determine transmission status  
LF programmes also face similar challenges with available diagnostic tools that 
become much more apparent as prevalence declines. Although CFA is likely an appropriate 
indicator for making decisions to stop MDA through TAS, the inability to measure changes in 
antigen prevalence in subsequent TAS (TAS 2 and TAS 3) highlights the need to identify 
more sensitive diagnostic tools. Failing TAS conducted after stopping MDA presents 
significant challenges to national programmes as they are forced to mobilize resources to 
restart treatment. Since WHO guidance for surveillance does not exist beyond TAS 3, these 
surveys represent opportunities to collect information needed to detect ongoing transmission 
and to support the programmatic decision to re-start MDA, if needed. As presented in chapter 
5, in American Samoa, all antigen-positive children identified during TAS had detectable 
antibody responses to all three markers (Bm14, Bm33, and Wb123) used, but there were 
also antigen-negative children who had positive antibody responses. It is possible that 
antibody-positive children were born before transmission was interrupted and that positive 
results represented a slow rate of decay of residual antibodies; alternatively, these responses 
may reflect ongoing transmission. In areas endemic for W. bancrofti, there is evidence that 
responses to Bm14 decline slowly after treatment. In Egypt, asymptomatic microfilaraemic 
adults were tested for antibody responses to Bm14 after repeated annual treatment with DEC 
and albendazole. Antibody levels cleared in 20%, 35%, 39%, and 53% of individuals after 12, 
24, 36, and 48 months, respectively (Helmy et al., 2006). However, results from a separate 
study of children in Egypt showed that Bm14 responses among children had nearly cleared 
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after five rounds of MDA (Ramzy et al., 2006). Similar findings from children in Haiti support 
the observations from Egypt. Bm14 responses significantly declined after treatment with DEC 
or DEC + albendazole, whereas there was no significant change among children given a 
placebo (Moss et al., 2011).  
Although no MDA was ever conducted in The Gambia, our findings in chapter 6 
support the conclusion that antibody responses will no longer be detectable in populations 
after transmission has been interrupted. Responses to Bm14 were nearly absent among 
most age groups, suggesting LF transmission had stopped in The Gambia. However, we 
were unable to determine the exact timeframe when transmission had ceased. Since the only 
evidence of Bm14 positivity was among individuals aged 50 years and above, we assume 
transmission had been interrupted sometime after these individuals were born. Furthermore, 
the overall prevalence of positive Wb123 responses was low (1.5%), and there were no 
antibody-positive individuals identiﬁed in 7 of 15 villages.  While the absence of seropositive 
individuals in populations strongly suggests the absence of transmission, assessing antibody 
responses in adults may underestimate the impact of interventions as antibody responses 
may persist for years after transmission has been broken. The slow clearance of Bm14 
responses in adult populations has important implications with respect to the suitability of 
using this marker to monitor changes.   
Because Wb123 was first described in 2011, limited information exists on the 
characteristics of responses to this marker in programme settings. As observed in the Cook 
Islands, results from samples collected 17 years apart indicated a significant decrease in 
Wb123 antibody positivity, suggesting LF transmission had significantly decreased (Steel et 
al., 2012). While there is limited information about the persistence of Wb123 responses, it 
appears that individuals will serorevert after clearing infections. Ideally, antibody markers 
used for surveillance will appear soon after exposure to parasites and will decline quickly 
after infection clears. While there is still a need to better define relative rates of decay of 
Wb123 responses, our results in chapter 7 indicated a significant relationship between the 
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presence of filarial DNA in mosquitoes and villages with individuals with responses to 
Wb123. However, the same relationship was not observed between positive mosquitoes and 
Bm14-positive individuals. Thus, responses to Wb123 may be an indication of ongoing 
transmission. In chapter 9, Wb123 prevalence in Kenya was low in sites that had an absence 
of CFA-positive individuals. In contrast, in other sites, elevated antibody levels among 
children was consistent with evidence of ongoing transmission. Furthermore, although it was 
not possible to directly compare Wb123 results from TAS 1 and TAS 2 in American Samoa 
(chapter 5), the apparent increase in Wb123 positivity added to the concern that focal areas 
of transmission existed. The same concern was not raised when examining CFA results 
alone. In this setting, antibody responses in young children may have been an early warning 
signal that was not detected by CFA. This concern was substantiated when results from TAS 
3 conducted in 2016 indicated antigen prevalence was above the threshold at which 
transmission is sustainable. Regardless of whether the TAS 3 results represent premature 
stopping of MDA or a recrudescence of transmission, the effort to restart MDA will carry 
significant political and financial consequences. It is possible that this outcome could have 
been avoided if antibody responses were taken into consideration at the time of TAS 1 and 
TAS 2.  
Based on our results from The Gambia, Kenya, and American Samoa, there is likely a 
role for antibody tools during the surveillance period. In these settings, the absence of 
antibody responses strongly suggested interruption of transmission, and persistence of 
responses among children indicated potential risk of transmission. In all cases, antibody tools 
appeared to be more sensitive than antigen tools. Furthermore, if seroreversion can be 
expected after clearing infection, there are options to design surveillance strategies that 
incorporate serologic tools. Because seroreversion is expected to take a long time in adults, 
children may be the appropriate population to monitor during surveillance. However, it is 
important to note that the absence of seropositive adults is a strong indication, if not definitive 
evidence that transmission has been interrupted.  
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10.3 Platforms for integrated disease surveillance  
Although the focus of this thesis was concentrated primarily on LF, our results should be 
considered in a broader context and not just that of a single disease. Often, NTD and other 
public health programmes face significant resource constraints, especially during the 
surveillance period. Integration of surveillance activities may provide cost-effective 
approaches for monitoring multiple programmes, and our work in Haiti (chapter 8) and Kenya 
(chapter 9) highlighted the potential value of conducting integrated surveillance.  
The LF TAS represents one potential platform for integrated activities, and this is 
facilitated because these surveys are currently being implemented globally as part of a 
standardised WHO framework. The ability to leverage resources to conduct a single survey 
represents a responsible way for programmes to gather information needed for public health 
interventions. For example, in the Pacific Islands where populations are scattered across 
multiple islands, the cost and effort needed to reach these populations is significant. When 
activities are coordinated, there is the potential to reduce the number of visits required to 
specific communities. Furthermore, the ability to collect a single sample (e.g. blood) will not 
only reduce cost, but will also be less disruptive to the target population. 
WHO guidance already exists for including soil-transmitted helminthiasis (STH) 
assessments in TAS. Since albendazole is delivered as part of the LF MDA package and is 
also used by STH control programmes, multiple rounds of MDA have likely had an impact on 
the prevalence of STH infections. As successfully passing TAS results in stopping MDA, it is 
important to understand the burden of STH that remains. While coordinated LF and STH 
assessments provide useful programmatic information, there are some drawbacks to the co-
implementation of these surveys. The different sample types needed, blood versus stool, add 
complexity to the planning and logistics of the survey. More feasible opportunities may exist 
around the ability to use a single sample type. In Haiti (chapter 8), the common goal of 
elimination led to the natural collaboration of the LF and malaria programmes. By collecting a 
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single blood sample both programmes were able to leverage a single survey to collect 
information for both diseases.  
 Areas co-endemic for LF and onchocerciasis illustrate another example where 
integrated TAS may be advantageous. Since ivermectin is delivered through MDA by both 
programmes, the TAS presents an opportunity to assess the impact the interventions have 
had on both diseases. In principle, the ability to discriminate between onchocerciasis- and 
LF-specific antibody responses could enable programmes to design programme activities as 
appropriate. Additionally, historically, onchocerciasis control programmes focused treatment 
efforts primarily in areas of high transmission only. As a result, areas of low transmission 
have routinely been excluded from programmatic activities. However, some of these areas 
may have been inadvertently treated through the LF MDA. As the goal of onchocerciasis 
programmes has shifted from morbidity control to elimination of transmission, there is an 
urgent need to identify all areas that require treatment. The inclusion of onchocerciasis-
specific antibody tests in the TAS may provide insight into areas where the onchocerciasis 
status was previously unknown and may help to define the treatment requirements for these 
settings.  
 TAS represents just one opportunity to integrate programmatic assessments. While 
this platform should be considered for multi-disease activities, it is important to recognize that 
this structure is not permanent. As LF programmes continue to meet criteria to reach 
validation of elimination, fewer TAS will be conducted globally each year and will eventually 
stop altogether. As a result, LF programmes should begin to explore opportunities for 
integration with other public health programmes and systems. In Cambodia, a nationally 
representative survey to assess immunity to vaccine preventable diseases (VPD) was used 
as a platform to integrate serologic assessment of multiple diseases including LF (Priest et 
al., 2016). In chapter 9, samples collected in Kenya were tested by MBA for detection of 
antibodies against multiple antigens from several parasitic infections as well as markers for 
immunity to VPDs. While the multiplex technology that was used is unlikely to be feasible for 
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routine surveillance activities, our results demonstrated the value of integrating assessments 
for multiple diseases. Results from these types of activities could greatly facilitate prioritizing 
areas where interventions are most needed.  With the appropriate diagnostic tools, routine 
sample collection in public health activities could provide the access to populations that could 
be a surveillance platform for LF. For example, malaria indicator surveys or routine 
demographic health surveys are two existing platforms that provide access to representative 
populations.  
10.4 Future considerations and research needs 
The work presented in this thesis outlines the utility and potential value of using antibody 
tools when conducting surveillance for LF. However, some knowledge gaps were identified 
during the course of activities conducted to date. The following issues should be considered 
when planning and conducting future studies: 
 Kinetics of antibody responses - our results did not allow us to clearly define the 
kinetics of antibody responses. This will likely be important as programmes adopt the 
newly WHO-endorsed IDA strategy. At present, it is unclear if the standard CFA 
indicator used for TAS will be appropriate for decision-making in IDA settings, and 
there may be a role for antibody tools in this context. It is important to recognize that 
seroreversion will occur after transmission has been interrupted, but the rate at which 
this occurs is not well understood. To further refine recommendations for the use of 
antibody tools, future work should be conducted to characterize the rate at which 
antibody responses can be expected to decline in populations after MDA.  
 Relationship between antibody responses and other indicators - there is a need 
to clearly define the relationship between antibody responses in populations to other 
indicators including CFA, MF and filarial DNA in mosquitoes. This thesis has 
described the limitations of using parasitologic indicators when prevalence is low, so it 
is important to identify alternative indicators that can feasibly and reliably be used for 
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surveillance. It is unlikely that sustainable platforms can be built on the collection and 
testing of mosquitoes, so tools to assess infection in humans will be necessary.  
 Defining antibody thresholds for programme decision making - our results 
suggest that Wb123 may be a transmission marker, thus making this the ideal 
candidate for a surveillance tool. If the relationship between Wb123 prevalence and 
other indicators can be clearly defined, antibody thresholds can be established below 
which transmission in not expected to be sustainable.  
 Defining spatial distribution of antibody responses - although the TAS design is 
robust, there are known limitations when using cluster-based sampling for focal 
diseases. However, there may be opportunity to use spatial distribution of antibody 
responses to identify hotspots of transmission. Future research should include spatial 
analyses to understand if antibody responses can be used to define areas of risk.   
 Optimal diagnostic tool formats - in addition to identifying the appropriate 
indicator(s), it is important to consider the format and performance characteristics of 
the test(s) to be used. While the MBA platform presented in this thesis has provided 
examples of the value of its use, alternative platforms are needed to ensure 
programmatic feasibility across all settings. More field-friendly simplified platforms will 
likely be required. While there are some settings where laboratory-based tests like 
ELISA can be relatively easily incorporated, the availability of a sensitive and specific 
RDT will be important to support the programmes. The ability to generate 
recommendations at the point of contact not only assists the programme in timely 
decision-making, but also builds trust in the population as samples are not removed 
from communities with a significant time lapse before results are provided back to the 
community. As another research need, the ability to accurately define sensitivity and 
specificity of serologic assays can be challenging and is often limited by the 
availability of well-characterized panels of samples. Cutoff values are routinely 
determined using sera from infected individuals and presumed negative sera from 
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persons with no known exposure to LF. However, positive samples used to define the 
performance characteristics of assays are usually collected pre-MDA or during the 
period of intervention and may not necessarily represent the same antibody profiles 
as samples collected post-MDA. Efforts should be made to collect samples from the 
appropriate programmatic stage to validate diagnostic tools intended for that stage.   
 Identifying new markers of infection - there is opportunity to investigate new 
candidate antigens that can complement or replace existing tools. At a minimum, an 
additional tool could be used as a confirmatory test which would strengthen the basis 
on which decisions are made. Target product profiles will be needed to define the 
characteristics required of a confirmatory test, and consideration should be given to 
identify the most appropriate isotypes and isotype subclasses to use for surveillance. 
Previous assumptions have been made on the use of IgG4 as the most appropriate 
surveillance target. However, it known that IgG4 responses develop later than some 
other isotypes and IgG subclasses. In the surveillance period, it is important to use 
sensitive and specific tools that will provide the earliest detection of potential 
recrudescence.  
Addressing these limitations will help to define and refine optimal approaches for conducting 
LF surveillance. 
10.5 Policy implications  
To sustain progress that has been made to date and to reach the ultimate goal of LF 
elimination, it is imperative that the M&E framework be adapted to the changing needs of the 
LF elimination programme. It is important to recognise that investments in field and 
laboratory research over the years have supported the development and refinement of 
important programme policies and guidance since the start of GPELF (Weil et al., 1997; 
Gass et al., 2012; Chu et al., 2013; Weil et al., 2013; Gass et al., 2017; Lammie et al., 2017). 
Despite the limitations of our work, our findings can help to reshape and strengthen the 
existing M&E framework. Potential policy implications related to our results include:  
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 Recommendation to include antibody tools in existing programme activities 
(e.g. TAS) - our results demonstrated the value of using serologic tools for 
surveillance as programmes reduce infection prevalence. Sensitive serologic tools 
can be used to more accurately monitor the impact of interventions.  
 Recommendation to conduct integrated surveillance when feasible – our work 
in Haiti and Kenya illustrated the feasibility of utilising the LF programme platform to 
conduct integrated assessments, reducing the need to carry out single-disease 
surveillance activities.
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11 Conclusions 
Although there is a need to better understand existing limitations, our results support the use 
of antibody tools to determine the status of LF transmission and suggest that serologic tools 
can have a role in guiding programmatic decision making. Furthermore, existing LF 
programme activities can provide a platform to conduct integrated assessments. Specifically, 
the conclusions substantiated through the findings presented in this thesis are as follows: 
 As prevalence declines, using parasitologic indicators to determine LF programme 
endpoints becomes challenging and there is a need to identify alternative indicators to 
use during the surveillance period. 
 Antibodies to Schistosoma spp. antigens among children declined after MDA, 
demonstrating antibody responses can be used to measure the impact of treatment.  
 The absence of antibody responses in The Gambia strongly suggests LF 
transmission has been interrupted. 
 The presence of antibody responses among children in American Samoa led to the 
concern that focal areas of LF transmission existed; the concern was confirmed with a 
TAS 3 failure in 2016.   
 TAS can be considered as a platform for integrated surveillance; the malaria 
programme in Haiti continues to use TAS as a platform.  
 Antibody responses to Wb123 among adults in American Samoa related to the 
presence of filarial DNA in mosquitoes, suggesting that Wb123 can be used as a 
marker of transmission during the surveillance period. 
 It was feasible to add malaria testing to TAS in Haiti indicating that TAS can be 
considered a viable platform for integrated surveillance. 
 In Kenya, utilising a multiplex approach, antibody responses to 10 antigens 
representing six parasitic infections and 3 antigens to assess immunity to vaccine 
preventable diseases were generated from a single sample collected from each 
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participant; integrated serosurveillance could greatly facilitate prioritizing areas where 
public health interventions are most needed. 
12. References 
___________________________________________________________________________ 
207 
  
 
12 References 
Addiss, D. G., Dimock, K. A., Eberhard, M. L. & Lammie, P. J. 1995. Clinical, parasitologic, 
and immunologic observations of patients with hydrocele and elephantiasis in an area 
with endemic lymphatic filariasis. J Infect Dis, 171, 755-8. 
Addiss, D. G., Beach, M. J., Streit, T. G., Lutwick, S., LeConte, F. H., Lafontant, J. G., 
Hightower, A. W. & Lammie, P. J. 1997. Randomised placebo-controlled comparison 
of ivermectin and albendazole alone and in combination for Wuchereria bancrofti 
microfilaraemia in Haitian children. Lancet, 350, 480-4. 
Addiss, D. G. & Brady, M. A. 2007. Morbidity management in the Global Programme to 
Eliminate Lymphatic Filariasis: a review of the scientific literature. Filaria J, 6, 2. 
Addiss, D. G., Louis-Charles, J., Roberts, J., Leconte, F., Wendt, J. M., Milord, M. D., 
Lammie, P. J. & Dreyer, G. 2010. Feasibility and effectiveness of basic lymphedema 
management in Leogane, Haiti, an area endemic for bancroftian filariasis. PLoS Negl 
Trop Dis, 4, e668. 
Ali, P. O., Jeffs, S. A., Meadows, H. M., Hollyer, T., Owen, C. A., Abath, F. G., Allen, R., 
Hackett, F., Smithers, S. R. & Simpson, A. J. 1991. Structure of Sm25, an antigenic 
integral membrane glycoprotein of adult Schistosoma mansoni. Mol Biochem 
Parasitol, 45, 215-22. 
Amaral, F., Dreyer, G., Figueredo-Silva, J., Noroes, J., Cavalcanti, A., Samico, S. C., Santos, 
A. & Coutinho, A. 1994. Live adult worms detected by ultrasonography in human 
Bancroftian filariasis. Am J Trop Med Hyg, 50, 753-7. 
Arnold, B. F., Priest, J. W., Hamlin, K. L., Moss, D. M., Colford, J. M., Jr. & Lammie, P. J. 
2014. Serological measures of malaria transmission in Haiti: comparison of 
longitudinal and cross-sectional methods. PLoS One, 9, e93684. 
Arnold, B. F., van der Laan, M. J., Hubbard, A. E., Steel, C., Kubofcik, J., Hamlin, K. L., 
Moss, D. M., Nutman, T. B., Priest, J. W. & Lammie, P. J. 2017. Measuring changes 
in transmission of neglected tropical diseases, malaria, and enteric pathogens from 
quantitative antibody levels. PLoS Negl Trop Dis, 11, e0005616. 
Aziz, M. A., Diallo, S., Diop, I. M., Lariviere, M. & Porta, M. 1982. Efficacy and tolerance of 
ivermectin in human onchocerciasis. Lancet, 2, 171-3. 
Aziz, M. A. 1986. Chemotherapeutic approach to control of onchocerciasis. Rev Infect Dis, 8, 
500-4. 
Badu, K., Afrane, Y. A., Larbi, J., Stewart, V. A., Waitumbi, J., Angov, E., Ong'echa, J. M., 
Perkins, D. J., Zhou, G., Githeko, A. & Yan, G. 2012. Marked variation in MSP-119 
antibody responses to malaria in western Kenyan highlands. BMC Infect Dis, 12, 50. 
Baird, J. B., Charles, J. L., Streit, T. G., Roberts, J. M., Addiss, D. G. & Lammie, P. J. 2002. 
Reactivity to bacterial, fungal, and parasite antigens in patients with lymphedema and 
elephantiasis. Am J Trop Med Hyg, 66, 163-9. 
Ballou, W. R., Rothbard, J., Wirtz, R. A., Gordon, D. M., Williams, J. S., Gore, R. W., 
Schneider, I., Hollingdale, M. R., Beaudoin, R. L., Maloy, W. L. & et al. 1985. 
Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium 
falciparum. Science, 228, 996-9. 
Beach, M. J., Streit, T. G., Addiss, D. G., Prospere, R., Roberts, J. M. & Lammie, P. J. 1999. 
Assessment of combined ivermectin and albendazole for treatment of intestinal 
helminth and Wuchereria bancrofti infections in Haitian schoolchildren. Am J Trop 
Med Hyg, 60, 479-86. 
Beau de Rochars, M. V., Milord, M. D., St Jean, Y., Desormeaux, A. M., Dorvil, J. J., 
Lafontant, J. G., Addiss, D. G. & Streit, T. G. 2004. Geographic distribution of 
lymphatic filariasis in Haiti. Am J Trop Med Hyg, 71, 598-601. 
Benaglia, T., Chauveau, D., Hunter, D. & Young, D. 2009. mixtools: An R Package for 
Analyzing Mixture Models. 2009, 32, 29. 
12. References 
___________________________________________________________________________ 
208 
  
 
Benitez, A., Priest, J. W., Ehigiator, H. N., McNair, N. & Mead, J. R. 2011. Evaluation of DNA 
encoding acidic ribosomal protein P2 of Cryptosporidium parvum as a potential 
vaccine candidate for cryptosporidiosis. Vaccine, 29, 9239-45. 
Bentley, M., Christian, P., Cohen, B. & Heath, A. 2006. Report of a collaborative study to 
assess the suitability of a replacement for the 2nd international standard for anti-
measles serum. 
Bergquist, R., Johansen, M. V. & Utzinger, J. 2009. Diagnostic dilemmas in helminthology: 
what tools to use and when? Trends Parasitol, 25, 151-6. 
Betson, M., Sousa-Figueiredo, J. C., Rowell, C., Kabatereine, N. B. & Stothard, J. R. 2010. 
Intestinal schistosomiasis in mothers and young children in Uganda: investigation of 
field-applicable markers of bowel morbidity. Am J Trop Med Hyg, 83, 1048-55. 
Betson, M., Sousa-Figueiredo, J. C., Kabatereine, N. B. & Stothard, J. R. 2012. Use of fecal 
occult blood tests as epidemiologic indicators of morbidity associated with intestinal 
schistosomiasis during preventive chemotherapy in young children. Am J Trop Med 
Hyg, 87, 694-700. 
Bird, A. C., el-Sheikh, H., Anderson, J. & Fuglsang, H. 1980. Changes in visual function and 
in the posterior segment of the eye during treatment of onchocerciasis with 
diethylcarbamazine citrate. Br J Ophthalmol, 64, 191-200. 
Bisoffi, Z., Buonfrate, D., Sequi, M., Mejia, R., Cimino, R. O., Krolewiecki, A. J., Albonico, M., 
Gobbo, M., Bonafini, S., Angheben, A., Requena-Mendez, A., Munoz, J. & Nutman, 
T. B. 2014. Diagnostic accuracy of five serologic tests for Strongyloides stercoralis 
infection. PLoS Negl Trop Dis, 8, e2640. 
Bockarie, M. J., Alexander, N. D., Kazura, J. W., Bockarie, F., Griffin, L. & Alpers, M. P. 
2000. Treatment with ivermectin reduces the high prevalence of scabies in a village in 
Papua New Guinea. Acta Trop, 75, 127-30. 
Bockarie, M. J., Tavul, L., Kastens, W., Michael, E. & Kazura, J. W. 2002. Impact of 
untreated bednets on prevalence of Wuchereria bancrofti transmitted by Anopheles 
farauti in Papua New Guinea. Med Vet Entomol, 16, 116-9. 
Bockarie, M. J. 2007. Molecular xenomonitoring of lymphatic filariasis. Am J Trop Med Hyg, 
77, 591-2. 
Bockarie, M. J., Pedersen, E. M., White, G. B. & Michael, E. 2009. Role of vector control in 
the global program to eliminate lymphatic filariasis. Annu Rev Entomol, 54, 469-87. 
Bogh, C., Pedersen, E. M., Mukoko, D. A. & Ouma, J. H. 1998. Permethrin-impregnated 
bednet effects on resting and feeding behaviour of lymphatic filariasis vector 
mosquitoes in Kenya. Med Vet Entomol, 12, 52-9. 
Borrow, R., Balmer, P. & Roper, M. 2006. The immunological basis for immunization series 
Module 3: Tetanus - Update 2006. 
Boyd, A., Won, K. Y., McClintock, S. K., Donovan, C. V., Laney, S. J., Williams, S. A., Pilotte, 
N., Streit, T. G., Beau de Rochars, M. V. & Lammie, P. J. 2010. A community-based 
study of factors associated with continuing transmission of lymphatic filariasis in 
Leogane, Haiti. PLoS Negl Trop Dis, 4, e640. 
Brenzel, L., Wolfson, L. J., Fox-Rushby, J., Miller, M. & Halsey, N. A. 2006. Vaccine-
preventable Diseases. In: ND, JAMISON, D. T., BREMAN, J. G., MEASHAM, A. R., 
ALLEYNE, G., CLAESON, M., EVANS, D. B., JHA, P., MILLS, A. & MUSGROVE, P. 
(eds.) Disease Control Priorities in Developing Countries. Washington (DC). 
Brooker, S., Clements, A. C., Hotez, P. J., Hay, S. I., Tatem, A. J., Bundy, D. A. & Snow, R. 
W. 2006. The co-distribution of Plasmodium falciparum and hookworm among African 
schoolchildren. Malar J, 5, 99. 
Brown, D. S., Jelnes, J. E., Kinoti, G. K. & Ouma, J. 1981. Distribution in Kenya of 
intermediate hosts of Schistosoma. Trop Geogr Med, 33, 95-103. 
Brown, K. R., Ricci, F. M. & Ottesen, E. A. 2000. Ivermectin: effectiveness in lymphatic 
filariasis. Parasitology, 121 Suppl, S133-46. 
12. References 
___________________________________________________________________________ 
209 
  
 
Burri, H., Loutan, L., Kumaraswami, V. & Vijayasekaran, V. 1996. Skin changes in chronic 
lymphatic filariasis. Trans R Soc Trop Med Hyg, 90, 671-4. 
Butcher, R., Sokana, O., Jack, K., Sui, L., Russell, C., Last, A., Martin, D. L., Burton, M. J., 
Solomon, A. W., Mabey, D. C. W. & Roberts, C. H. 2018. Clinical signs of trachoma 
are prevalent among Solomon Islanders who have no persistent markers of prior 
infection with Chlamydia trachomatis. Wellcome Open Res, 3, 14. 
Campbell, W. C. 1982. Efficacy of the avermectins against filarial parasites: a short review. 
Vet Res Commun, 5, 251-62. 
Campello, T. R., Ferreira, R. S., Pires, M. L., De Melo, P. G., Albuquerque, R., Araujo, S. & 
Dreyer, G. 1993. A study of placentas from Wuchereria bancrofti microfilaraemic and 
amicrofilaraemic mothers. J Trop Med Hyg, 96, 251-5. 
Cano, J., Rebollo, M. P., Golding, N., Pullan, R. L., Crellen, T., Soler, A., Kelly-Hope, L. A., 
Lindsay, S. W., Hay, S. I., Bockarie, M. J. & Brooker, S. J. 2014. The global 
distribution and transmission limits of lymphatic filariasis: past and present. Parasit 
Vectors, 7, 466. 
Cao, W. C., Van der Ploeg, C. P., Plaisier, A. P., van der Sluijs, I. J. & Habbema, J. D. 1997. 
Ivermectin for the chemotherapy of bancroftian filariasis: a meta-analysis of the effect 
of single treatment. Trop Med Int Health, 2, 393-403. 
Carme, B., Boulesteix, J., Boutes, H. & Puruehnce, M. F. 1991. Five cases of encephalitis 
during treatment of loiasis with diethylcarbamazine. Am J Trop Med Hyg, 44, 684-90. 
Carter, C. E. & Colley, D. G. 1978. An electrophoretic analysis of Schistosoma mansoni 
soluble egg antigen preparation. J Parasitol, 64, 285-90. 
CDC 1993. Recommendations of the International Task Force for Disease Eradication. 
MMWR Recomm Rep, 42, 1-38. 
Ceesay, S. J., Casals-Pascual, C., Erskine, J., Anya, S. E., Duah, N. O., Fulford, A. J., 
Sesay, S. S., Abubakar, I., Dunyo, S., Sey, O., Palmer, A., Fofana, M., Corrah, T., 
Bojang, K. A., Whittle, H. C., Greenwood, B. M. & Conway, D. J. 2008. Changes in 
malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. 
Lancet, 372, 1545-54. 
Cham, M. K., D'Alessandro, U., Todd, J., Bennett, S., Fegan, G., Cham, B. A. & Greenwood, 
B. M. 1996. Implementing a nationwide insecticide-impregnated bednet programme in 
The Gambia. Health Policy Plan, 11, 292-8. 
Chambers, E. W., McClintock, S. K., Avery, M. F., King, J. D., Bradley, M. H., Schmaedick, 
M. A., Lammie, P. J. & Burkot, T. R. 2009. Xenomonitoring of Wuchereria bancrofti 
and Dirofilaria immitis infections in mosquitoes from American Samoa: trapping 
considerations and a comparison of polymerase chain reaction assays with 
dissection. Am J Trop Med Hyg, 80, 774-81. 
Chandrasena, T. G., Premaratna, R., Abeyewickrema, W. & de Silva, N. R. 2002. Evaluation 
of the ICT whole-blood antigen card test to detect infection due to Wuchereria 
bancrofti in Sri Lanka. Trans R Soc Trop Med Hyg, 96, 60-3. 
Chandrashekar, R., Curtis, K. C., Ramzy, R. M., Liftis, F., Li, B. W. & Weil, G. J. 1994. 
Molecular cloning of Brugia malayi antigens for diagnosis of lymphatic filariasis. Mol 
Biochem Parasitol, 64, 261-71. 
Chesnais, C. B., Awaca-Uvon, N. P., Bolay, F. K., Boussinesq, M., Fischer, P. U., Gankpala, 
L., Meite, A., Missamou, F., Pion, S. D. & Weil, G. J. 2017. A multi-center field study 
of two point-of-care tests for circulating Wuchereria bancrofti antigenemia in Africa. 
PLoS Negl Trop Dis, 11, e0005703. 
Chu, B. K., Deming, M., Biritwum, N. K., Bougma, W. R., Dorkenoo, A. M., El-Setouhy, M., 
Fischer, P. U., Gass, K., Gonzalez de Pena, M., Mercado-Hernandez, L., Kyelem, D., 
Lammie, P. J., Flueckiger, R. M., Mwingira, U. J., Noordin, R., Offei Owusu, I., 
Ottesen, E. A., Pavluck, A., Pilotte, N., Rao, R. U., Samarasekera, D., Schmaedick, 
M. A., Settinayake, S., Simonsen, P. E., Supali, T., Taleo, F., Torres, M., Weil, G. J. & 
Won, K. Y. 2013. Transmission assessment surveys (TAS) to define endpoints for 
12. References 
___________________________________________________________________________ 
210 
  
 
lymphatic filariasis mass drug administration: a multicenter evaluation. PLoS Negl 
Trop Dis, 7, e2584. 
Chu, B. K., Gass, K., Batcho, W., Ake, M., Dorkenoo, A. M., Adjinacou, E., Mafi & Addiss, D. 
G. 2014. Pilot assessment of soil-transmitted helminthiasis in the context of 
transmission assessment surveys for lymphatic filariasis in Benin and Tonga. PLoS 
Negl Trop Dis, 8, e2708. 
Clennon, J. A., King, C. H., Muchiri, E. M., Kariuki, H. C., Ouma, J. H., Mungai, P. & Kitron, 
U. 2004. Spatial patterns of urinary schistosomiasis infection in a highly endemic area 
of coastal Kenya. Am J Trop Med Hyg, 70, 443-8. 
Colley, D. G., Binder, S., Campbell, C., King, C. H., Tchuem Tchuente, L. A., N'Goran, E. K., 
Erko, B., Karanja, D. M., Kabatereine, N. B., van Lieshout, L. & Rathbun, S. 2013. A 
five-country evaluation of a point-of-care circulating cathodic antigen urine assay for 
the prevalence of Schistosoma mansoni. Am J Trop Med Hyg, 88, 426-32. 
Commerce, A. S. D. o. 2012. 2012 Statistical Yearbook  
Conteh, L., Engels, T. & Molyneux, D. H. 2010. Socioeconomic aspects of neglected tropical 
diseases. Lancet, 375, 239-47. 
Cook, J., Reid, H., Iavro, J., Kuwahata, M., Taleo, G., Clements, A., McCarthy, J., Vallely, A. 
& Drakeley, C. 2010. Using serological measures to monitor changes in malaria 
transmission in Vanuatu. Malar J, 9, 169. 
Corbel, V., N'Guessan, R., Brengues, C., Chandre, F., Djogbenou, L., Martin, T., Akogbeto, 
M., Hougard, J. M. & Rowland, M. 2007. Multiple insecticide resistance mechanisms 
in Anopheles gambiae and Culex quinquefasciatus from Benin, West Africa. Acta 
Trop, 101, 207-16. 
Coreil, J., Mayard, G., Louis-Charles, J. & Addiss, D. 1998. Filarial elephantiasis among 
Haitian women: social context and behavioural factors in treatment. Trop Med Int 
Health, 3, 467-73. 
Coutts, S. P., King, J. D., Pa'au, M., Fuimaono, S., Roth, J., King, M. R., Lammie, P. J., Lau, 
C. L. & Graves, P. M. 2017. Prevalence and risk factors associated with lymphatic 
filariasis in American Samoa after mass drug administration. Trop Med Health, 45, 22. 
DA, B. 1983. On the Variances of Asymptotically Normal Estimators from Complex Surveys. 
International Statstical Review, 51, 279-292. 
Dame, J. B., Williams, J. L., McCutchan, T. F., Weber, J. L., Wirtz, R. A., Hockmeyer, W. T., 
Maloy, W. L., Haynes, J. D., Schneider, I., Roberts, D. & et al. 1984. Structure of the 
gene encoding the immunodominant surface antigen on the sporozoite of the human 
malaria parasite Plasmodium falciparum. Science, 225, 593-9. 
Das, P. K., Manoharan, A., Srividya, A., Grenfell, B. T., Bundy, D. A. & Vanamail, P. 1990. 
Frequency distribution of Wuchereria bancrofti microfilariae in human populations and 
its relationships with age and sex. Parasitology, 101 Pt 3, 429-34. 
Davis, S. M., Wiegand, R. E., Mulama, F., Kareko, E. I., Harris, R., Ochola, E., Samuels, A. 
M., Rawago, F., Mwinzi, P. M., Fox, L. M., Odiere, M. R. & Won, K. Y. 2015. Morbidity 
Associated with Schistosomiasis Before and After Treatment in Young Children in 
Rusinga Island, Western Kenya. Am J Trop Med Hyg. 
de Souza, D. K., Ansumana, R., Sessay, S., Conteh, A., Koudou, B., Rebollo, M. P., Koroma, 
J., Boakye, D. A. & Bockarie, M. J. 2015. The impact of residual infections on 
Anopheles-transmitted Wuchereria bancrofti after multiple rounds of mass drug 
administration. Parasit Vectors, 8, 488. 
Dewasurendra, R. L., Dias, J. N., Sepulveda, N., Gunawardena, G. S., Chandrasekharan, N., 
Drakeley, C. & Karunaweera, N. D. 2017. Effectiveness of a serological tool to predict 
malaria transmission intensity in an elimination setting. BMC Infect Dis, 17, 49. 
Dewi, R. M., Tuti, S., Ganefa, S., Anwar, C., Larasati, R., Ariyanti, E., Herjati, H. & Brady, M. 
2015. Brugia Rapid antibody responses in communities of Indonesia in relation to the 
results of 'transmission assessment surveys' (TAS) for the lymphatic filariasis 
elimination program. Parasit Vectors, 8, 499. 
12. References 
___________________________________________________________________________ 
211 
  
 
Dissanayake, S., Xu, M. & Piessens, W. F. 1992. A cloned antigen for serological diagnosis 
of Wuchereria bancrofti microfilaremia with daytime blood samples. Mol Biochem 
Parasitol, 56, 269-77. 
Dissanayake, S., Xu, M., Nkenfou, C. & Piessens, W. F. 1993. Molecular cloning and 
serological characterization of a Brugia malayi pepsin inhibitor homolog. Mol Biochem 
Parasitol, 62, 143-6. 
Dissanayake, S. 2001. In Wuchereria bancrofti filariasis, asymptomatic microfilaraemia does 
not progress to amicrofilaraemic lymphatic disease. Int J Epidemiol, 30, 394-9. 
DoPTS, W. W. P. R. 2013. Pacific Programme to Eliminate Lymphatic Filariasis. 
Drabo, F., Ouedraogo, H., Bougma, R., Bougouma, C., Bamba, I., Zongo, D., Bagayan, M., 
Barrett, L., Yago-Wienne, F., Palmer, S., Chu, B., Toubali, E. & Zhang, Y. 2016. 
Successful Control of Soil-Transmitted Helminthiasis in School Age Children in 
Burkina Faso and an Example of Community-Based Assessment via Lymphatic 
Filariasis Transmission Assessment Survey. PLoS Negl Trop Dis, 10, e0004707. 
Drakeley, C. J., Corran, P. H., Coleman, P. G., Tongren, J. E., McDonald, S. L., Carneiro, I., 
Malima, R., Lusingu, J., Manjurano, A., Nkya, W. M., Lemnge, M. M., Cox, J., 
Reyburn, H. & Riley, E. M. 2005. Estimating medium- and long-term trends in malaria 
transmission by using serological markers of malaria exposure. Proc Natl Acad Sci U 
S A, 102, 5108-13. 
Dreyer, G., Amaral, F., Noroes, J. & Medeiros, Z. 1994. Ultrasonographic evidence for 
stability of adult worm location in bancroftian filariasis. Trans R Soc Trop Med Hyg, 
88, 558. 
Dreyer, G., Medeiros, Z., Netto, M. J., Leal, N. C., de Castro, L. G. & Piessens, W. F. 1999. 
Acute attacks in the extremities of persons living in an area endemic for bancroftian 
filariasis: differentiation of two syndromes. Trans R Soc Trop Med Hyg, 93, 413-7. 
Dreyer, G., Noroes, J., Figueredo-Silva, J. & Piessens, W. F. 2000. Pathogenesis of 
lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitol Today, 16, 
544-8. 
Dunyo, S. K., Nkrumah, F. K. & Simonsen, P. E. 2000. Single-dose treatment of Wuchereria 
bancrofti infections with ivermectin and albendazole alone or in combination: 
evaluation of the potential for control at 12 months after treatment. Trans R Soc Trop 
Med Hyg, 94, 437-43. 
Eberhard, M. L., Hitch, W. L., McNeeley, D. F. & Lammie, P. J. 1993. Transplacental 
transmission of Wuchereria bancrofti in Haitian women. J Parasitol, 79, 62-6. 
Eberhard, M. L., Hightower, A. W., Addiss, D. G. & Lammie, P. J. 1997. Clearance of 
Wuchereria bancrofti antigen after treatment with diethylcarbamazine or ivermectin. 
Am J Trop Med Hyg, 57, 483-6. 
Ekpo, U. F., Oluwole, A. S., Abe, E. M., Etta, H. E., Olamiju, F. & Mafiana, C. F. 2012. 
Schistosomiasis in infants and pre-school-aged children in sub-Saharan Africa: 
implication for control. Parasitology, 139, 835-41. 
el Serougi, A. O., Fekry, A. A., Farrag, A. M. & Saleh, W. A. 2000. Evaluation of the IgG4 in 
Egyptian bancroftian filariasis. J Egypt Soc Parasitol, 30, 59-67. 
El Setouhy, M., Ramzy, R. M., Ahmed, E. S., Kandil, A. M., Hussain, O., Farid, H. A., Helmy, 
H. & Weil, G. J. 2004. A randomized clinical trial comparing single- and multi-dose 
combination therapy with diethylcarbamazine and albendazole for treatment of 
bancroftian filariasis. Am J Trop Med Hyg, 70, 191-6. 
Elbadry, M. A., Al-Khedery, B., Tagliamonte, M. S., Yowell, C. A., Raccurt, C. P., Existe, A., 
Boncy, J., Weppelmann, T. A., Beau De Rochars, V. E., Lemoine, J. F., Okech, B. A. 
& Dame, J. B. 2015. High prevalence of asymptomatic malaria infections: a cross-
sectional study in rural areas in six departments in Haiti. Malar J, 14, 510. 
Engels, D. & Savioli, L. 2006. Reconsidering the underestimated burden caused by 
neglected tropical diseases. Trends Parasitol, 22, 363-6. 
12. References 
___________________________________________________________________________ 
212 
  
 
Estambale, B. B., Simonsen, P. E., Knight, R. & Bwayo, J. J. 1994. Bancroftian filariasis in 
Kwale District of Kenya. I. Clinical and parasitological survey in an endemic 
community. Ann Trop Med Parasitol, 88, 145-51. 
Esterre, P., Plichart, C., Huin-Blondey, M. O. & Nguyen, L. 2000. Role of streptococcal 
infection in the acute pathology of lymphatic filariasis. Parasite, 7, 91-4. 
Farid, H. A., Hammad, R. E., Hassan, M. M., Morsy, Z. S., Kamal, I. H., Weil, G. J. & Ramzy, 
R. M. 2001. Detection of Wuchereria bancrofti in mosquitoes by the polymerase chain 
reaction: a potentially useful tool for large-scale control programmes. Trans R Soc 
Trop Med Hyg, 95, 29-32. 
Farid, H. A., Morsy, Z. S., Helmy, H., Ramzy, R. M., El Setouhy, M. & Weil, G. J. 2007. A 
critical appraisal of molecular xenomonitoring as a tool for assessing progress toward 
elimination of Lymphatic Filariasis. Am J Trop Med Hyg, 77, 593-600. 
Faris, R., Hussain, O., El Setouhy, M., Ramzy, R. M. & Weil, G. J. 1998. Bancroftian filariasis 
in Egypt: visualization of adult worms and subclinical lymphatic pathology by scrotal 
ultrasound. Am J Trop Med Hyg, 59, 864-7. 
Fischer, P., Bonow, I., Supali, T., Ruckert, P. & Rahmah, N. 2005. Detection of filaria-specific 
IgG4 antibodies and filarial DNA, for the screening of blood spots for Brugia timori. 
Ann Trop Med Parasitol, 99, 53-60. 
Fischer, P., Erickson, S. M., Fischer, K., Fuchs, J. F., Rao, R. U., Christensen, B. M. & Weil, 
G. J. 2007. Persistence of Brugia malayi DNA in vector and non-vector mosquitoes: 
implications for xenomonitoring and transmission monitoring of lymphatic filariasis. 
Am J Trop Med Hyg, 76, 502-7. 
Foo, K. T., Blackstock, A. J., Ochola, E. A., Matete, D. O., Mwinzi, P. N., Montgomery, S. P., 
Karanja, D. M. & Secor, W. E. 2015. Evaluation of point-of-contact circulating 
cathodic antigen assays for the detection of Schistosoma mansoni infection in low-, 
moderate-, and high-prevalence schools in western Kenya. Am J Trop Med Hyg, 92, 
1227-32. 
Fox, L. M., Furness, B. W., Haser, J. K., Brissau, J. M., Louis-Charles, J., Wilson, S. F., 
Addiss, D. G., Lammie, P. J. & Beach, M. J. 2005. Ultrasonographic examination of 
Haitian children with lymphatic filariasis: a longitudinal assessment in the context of 
antifilarial drug treatment. Am J Trop Med Hyg, 72, 642-8. 
Gardon, J., Gardon-Wendel, N., Demanga, N., Kamgno, J., Chippaux, J. P. & Boussinesq, 
M. 1997. Serious reactions after mass treatment of onchocerciasis with ivermectin in 
an area endemic for Loa loa infection. Lancet, 350, 18-22. 
Gass, K., Beau de Rochars, M. V., Boakye, D., Bradley, M., Fischer, P. U., Gyapong, J., Itoh, 
M., Ituaso-Conway, N., Joseph, H., Kyelem, D., Laney, S. J., Legrand, A. M., 
Liyanage, T. S., Melrose, W., Mohammed, K., Pilotte, N., Ottesen, E. A., Plichart, C., 
Ramaiah, K., Rao, R. U., Talbot, J., Weil, G. J., Williams, S. A., Won, K. Y. & Lammie, 
P. 2012. A multicenter evaluation of diagnostic tools to define endpoints for programs 
to eliminate bancroftian filariasis. PLoS Negl Trop Dis, 6, e1479. 
Gass, K. M., Sime, H., Mwingira, U. J., Nshala, A., Chikawe, M., Pelletreau, S., Barbre, K. A., 
Deming, M. S. & Rebollo, M. P. 2017. The rationale and cost-effectiveness of a 
confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and 
Tanzania. PLoS Negl Trop Dis, 11, e0005944. 
GBD 2017. Global, regional, and national disability-adjusted life-years (DALYs) for 333 
diseases and injuries and healthy life expectancy (HALE) for 195 countries and 
territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 
2016. The Lancet, 390, 1260-1344. 
Glinz, D., Silué, K. D., Knopp, S., Lohourignon, L. K., Yao, K. P., Steinmann, P., Rinaldi, L., 
Cringoli, G., N'Goran, E. K. & Utzinger, J. 2010. Comparing diagnostic accuracy of 
Kato-Katz, Koga agar plate, ether-concentration, and FLOTAC for Schistosoma 
mansoni and soil-transmitted helminths. PLoS Negl Trop Dis, 4, e754. 
12. References 
___________________________________________________________________________ 
213 
  
 
Goodhew, E. B., Priest, J. W., Moss, D. M., Zhong, G., Munoz, B., Mkocha, H., Martin, D. L., 
West, S. K., Gaydos, C. & Lammie, P. J. 2012. CT694 and pgp3 as serological tools 
for monitoring trachoma programs. PLoS Negl Trop Dis, 6, e1873. 
Goodhew, E. B., Morgan, S. M., Switzer, A. J., Munoz, B., Dize, L., Gaydos, C., Mkocha, H., 
West, S. K., Wiegand, R. E., Lammie, P. J. & Martin, D. L. 2014. Longitudinal analysis 
of antibody responses to trachoma antigens before and after mass drug 
administration. BMC Infect Dis, 14, 216. 
Goodman, D. S., Orelus, J. N., Roberts, J. M., Lammie, P. J. & Streit, T. G. 2003. PCR and 
Mosquito dissection as tools to monitor filarial infection levels following mass 
treatment. Filaria J, 2, 11. 
Gounoue-Kamkumo, R., Nana-Djeunga, H. C., Bopda, J., Akame, J., Tarini, A. & Kamgno, J. 
2015. Loss of sensitivity of immunochromatographic test (ICT) for lymphatic filariasis 
diagnosis in low prevalence settings: consequence in the monitoring and evaluation 
procedures. BMC Infect Dis, 15, 579. 
Gouvras, A. N., Kariuki, C., Koukounari, A., Norton, A. J., Lange, C. N., Ireri, E., Fenwick, A., 
Mkoji, G. M. & Webster, J. P. 2013. The impact of single versus mixed Schistosoma 
haematobium and S. mansoni infections on morbidity profiles amongst school-
children in Taveta, Kenya. Acta Trop, 128, 309-17. 
Green, H. K., Sousa-Figueiredo, J. C., Basanez, M. G., Betson, M., Kabatereine, N. B., 
Fenwick, A. & Stothard, J. R. 2011. Anaemia in Ugandan preschool-aged children: 
the relative contribution of intestinal parasites and malaria. Parasitology, 138, 1534-
45. 
Gunawardena, S., Gunawardena, N. K., Kahathuduwa, G., Karunaweera, N. D., de Silva, N. 
R., Ranasinghe, U. B., Samarasekara, S. D., Nagodavithana, K. C., Rao, R. U., 
Rebollo, M. P. & Weil, G. J. 2014. Integrated school-based surveillance for soil-
transmitted helminth infections and lymphatic filariasis in Gampaha district, Sri Lanka. 
Am J Trop Med Hyg, 90, 661-6. 
Gyapong, J. O., Magnussen, P. & Binka, F. N. 1994. Parasitological and clinical aspects of 
bancroftian filariasis in Kassena-Nankana District, upper east region, Ghana. Trans R 
Soc Trop Med Hyg, 88, 555-7. 
Gyapong, J. O., Gyapong, M., Evans, D. B., Aikins, M. K. & Adjei, S. 1996. The economic 
burden of lymphatic filariasis in northern Ghana. Ann Trop Med Parasitol, 90, 39-48. 
Gyapong, J. O., Kumaraswami, V., Biswas, G. & Ottesen, E. A. 2005. Treatment strategies 
underpinning the global programme to eliminate lymphatic filariasis. Expert Opin 
Pharmacother, 6, 179-200. 
Hamlin, K. L., Moss, D. M., Priest, J. W., Roberts, J., Kubofcik, J., Gass, K., Streit, T. G., 
Nutman, T. B., Eberhard, M. L. & Lammie, P. J. 2012. Longitudinal monitoring of the 
development of antifilarial antibodies and acquisition of Wuchereria bancrofti in a 
highly endemic area of Haiti. PLoS Negl Trop Dis, 6, e1941. 
Handzel, T., Karanja, D. M., Addiss, D. G., Hightower, A. W., Rosen, D. H., Colley, D. G., 
Andove, J., Slutsker, L. & Secor, W. E. 2003. Geographic distribution of 
schistosomiasis and soil-transmitted helminths in Western Kenya: implications for 
anthelminthic mass treatment. Am J Trop Med Hyg, 69, 318-23. 
Hardy, M., Engelman, D. & Steer, A. 2017. Scabies: A clinical update. Aust Fam Physician, 
46, 264-268. 
Harris, J. R., Worrell, C. M., Davis, S. M., Odero, K., Mogeni, O. D., Deming, M. S., 
Mohammed, A., Montgomery, J. M., Njenga, S. M., Fox, L. M. & Addiss, D. G. 2015. 
Unprogrammed deworming in the Kibera slum, Nairobi: implications for control of soil-
transmitted helminthiases. PLoS Negl Trop Dis, 9, e0003590. 
Hati, A. K., Chandra, G., Bhattacharyya, A., Biswas, D., Chatterjee, K. K. & Dwibedi, H. N. 
1989. Annual transmission potential of bancroftian filariasis in an urban and a rural 
area of West Bengal, India. Am J Trop Med Hyg, 40, 365-7. 
12. References 
___________________________________________________________________________ 
214 
  
 
Hawking, F. 1977. The distribution of human filariasis throughout the world. Part III. Africa. 
Trop Dis Bull, 74, 649-79. 
Hawking, F. 1979. Diethylcarbamazine and new compounds for the treatment of filariasis. 
Adv Pharmacol Chemother, 16, 129-94. 
Health, G. o. K. M. o. 2002. Clinical Guidelines for Diagnosis and Treatment of Common 
Conditions in Kenya. The Regal Press Kenya Ltd. . 
Health, T. F. f. G. TAS STH Survey Sample Builder, version 1.51. 
Helmy, H., Weil, G. J., Ellethy, A. S., Ahmed, E. S., Setouhy, M. E. & Ramzy, R. M. 2006. 
Bancroftian filariasis: effect of repeated treatment with diethylcarbamazine and 
albendazole on microfilaraemia, antigenaemia and antifilarial antibodies. Trans R Soc 
Trop Med Hyg, 100, 656-62. 
Herricks, J. R., Hotez, P. J., Wanga, V., Coffeng, L. E., Haagsma, J. A., Basanez, M. G., 
Buckle, G., Budke, C. M., Carabin, H., Fevre, E. M., Furst, T., Halasa, Y. A., King, C. 
H., Murdoch, M. E., Ramaiah, K. D., Shepard, D. S., Stolk, W. A., Undurraga, E. A., 
Stanaway, J. D., Naghavi, M. & Murray, C. J. L. 2017. The global burden of disease 
study 2013: What does it mean for the NTDs? PLoS Negl Trop Dis, 11, e0005424. 
Hewitt, R. I., White, E. & et al. 1947. Experimental chemotherapy of filariasis; effect of 
piperazine derivatives against naturally acquired filarial infections in cotton rats and 
dogs. J Lab Clin Med, 32, 1304-13. 
Hitch, W. L., Lammie, P. J. & Eberhard, M. L. 1989. Heightened anti-filarial immune 
responsiveness in a Haitian pediatric population. Am J Trop Med Hyg, 41, 657-63. 
Hooper, P. J., Chu, B. K., Mikhailov, A., Ottesen, E. A. & Bradley, M. 2014. Assessing 
progress in reducing the at-risk population after 13 years of the global programme to 
eliminate lymphatic filariasis. PLoS Negl Trop Dis, 8, e3333. 
Horton, J., Witt, C., Ottesen, E. A., Lazdins, J. K., Addiss, D. G., Awadzi, K., Beach, M. J., 
Belizario, V. Y., Dunyo, S. K., Espinel, M., Gyapong, J. O., Hossain, M., Ismail, M. M., 
Jayakody, R. L., Lammie, P. J., Makunde, W., Richard-Lenoble, D., Selve, B., 
Shenoy, R. K., Simonsen, P. E., Wamae, C. N. & Weerasooriya, M. V. 2000. An 
analysis of the safety of the single dose, two drug regimens used in programmes to 
eliminate lymphatic filariasis. Parasitology, 121 Suppl, S147-60. 
Horton, J. 2000. Albendazole: a review of anthelmintic efficacy and safety in humans. 
Parasitology, 121 Suppl, S113-32. 
Hotez, P., Molyneux, D., Fenwick, A., Ottesen, E., Ehrlich Sachs, S. & Sachs, J. 2006a. 
Incorporating a rapid-impact package for neglected tropical diseases with programs 
for HIV/AIDS, tuberculosis, and malaria. PLoS Med, 3, e102. 
Hotez, P., Ottesen, E., Fenwick, A. & Molyneux, D. 2006b. The neglected tropical diseases: 
the ancient afflictions of stigma and poverty and the prospects for their control and 
elimination. Adv Exp Med Biol, 582, 23-33. 
Hotez, P. 2007. A new voice for the poor. PLoS Negl Trop Dis, 1, e77. 
Hotez, P. J., Fenwick, A., Savioli, L. & Molyneux, D. H. 2009. Rescuing the bottom billion 
through control of neglected tropical diseases. Lancet, 373, 1570-5. 
Hoti, S. L., Pani, S. P., Vanamail, P., Athisaya Mary, K., Das, L. K. & Das, P. K. 2010. Effect 
of a single dose of diethylcarbamazine, albendazole or both on the clearance of 
Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a 
randomized trial. Natl Med J India, 23, 72-6. 
Houweling, T. A., Karim-Kos, H. E., Kulik, M. C., Stolk, W. A., Haagsma, J. A., Lenk, E. J., 
Richardus, J. H. & de Vlas, S. J. 2016. Socioeconomic Inequalities in Neglected 
Tropical Diseases: A Systematic Review. PLoS Negl Trop Dis, 10, e0004546. 
Hummel, K. B., Erdman, D. D., Heath, J. & Bellini, W. J. 1992. Baculovirus expression of the 
nucleoprotein gene of measles virus and utility of the recombinant protein in 
diagnostic enzyme immunoassays. J Clin Microbiol, 30, 2874-80. 
Hürlimann, E., Yapi, R. B., Houngbedji, C. A., Schmidlin, T., Kouadio, B. A., Silué, K. D., 
Ouattara, M., N'Goran, E. K., Utzinger, J. & Raso, G. 2014. The epidemiology of 
12. References 
___________________________________________________________________________ 
215 
  
 
polyparasitism and implications for morbidity in two rural communities of Cote d'Ivoire. 
Parasit Vectors, 7, 81. 
Hussain, R., Hamilton, R. G., Kumaraswami, V., Adkinson, N. F., Jr. & Ottesen, E. A. 1981. 
IgE responses in human filariasis. I. Quantitation of filaria-specific IgE. J Immunol, 
127, 1623-9. 
Hussain, R. & Ottesen, E. A. 1985. IgE responses in human filariasis. III. Specificities of IgE 
and IgG antibodies compared by immunoblot analysis. J Immunol, 135, 1415-20. 
Hussain, R., Grogl, M. & Ottesen, E. A. 1987. IgG antibody subclasses in human filariasis. 
Differential subclass recognition of parasite antigens correlates with different clinical 
manifestations of infection. J Immunol, 139, 2794-8. 
Hussein, O., El Setouhy, M., Ahmed, E. S., Kandil, A. M., Ramzy, R. M., Helmy, H. & Weil, G. 
J. 2004. Duplex Doppler sonographic assessment of the effects of 
diethylcarbamazine and albendazole therapy on adult filarial worms and adjacent host 
tissues in Bancroftian filariasis. Am J Trop Med Hyg, 71, 471-7. 
Ichimori, K. & Crump, A. 2005. Pacific collaboration to eliminate lymphatic filariasis. Trends 
Parasitol, 21, 441-4. 
Ichimori, K., King, J. D., Engels, D., Yajima, A., Mikhailov, A., Lammie, P. & Ottesen, E. A. 
2014. Global programme to eliminate lymphatic filariasis: the processes underlying 
programme success. PLoS Negl Trop Dis, 8, e3328. 
Ismail, M. M., Jayakody, R. L., Weil, G. J., Nirmalan, N., Jayasinghe, K. S., Abeyewickrema, 
W., Rezvi Sheriff, M. H., Rajaratnam, H. N., Amarasekera, N., de Silva, D. C., 
Michalski, M. L. & Dissanaike, A. S. 1998. Efficacy of single dose combinations of 
albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian 
filariasis. Trans R Soc Trop Med Hyg, 92, 94-7. 
Ismail, M. M., Jayakody, R. L., Weil, G. J., Fernando, D., De Silva, M. S., De Silva, G. A. & 
Balasooriya, W. K. 2001. Long-term efficacy of single-dose combinations of 
albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian 
filariasis. Trans R Soc Trop Med Hyg, 95, 332-5. 
Jachowski, L. A., Jr. 1954. Filariasis in American Samoa. V. Bionomics of the principal 
vector, Aedes polynesiensis Marks. Am J Hyg, 60, 186-203. 
Joseph, H., Maiava, F., Naseri, T., Silva, U., Lammie, P. & Melrose, W. 2011. 
Epidemiological assessment of continuing transmission of lymphatic filariasis in 
Samoa. Ann Trop Med Parasitol, 105, 567-78. 
Jullien, P., Some, J., Brantus, P., Bougma, R. W., Bamba, I. & Kyelem, D. 2011. Efficacy of 
home-based lymphoedema management in reducing acute attacks in subjects with 
lymphatic filariasis in Burkina Faso. Acta Trop, 120 Suppl 1, S55-61. 
Kagan, I. G., Norman, L. & Allain, D. S. 1963. An Evaluation of the Bentonite Flocculation 
and Indirect Hemagglutination Tests for the Diagnosis of Filariasis. Am J Trop Med 
Hyg, 12, 548-55. 
Kagan, I. G. 1963. A Review of Immunologic Methods for the Diagnosis of Filariasis. J 
Parasitol, 49, 773-98. 
Kar, S. K., Dwibedi, B., Das, B. K., Agrawala, B. K., Ramachandran, C. P. & Horton, J. 2017. 
Lymphatic pathology in asymptomatic and symptomatic children with Wuchereria 
bancrofti infection in children from Odisha, India and its reversal with DEC and 
albendazole treatment. PLoS Negl Trop Dis, 11, e0005631. 
Kazura, J. W., Bockarie, M., Alexander, N., Perry, R., Bockarie, F., Dagoro, H., Dimber, Z., 
Hyun, P. & Alpers, M. P. 1997. Transmission intensity and its relationship to infection 
and disease due to Wuchereria bancrofti in Papua New Guinea. J Infect Dis, 176, 
242-6. 
Kearns, T. M., Currie, B. J., Cheng, A. C., McCarthy, J., Carapetis, J. R., Holt, D. C., Page, 
W., Shield, J., Gundjirryirr, R., Mulholland, E., Ward, L. & Andrews, R. M. 2017. 
Strongyloides seroprevalence before and after an ivermectin mass drug 
12. References 
___________________________________________________________________________ 
216 
  
 
administration in a remote Australian Aboriginal community. PLoS Negl Trop Dis, 11, 
e0005607. 
Keiser, J., N'Goran, E. K., Traore, M., Lohourignon, K. L., Singer, B. H., Lengeler, C., Tanner, 
M. & Utzinger, J. 2002. Polyparasitism with Schistosoma mansoni, geohelminths, and 
intestinal protozoa in rural Cote d'Ivoire. J Parasitol, 88, 461-6. 
Kelly-Hope, L. A., Molyneux, D. H. & Bockarie, M. J. 2013. Can malaria vector control 
accelerate the interruption of lymphatic filariasis transmission in Africa; capturing a 
window of opportunity? Parasit Vectors, 6, 39. 
Khieu, V., Or, V., Tep, C., Odermatt, P., Tsuyuoka, R., Char, M. C., Brady, M. A., Sidwell, J., 
Yajima, A., Huy, R., Ramaiah, K. D. & Muth, S. 2018. How elimination of lymphatic 
filariasis as a public health problem in the Kingdom of Cambodia was achieved. Infect 
Dis Poverty, 7, 15. 
Kimura, E. & Mataika, J. U. 1996. Control of lymphatic filariasis by annual single-dose 
diethylcarbamazine treatments. Parasitol Today, 12, 240-4. 
King, C. H. & Dangerfield-Cha, M. 2008. The unacknowledged impact of chronic 
schistosomiasis. Chronic Illn, 4, 65-79. 
King, C. H. 2015. It's time to dispel the myth of "asymptomatic" schistosomiasis. PLoS Negl 
Trop Dis, 9, e0003504. 
King, J. D., Zielinski-Gutierrez, E., Pa'au, M. & Lammie, P. 2011. Improving community 
participation to eliminate lymphatic filariasis in American Samoa. Acta Trop, 120 
Suppl 1, S48-54. 
Kircik, L. H., Del Rosso, J. Q., Layton, A. M. & Schauber, J. 2016. Over 25 Years of Clinical 
Experience With Ivermectin: An Overview of Safety for an Increasing Number of 
Indications. J Drugs Dermatol, 15, 325-32. 
Knight, R. 1980. Current status of filarial infections in The Gambia. Ann Trop Med Parasitol, 
74, 63-8. 
Korn EL, G. B. 1998. Confidence Intervals For Proportions With Small Expected Number of 
Positive Counts Estimated From Survey Data. Survey Methodology, 193-201. 
Kristiansen, M., Aggerbeck, H. & Heron, I. 1997. Improved ELISA for determination of anti-
diphtheria and/or anti-tetanus antitoxin antibodies in sera. APMIS, 105, 843-53. 
Krolewiecki, A. J., Ramanathan, R., Fink, V., McAuliffe, I., Cajal, S. P., Won, K., Juarez, M., 
Di Paolo, A., Tapia, L., Acosta, N., Lee, R., Lammie, P., Abraham, D. & Nutman, T. B. 
2010. Improved diagnosis of Strongyloides stercoralis using recombinant antigen-
based serologies in a community-wide study in northern Argentina. Clin Vaccine 
Immunol, 17, 1624-30. 
Kubofcik, J., Fink, D. L. & Nutman, T. B. 2012. Identification of Wb123 as an early and 
specific marker of Wuchereria bancrofti infection. PLoS Negl Trop Dis, 6, e1930. 
Kurniawan, A., Yazdanbakhsh, M., van Ree, R., Aalberse, R., Selkirk, M. E., Partono, F. & 
Maizels, R. M. 1993. Differential expression of IgE and IgG4 specific antibody 
responses in asymptomatic and chronic human filariasis. J Immunol, 150, 3941-50. 
Kwan-Lim, G. E., Forsyth, K. P. & Maizels, R. M. 1990. Filarial-specific IgG4 response 
correlates with active Wuchereria bancrofti infection. J Immunol, 145, 4298-305. 
Lammie, P. J., Hitch, W. L., Walker Allen, E. M., Hightower, W. & Eberhard, M. L. 1991. 
Maternal filarial infection as risk factor for infection in children. Lancet, 337, 1005-6. 
Lammie, P. J., Addiss, D. G., Leonard, G., Hightower, A. W. & Eberhard, M. L. 1993. 
Heterogeneity in filarial-specific immune responsiveness among patients with 
lymphatic obstruction. J Infect Dis, 167, 1178-83. 
Lammie, P. J., Hightower, A. W. & Eberhard, M. L. 1994. Age-specific prevalence of 
antigenemia in a Wuchereria bancrofti-exposed population. Am J Trop Med Hyg, 51, 
348-55. 
Lammie, P. J., Reiss, M. D., Dimock, K. A., Streit, T. G., Roberts, J. M. & Eberhard, M. L. 
1998. Longitudinal analysis of the development of filarial infection and antifilarial 
immunity in a cohort of Haitian children. Am J Trop Med Hyg, 59, 217-21. 
12. References 
___________________________________________________________________________ 
217 
  
 
Lammie, P. J., Weil, G., Noordin, R., Kaliraj, P., Steel, C., Goodman, D., Lakshmikanthan, V. 
B. & Ottesen, E. 2004. Recombinant antigen-based antibody assays for the diagnosis 
and surveillance of lymphatic filariasis - a multicenter trial. Filaria J, 3, 9. 
Lammie, P. J., Moss, D. M., Brook Goodhew, E., Hamlin, K., Krolewiecki, A., West, S. K. & 
Priest, J. W. 2012. Development of a new platform for neglected tropical disease 
surveillance. Int J Parasitol, 42, 797-800. 
Lammie, P. J., Eberhard, M. L., Addiss, D. G., Won, K. Y., Beau de Rochars, M., Direny, A. 
N., Milord, M. D., Lafontant, J. G. & Streit, T. G. 2017. Translating Research into 
Reality: Elimination of Lymphatic Filariasis from Haiti. Am J Trop Med Hyg, 97, 71-75. 
Laney, S. J., Buttaro, C. J., Visconti, S., Pilotte, N., Ramzy, R. M., Weil, G. J. & Williams, S. 
A. 2008. A reverse transcriptase-PCR assay for detecting filarial infective larvae in 
mosquitoes. PLoS Negl Trop Dis, 2, e251. 
Laney, S. J., Ramzy, R. M., Helmy, H. H., Farid, H. A., Ashour, A. A., Weil, G. J. & Williams, 
S. A. 2010. Detection of Wuchereria bancrofti L3 larvae in mosquitoes: a reverse 
transcriptase PCR assay evaluating infection and infectivity. PLoS Negl Trop Dis, 4, 
e602. 
Lau, C. L., Clements, A. C., Skelly, C., Dobson, A. J., Smythe, L. D. & Weinstein, P. 2012a. 
Leptospirosis in American Samoa--estimating and mapping risk using environmental 
data. PLoS Negl Trop Dis, 6, e1669. 
Lau, C. L., Dobson, A. J., Smythe, L. D., Fearnley, E. J., Skelly, C., Clements, A. C., Craig, 
S. B., Fuimaono, S. D. & Weinstein, P. 2012b. Leptospirosis in American Samoa 
2010: epidemiology, environmental drivers, and the management of emergence. Am 
J Trop Med Hyg, 86, 309-19. 
Lau, C. L., Won, K. Y., Becker, L., Soares Magalhaes, R. J., Fuimaono, S., Melrose, W., 
Lammie, P. J. & Graves, P. M. 2014a. Seroprevalence and spatial epidemiology of 
Lymphatic Filariasis in American Samoa after successful mass drug administration. 
PLoS Negl Trop Dis, 8, e3297. 
Lau, C. L., Won, K. Y., Becker, L., Soares Magalhaes, R. J., Fuimaono, S., Melrose, W., 
Lammie, P. J. & Graves, P. M. 2014b. Seroprevalence and spatial epidemiology of 
Lymphatic Filariasis inAmerican Samoa after successful mass drug administration. 
PLoS Negl Trop Dis, 8, e3297. 
Lau, C. L., Won, K. Y., Lammie, P. J. & Graves, P. M. 2016. Lymphatic Filariasis Elimination 
in American Samoa: Evaluation of Molecular Xenomonitoring as a Surveillance Tool 
in the Endgame. PLoS Negl Trop Dis, 10, e0005108. 
Lau, C. L., Sheridan, S., Ryan, S., Roineau, M., Andreosso, A., Fuimaono, S., Tufa, J. & 
Graves, P. M. 2017. Detecting and confirming residual hotspots of lymphatic filariasis 
transmission in American Samoa 8 years after stopping mass drug administration. 
PLoS Negl Trop Dis, 11, e0005914. 
Lemoine, J. F., Desormeaux, A. M., Monestime, F., Fayette, C. R., Desir, L., Direny, A. N., 
Carciunoiu, S., Miller, L., Knipes, A., Lammie, P., Smith, P., Stockton, M., 
Trofimovich, L., Bhandari, K., Reithinger, R., Crowley, K., Ottesen, E. & Baker, M. 
2016. Controlling Neglected Tropical Diseases (NTDs) in Haiti: Implementation 
Strategies and Evidence of Their Success. PLoS Negl Trop Dis, 10, e0004954. 
Liang, J. L., King, J. D., Ichimori, K., Handzel, T., Pa'au, M. & Lammie, P. J. 2008. Impact of 
five annual rounds of mass drug administration with diethylcarbamazine and 
albendazole on Wuchereria bancrofti infection in American Samoa. Am J Trop Med 
Hyg, 78, 924-8. 
Lim, K. H., Speare, R., Thomas, G. & Graves, P. 2015. Surgical Treatment of Genital 
Manifestations of Lymphatic Filariasis: A Systematic Review. World J Surg, 39, 2885-
99. 
Lindblade, K. A., Gimnig, J. E., Kamau, L., Hawley, W. A., Odhiambo, F., Olang, G., Ter 
Kuile, F. O., Vulule, J. M. & Slutsker, L. 2006. Impact of sustained use of insecticide-
12. References 
___________________________________________________________________________ 
218 
  
 
treated bednets on malaria vector species distribution and culicine mosquitoes. J Med 
Entomol, 43, 428-32. 
Lindblade, K. A., Steinhardt, L., Samuels, A., Kachur, S. P. & Slutsker, L. 2013. The silent 
threat: asymptomatic parasitemia and malaria transmission. Expert Rev Anti Infect 
Ther, 11, 623-39. 
Lizotte, M. R., Supali, T., Partono, F. & Williams, S. A. 1994. A polymerase chain reaction 
assay for the detection of Brugia malayi in blood. Am J Trop Med Hyg, 51, 314-21. 
Lucchi, N. W., Karell, M. A., Journel, I., Rogier, E., Goldman, I., Ljolje, D., Huber, C., Mace, 
K. E., Jean, S. E., Akom, E. E., Oscar, R., Buteau, J., Boncy, J., Barnwell, J. W. & 
Udhayakumar, V. 2014. PET-PCR method for the molecular detection of malaria 
parasites in a national malaria surveillance study in Haiti, 2011. Malar J, 13, 462. 
Lumley, T. 2004. Analysis of Complex Survey Samples. 2004, 9, 19. 
Lumley, T., Scott, A. J 2013. Two-sample rank tests under complex sampling. Biometrika, 
100, 831-842. 
Macleod, C. K., Butcher, R., Mudaliar, U., Natutusau, K., Pavluck, A. L., Willis, R., Alexander, 
N., Mabey, D. C., Cikamatana, L., Kama, M., Rafai, E., Roberts, C. H. & Solomon, A. 
W. 2016. Low Prevalence of Ocular Chlamydia trachomatis Infection and Active 
Trachoma in the Western Division of Fiji. PLoS Negl Trop Dis, 10, e0004798. 
Madinga, J., Polman, K., Kanobana, K., van Lieshout, L., Brienen, E., Praet, N., Kabwe, C., 
Gabriel, S., Dorny, P., Lutumba, P. & Speybroeck, N. 2017. Epidemiology of 
polyparasitism with Taenia solium, schistosomes and soil-transmitted helminths in the 
co-endemic village of Malanga, Democratic Republic of Congo. Acta Trop, 171, 186-
193. 
Magalhaes, R. J. & Clements, A. C. 2011. Mapping the risk of anaemia in preschool-age 
children: the contribution of malnutrition, malaria, and helminth infections in West 
Africa. PLoS Med, 8, e1000438. 
Maizels, R. M., Sutanto, I., Gomez-Priego, A., Lillywhite, J. & Denham, D. A. 1985. Specificity 
of surface molecules of adult Brugia parasites: cross-reactivity with antibody from 
Wuchereria, Onchocerca and other human filarial infections. Trop Med Parasitol, 36, 
233-7. 
Mand, S., Debrah, A. Y., Klarmann, U., Mante, S., Kwarteng, A., Batsa, L., Marfo-Debrekyei, 
Y., Adjei, O. & Hoerauf, A. 2011. The role of ultrasonography in the differentiation of 
the various types of filaricele due to bancroftian filariasis. Acta Trop, 120 Suppl 1, 
S23-32. 
Mand, S., Debrah, A. Y., Klarmann, U., Batsa, L., Marfo-Debrekyei, Y., Kwarteng, A., Specht, 
S., Belda-Domene, A., Fimmers, R., Taylor, M., Adjei, O. & Hoerauf, A. 2012. 
Doxycycline improves filarial lymphedema independent of active filarial infection: a 
randomized controlled trial. Clin Infect Dis, 55, 621-30. 
Martin, D. L., Wiegand, R., Goodhew, B., Lammie, P., Black, C. M., West, S., Gaydos, C. A., 
Dize, L., Mkocha, H., Kasubi, M. & Gambhir, M. 2015. Serological Measures of 
Trachoma Transmission Intensity. Scientific Reports, 5, 18532. 
Mbogo, C. M., Mwangangi, J. M., Nzovu, J., Gu, W., Yan, G., Gunter, J. T., Swalm, C., 
Keating, J., Regens, J. L., Shililu, J. I., Githure, J. I. & Beier, J. C. 2003. Spatial and 
temporal heterogeneity of Anopheles mosquitoes and Plasmodium falciparum 
transmission along the Kenyan coast. Am J Trop Med Hyg, 68, 734-42. 
McFadzean, J. 1954. Filariasis in Gambla and Casamance, West Africa. Trans R Soc Trop 
Med Hyg, 48, 267-73. 
McGregor, I. A., Hawking, F. & Smith, D. A. 1952. The control of filariasis with hetrazan; a 
field trial in a rural village (Keneba) in the Gambia. Br Med J, 2, 908-11. 
McMahon, J. E., Marshall, T. F., Vaughan, J. P. & Abaru, D. E. 1979. Bancroftian filariasis: a 
comparison of microfilariae counting techniques using counting chamber, standard 
slide and membrane (nuclepore) filtration. Ann Trop Med Parasitol, 73, 457-64. 
12. References 
___________________________________________________________________________ 
219 
  
 
McPherson, T., Persaud, S., Singh, S., Fay, M. P., Addiss, D., Nutman, T. B. & Hay, R. 2006. 
Interdigital lesions and frequency of acute dermatolymphangioadenitis in 
lymphoedema in a filariasis-endemic area. Br J Dermatol, 154, 933-41. 
Meinking, T. L., Taplin, D., Hermida, J. L., Pardo, R. & Kerdel, F. A. 1995. The treatment of 
scabies with ivermectin. N Engl J Med, 333, 26-30. 
Meyrowitsch, D. W., Simonsen, P. E. & Makunde, W. H. 1995. Bancroftian filariasis: analysis 
of infection and disease in five endemic communities of north-eastern Tanzania. Ann 
Trop Med Parasitol, 89, 653-63. 
Meyrowitsch, D. W., Simonsen, P. E. & Makunde, W. H. 1996. Mass diethylcarbamazine 
chemotherapy for control of bancroftian filariasis: comparative efficacy of standard 
treatment and two semi-annual single-dose treatments. Trans R Soc Trop Med Hyg, 
90, 69-73. 
Michael, E., Bundy, D. A. & Grenfell, B. T. 1996. Re-assessing the global prevalence and 
distribution of lymphatic filariasis. Parasitology, 112 ( Pt 4), 409-28. 
Michael, E., Malecela-Lazaro, M. N., Simonsen, P. E., Pedersen, E. M., Barker, G., Kumar, 
A. & Kazura, J. W. 2004. Mathematical modelling and the control of lymphatic 
filariasis. Lancet Infect Dis, 4, 223-34. 
Michael, E., Malecela-Lazaro, M. N., Kabali, C., Snow, L. C. & Kazura, J. W. 2006. 
Mathematical models and lymphatic filariasis control: endpoints and optimal 
interventions. Trends Parasitol, 22, 226-33. 
Migchelsen, S. J., Martin, D. L., Southisombath, K., Turyaguma, P., Heggen, A., 
Rubangakene, P. P., Joof, H., Makalo, P., Cooley, G., Gwyn, S., Solomon, A. W., 
Holland, M. J., Courtright, P., Willis, R., Alexander, N. D., Mabey, D. C. & Roberts, C. 
H. 2017. Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies. 
PLoS Negl Trop Dis, 11, e0005230. 
Minakawa, N., Kongere, J. O., Dida, G. O., Ikeda, E., Hu, J., Minagawa, K., Futami, K., 
Kawada, H., Njenga, S. M. & Larson, P. S. 2015. Sleeping on the floor decreases 
insecticide treated bed net use and increases risk of malaria in children under 5 years 
of age in Mbita District, Kenya. Parasitology, 142, 1516-22. 
Mladonicky, J. M., King, J. D., Liang, J. L., Chambers, E., Pa'au, M., Schmaedick, M. A., 
Burkot, T. R., Bradley, M. & Lammie, P. J. 2009. Assessing transmission of lymphatic 
filariasis using parasitologic, serologic, and entomologic tools after mass drug 
administration in American Samoa. Am J Trop Med Hyg, 80, 769-73. 
Molyneux, D. H., Hotez, P. J. & Fenwick, A. 2005. "Rapid-impact interventions": how a policy 
of integrated control for Africa's neglected tropical diseases could benefit the poor. 
PLoS Med, 2, e336. 
Moraga, P., Cano, J., Baggaley, R. F., Gyapong, J. O., Njenga, S. M., Nikolay, B., Davies, E., 
Rebollo, M. P., Pullan, R. L., Bockarie, M. J., Hollingsworth, T. D., Gambhir, M. & 
Brooker, S. J. 2015. Modelling the distribution and transmission intensity of lymphatic 
filariasis in sub-Saharan Africa prior to scaling up interventions: integrated use of 
geostatistical and mathematical modelling. Parasit Vectors, 8, 560. 
More, S. J. & Copeman, D. B. 1990. A highly specific and sensitive monoclonal antibody-
based ELISA for the detection of circulating antigen in bancroftian filariasis. Trop Med 
Parasitol, 41, 403-6. 
Moss, D. M., Priest, J. W., Boyd, A., Weinkopff, T., Kucerova, Z., Beach, M. J. & Lammie, P. 
J. 2011. Multiplex bead assay for serum samples from children in Haiti enrolled in a 
drug study for the treatment of lymphatic filariasis. Am J Trop Med Hyg, 85, 229-37. 
Moulia-Pelat, J. P., Glaziou, P., Nguyen-Ngoc, L., Cardines, D., Spiegel, A. & Cartel, J. L. 
1992. A comparative study of detection methods for evaluation of microfilaremia in 
lymphatic filariasis control programmes. Trop Med Parasitol, 43, 146-8. 
Mounsey, K., Kearns, T., Rampton, M., Llewellyn, S., King, M., Holt, D., Currie, B. J., 
Andrews, R., Nutman, T. & McCarthy, J. 2014. Use of dried blood spots to define 
12. References 
___________________________________________________________________________ 
220 
  
 
antibody response to the Strongyloides stercoralis recombinant antigen NIE. Acta 
Trop, 138, 78-82. 
Muck, A. E., Pires, M. L. & Lammie, P. J. 2003. Influence of infection with non-filarial 
helminths on the specificity of serological assays for antifilarial immunoglobulin G4. 
Trans R Soc Trop Med Hyg, 97, 88-90. 
Munywoki, P. K., Ohuma, E. O., Ngama, M., Bauni, E., Scott, J. A. & Nokes, D. J. 2013. 
Severe lower respiratory tract infection in early infancy and pneumonia 
hospitalizations among children, Kenya. Emerg Infect Dis, 19, 223-9. 
Mwandawiro, C. S., Nikolay, B., Kihara, J. H., Ozier, O., Mukoko, D. A., Mwanje, M. T., 
Hakobyan, A., Pullan, R. L., Brooker, S. J. & Njenga, S. M. 2013. Monitoring and 
evaluating the impact of national school-based deworming in Kenya: study design 
and baseline results. Parasit Vectors, 6, 198. 
Mwinzi, P. N., Kittur, N., Ochola, E., Cooper, P. J., Campbell, C. H., Jr., King, C. H. & Colley, 
D. G. 2015. Additional Evaluation of the Point-of-Contact Circulating Cathodic Antigen 
Assay for Schistosoma mansoni Infection. Front Public Health, 3, 48. 
N'Guessan, R., Corbel, V., Akogbeto, M. & Rowland, M. 2007. Reduced efficacy of 
insecticide-treated nets and indoor residual spraying for malaria control in pyrethroid 
resistance area, Benin. Emerg Infect Dis, 13, 199-206. 
Naito, H. 2012. Eisai Increases Its Commitment to Fight Neglected Tropical Diseases. 
Neva, F. A. & Ottesen, E. A. 1978. Tropical (filarial) eosinophilia. N Engl J Med, 298, 1129-
31. 
Nicolas, L., Luquiaud, P., Lardeux, F. & Mercer, D. R. 1996. A polymerase chain reaction 
assay to determine infection of Aedes polynesiensis by Wuchereria bancrofti. Trans R 
Soc Trop Med Hyg, 90, 136-9. 
Nikolay, B., Brooker, S. J. & Pullan, R. L. 2014. Sensitivity of diagnostic tests for human soil-
transmitted helminth infections: a meta-analysis in the absence of a true gold 
standard. Int J Parasitol, 44, 765-74. 
Njaanake, K. H., Vennervald, B. J., Simonsen, P. E., Madsen, H., Mukoko, D. A., Kimani, G., 
Jaoko, W. G. & Estambale, B. B. 2016. Schistosoma haematobium and soil-
transmitted Helminths in Tana Delta District of Kenya: infection and morbidity patterns 
in primary schoolchildren from two isolated villages. BMC Infect Dis, 16, 57. 
Njenga, S. M. & Wamae, C. N. 2001. Evaluation of ICT filariasis card test using whole 
capillary blood: comparison with Knott's concentration and counting chamber 
methods. J Parasitol, 87, 1140-3. 
Njenga, S. M., Wamae, C. N., Njomo, D. W., Mwandawiro, C. S. & Molyneux, D. H. 2007. 
Chronic clinical manifestations related to Wuchereria bancrofti infection in a highly 
endemic area in Kenya. Trans R Soc Trop Med Hyg, 101, 439-44. 
Njenga, S. M., Wamae, C. N., Njomo, D. W., Mwandawiro, C. S. & Molyneux, D. H. 2008. 
Impact of two rounds of mass treatment with diethylcarbamazine plus albendazole on 
Wuchereria bancrofti infection and the sensitivity of immunochromatographic test in 
Malindi, Kenya. Trans R Soc Trop Med Hyg, 102, 1017-24. 
Njenga, S. M., Mwandawiro, C. S., Wamae, C. N., Mukoko, D. A., Omar, A. A., Shimada, M., 
Bockarie, M. J. & Molyneux, D. H. 2011a. Sustained reduction in prevalence of 
lymphatic filariasis infection in spite of missed rounds of mass drug administration in 
an area under mosquito nets for malaria control. Parasit Vectors, 4, 90. 
Njenga, S. M., Mwandawiro, C. S., Muniu, E., Mwanje, M. T., Haji, F. M. & Bockarie, M. J. 
2011b. Adult population as potential reservoir of NTD infections in rural villages of 
Kwale district, Coastal Kenya: implications for preventive chemotherapy interventions 
policy. Parasit Vectors, 4, 175. 
Njenga, S. M., Kanyi, H. M., Mutungi, F. M., Okoyo, C., Matendechero, H. S., Pullan, R. L., 
Halliday, K. E., Brooker, S. J., Wamae, C. N., Onsongo, J. K. & Won, K. Y. 2017. 
Assessment of lymphatic filariasis prior to re-starting mass drug administration 
campaigns in coastal Kenya. Parasit Vectors, 10, 99. 
12. References 
___________________________________________________________________________ 
221 
  
 
Noor, A. M., Mutheu, J. J., Tatem, A. J., Hay, S. I. & Snow, R. W. 2009. Insecticide-treated 
net coverage in Africa: mapping progress in 2000-07. Lancet, 373, 58-67. 
Noroes, J., Addiss, D., Santos, A., Medeiros, Z., Coutinho, A. & Dreyer, G. 1996a. 
Ultrasonographic evidence of abnormal lymphatic vessels in young men with adult 
Wuchereria bancrofti infection in the scrotal area. J Urol, 156, 409-12. 
Noroes, J., Addiss, D., Amaral, F., Coutinho, A., Medeiros, Z. & Dreyer, G. 1996b. 
Occurrence of living adult Wuchereria bancrofti in the scrotal area of men with 
microfilaraemia. Trans R Soc Trop Med Hyg, 90, 55-6. 
Noroes, J., Dreyer, G., Santos, A., Mendes, V. G., Medeiros, Z. & Addiss, D. 1997. 
Assessment of the efficacy of diethylcarbamazine on adult Wuchereria bancrofti in 
vivo. Trans R Soc Trop Med Hyg, 91, 78-81. 
Noroes, J., Addiss, D., Cedenho, A., Figueredo-Silva, J., Lima, G. & Dreyer, G. 2003. 
Pathogenesis of filarial hydrocele: risk associated with intrascrotal nodules caused by 
death of adult Wuchereria bancrofti. Trans R Soc Trop Med Hyg, 97, 561-6. 
NTDs, U. t. C. 2012. London Declaration on Neglected Tropical Diseases. 
Nutman, T. B. 2013. Insights into the pathogenesis of disease in human lymphatic filariasis. 
Lymphat Res Biol, 11, 144-8. 
Odermatt, P., Leang, R., Bin, B., Bunkea, T. & Socheat, D. 2008. Prevention of lymphatic 
filariasis with insecticide-treated bednets in Cambodia. Ann Trop Med Parasitol, 102, 
135-42. 
Odiere, M. R., Rawago, F. O., Ombok, M., Secor, W. E., Karanja, D. M., Mwinzi, P. N., 
Lammie, P. J. & Won, K. 2012. High prevalence of schistosomiasis in Mbita and its 
adjacent islands of Lake Victoria, western Kenya. Parasit Vectors, 5, 278. 
Okiro, E. A., Hay, S. I., Gikandi, P. W., Sharif, S. K., Noor, A. M., Peshu, N., Marsh, K. & 
Snow, R. W. 2007. The decline in paediatric malaria admissions on the coast of 
Kenya. Malar J, 6, 151. 
Oliveira, P., Braga, C., Alexander, N., Brandao, E., Silva, A., Wanderley, L., Aguiar, A. M., 
Diniz, G., Medeiros, Z. & Rocha, A. 2014. Evaluation of diagnostic tests for 
Wuchereria bancrofti infection in Brazilian schoolchildren. Rev Soc Bras Med Trop, 
47, 359-66. 
Olszewski, W. L., Jamal, S., Manokaran, G., Lukomska, B. & Kubicka, U. 1993. Skin 
changes in filarial and non-filarial lymphoedema of the lower extremities. Trop Med 
Parasitol, 44, 40-4. 
Olszewski, W. L., Jamal, S., Manokaran, G., Pani, S., Kumaraswami, V., Kubicka, U., 
Lukomska, B., Dworczynski, A., Swoboda, E. & Meisel-Mikolajczyk, F. 1997. 
Bacteriologic studies of skin, tissue fluid, lymph, and lymph nodes in patients with 
filarial lymphedema. Am J Trop Med Hyg, 57, 7-15. 
Olszewski, W. L., Jamal, S., Manokaran, G., Pani, S., Kumaraswami, V., Kubicka, U., 
Lukomska, B., Tripathi, F. M., Swoboda, E., Meisel-Mikolajczyk, F., Stelmach, E. & 
Zaleska, M. 1999. Bacteriological studies of blood, tissue fluid, lymph and lymph 
nodes in patients with acute dermatolymphangioadenitis (DLA) in course of 'filarial' 
lymphedema. Acta Trop, 73, 217-24. 
Ong, R. K. & Doyle, R. L. 1998. Tropical pulmonary eosinophilia. Chest, 113, 1673-9. 
Ottesen, E. A., Neva, F. A., Paranjape, R. S., Tripathy, S. P., Thiruvengadam, K. V. & 
Beaven, M. A. 1979. Specific allergic sensitsation to filarial antigens in tropical 
eosinophilia syndrome. Lancet, 1, 1158-61. 
Ottesen, E. A., Weller, P. F., Lunde, M. N. & Hussain, R. 1982. Endemic filariasis on a Pacific 
Island. II. Immunologic aspects: immunoglobulin, complement, and specific antifilarial 
IgG, IgM, and IgE antibodies. Am J Trop Med Hyg, 31, 953-61. 
Ottesen, E. A. 1985. Efficacy of diethylcarbamazine in eradicating infection with lymphatic-
dwelling filariae in humans. Rev Infect Dis, 7, 341-56. 
12. References 
___________________________________________________________________________ 
222 
  
 
Ottesen, E. A., Skvaril, F., Tripathy, S. P., Poindexter, R. W. & Hussain, R. 1985. 
Prominence of IgG4 in the IgG antibody response to human filariasis. J Immunol, 134, 
2707-12. 
Ottesen, E. A. & Nutman, T. B. 1992. Tropical pulmonary eosinophilia. Annu Rev Med, 43, 
417-24. 
Ottesen, E. A., Duke, B. O., Karam, M. & Behbehani, K. 1997. Strategies and tools for the 
control/elimination of lymphatic filariasis. Bull World Health Organ, 75, 491-503. 
Ottesen, E. A. 2000. The global programme to eliminate lymphatic filariasis. Trop Med Int 
Health, 5, 591-4. 
Ottesen, E. A. 2006. Lymphatic filariasis: Treatment, control and elimination. Adv Parasitol, 
61, 395-441. 
Owusu, I. O., de Souza, D. K., Anto, F., Wilson, M. D., Boakye, D. A., Bockarie, M. J. & 
Gyapong, J. O. 2015. Evaluation of human and mosquito based diagnostic tools for 
defining endpoints for elimination of Anopheles transmitted lymphatic filariasis in 
Ghana. Trans R Soc Trop Med Hyg, 109, 628-35. 
Oxborough, R. M., Kitau, J., Matowo, J., Mndeme, R., Feston, E., Boko, P., Odjo, A., 
Metonnou, C. G., Irish, S., N'Guessan, R., Mosha, F. W. & Rowland, M. W. 2010. 
Evaluation of indoor residual spraying with the pyrrole insecticide chlorfenapyr against 
pyrethroid-susceptible Anopheles arabiensis and pyrethroid-resistant Culex 
quinquefasciatus mosquitoes. Trans R Soc Trop Med Hyg, 104, 639-45. 
Pacific, W. H. O. R. O. f. t. W. 2006. The PacELF way : towards the elimination of lymphatic 
filariasis from the Pacific, 1999-2005, Manila : WHO Regional Office for the Western 
Pacific. 
Pani, S. P., Krishnamoorthy, K., Rao, A. S. & Prathiba, J. 1990. Clinical manifestations in 
malayan filariasis infection with special reference to lymphoedema grading. Indian J 
Med Res, 91, 200-7. 
Pani, S. P., Balakrishnan, N., Srividya, A., Bundy, D. A. & Grenfell, B. T. 1991. Clinical 
epidemiology of bancroftian filariasis: effect of age and gender. Trans R Soc Trop 
Med Hyg, 85, 260-4. 
Pani, S. P., Hoti, S. L., Vanamail, P. & Das, L. K. 2004. Comparison of an 
immunochromatographic card test with night blood smear examination for detection of 
Wuchereria bancrofti microfilaria carriers. Natl Med J India, 17, 304-6. 
Pavluck, A., Chu, B., Mann Flueckiger, R. & Ottesen, E. 2014. Electronic data capture tools 
for global health programs: evolution of LINKS, an Android-, web-based system. 
PLoS Negl Trop Dis, 8, e2654. 
Pedersen, E. M. & Mukoko, D. A. 2002. Impact of insecticide-treated materials on filaria 
transmission by the various species of vector mosquito in Africa. Ann Trop Med 
Parasitol, 96 Suppl 2, S91-5. 
Pedersen, E. M., Stolk, W. A., Laney, S. J. & Michael, E. 2009. The role of monitoring 
mosquito infection in the Global Programme to Eliminate Lymphatic Filariasis. Trends 
Parasitol, 25, 319-27. 
Pene, P., Mojon, M., Garin, J. P., Coulaud, J. P. & Rossignol, J. F. 1982. Albendazole: a new 
broad spectrum anthelmintic. Double-blind multicenter clinical trial. Am J Trop Med 
Hyg, 31, 263-6. 
Pinkston, P., Vijayan, V. K., Nutman, T. B., Rom, W. N., O'Donnell, K. M., Cornelius, M. J., 
Kumaraswami, V., Ferrans, V. J., Takemura, T., Yenokida, G. & et al. 1987. Acute 
tropical pulmonary eosinophilia. Characterization of the lower respiratory tract 
inflammation and its response to therapy. J Clin Invest, 80, 216-25. 
Pion, S. D., Montavon, C., Chesnais, C. B., Kamgno, J., Wanji, S., Klion, A. D., Nutman, T. B. 
& Boussinesq, M. 2016. Positivity of Antigen Tests Used for Diagnosis of Lymphatic 
Filariasis in Individuals Without Wuchereria bancrofti Infection But with High Loa loa 
Microfilaremia. Am J Trop Med Hyg, 95, 1417-1423. 
12. References 
___________________________________________________________________________ 
223 
  
 
Pion, S. D. S., Chesnais, C. B., Weil, G. J., Fischer, P. U., Missamou, F. & Boussinesq, M. 
2017. Effect of 3 years of biannual mass drug administration with albendazole on 
lymphatic filariasis and soil-transmitted helminth infections: a community-based study 
in Republic of the Congo. Lancet Infect Dis, 17, 763-769. 
Plichart, C., Sechan, Y., Davies, N. & Legrand, A. M. 2006. PCR and dissection as tools to 
monitor filarial infection of Aedes polynesiensis mosquitoes in French Polynesia. 
Filaria J, 5, 2. 
Pothin, E., Ferguson, N. M., Drakeley, C. J. & Ghani, A. C. 2016. Estimating malaria 
transmission intensity from Plasmodium falciparum serological data using antibody 
density models. Malar J, 15, 79. 
Priest, J. W., Moss, D. M., Visvesvara, G. S., Jones, C. C., Li, A. & Isaac-Renton, J. L. 2010. 
Multiplex assay detection of immunoglobulin G antibodies that recognize Giardia 
intestinalis and Cryptosporidium parvum antigens. Clin Vaccine Immunol, 17, 1695-
707. 
Priest, J. W., Jenks, M. H., Moss, D. M., Mao, B., Buth, S., Wannemuehler, K., Soeung, S. 
C., Lucchi, N. W., Udhayakumar, V., Gregory, C. J., Huy, R., Muth, S. & Lammie, P. 
J. 2016. Integration of Multiplex Bead Assays for Parasitic Diseases into a National, 
Population-Based Serosurvey of Women 15-39 Years of Age in Cambodia. PLoS 
Negl Trop Dis, 10, e0004699. 
Raccurt, C. 2004. [Malaria in Haiti today]. Sante, 14, 201-4. 
Rahmah, N., Anuar, A. K., Karim, R., Mehdi, R., Sinniah, B. & Omar, A. W. 1994. Potential 
use of IgG2-ELISA in the diagnosis of chronic elephantiasis and IgG4-ELISA in the 
follow-up of microfilaraemic patients infected with Brugia malayi. Biochem Biophys 
Res Commun, 205, 202-7. 
Rahmah, N., Lim, B. H., Khairul Anuar, A., Shenoy, R. K., Kumaraswami, V., Lokman Hakim, 
S., Chotechuang, P., Kanjanopas, K. & Ramachandran, C. P. 2001. A recombinant 
antigen-based IgG4 ELISA for the specific and sensitive detection of Brugia malayi 
infection. Trans R Soc Trop Med Hyg, 95, 280-4. 
Ramaiah, K. D., Ramu, K., Guyatt, H., Kumar, K. N. & Pani, S. P. 1998. Direct and indirect 
costs of the acute form of lymphatic filariasis to households in rural areas of Tamil 
Nadu, south India. Trop Med Int Health, 3, 108-15. 
Ramaiah, K. D. & Ottesen, E. A. 2014. Progress and impact of 13 years of the global 
programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. 
PLoS Negl Trop Dis, 8, e3319. 
Ramalingam, S. & Belkin, J. N. 1964. Vectors of Sub-Periodic Bancroftian Filariasis in the 
Samoa-Tonga Area. Nature, 201, 105-6. 
Ramalingam, S. 1968. The epidemiology of filarial transmission in Samoa and Tonga. Ann 
Trop Med Parasitol, 62, 305-24. 
Ramzy, R. M., Farid, H. A., Kamal, I. H., Ibrahim, G. H., Morsy, Z. S., Faris, R., Weil, G. J., 
Williams, S. A. & Gad, A. M. 1997. A polymerase chain reaction-based assay for 
detection of Wuchereria bancrofti in human blood and Culex pipiens. Trans R Soc 
Trop Med Hyg, 91, 156-60. 
Ramzy, R. M., El Setouhy, M., Helmy, H., Ahmed, E. S., Abd Elaziz, K. M., Farid, H. A., 
Shannon, W. D. & Weil, G. J. 2006. Effect of yearly mass drug administration with 
diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a 
comprehensive assessment. Lancet, 367, 992-9. 
Rao JN, S. A. 1984. On chi-sqaured tests for multiway contingency tables with cell 
proportions estimated from survey data. The Annals of Statistics, 12, 46-60. 
Rao, R. U., Atkinson, L. J., Ramzy, R. M., Helmy, H., Farid, H. A., Bockarie, M. J., Susapu, 
M., Laney, S. J., Williams, S. A. & Weil, G. J. 2006a. A real-time PCR-based assay for 
detection of Wuchereria bancrofti DNA in blood and mosquitoes. Am J Trop Med Hyg, 
74, 826-32. 
12. References 
___________________________________________________________________________ 
224 
  
 
Rao, R. U., Weil, G. J., Fischer, K., Supali, T. & Fischer, P. 2006b. Detection of Brugia 
parasite DNA in human blood by real-time PCR. J Clin Microbiol, 44, 3887-93. 
Rao, R. U., Nagodavithana, K. C., Samarasekera, S. D., Wijegunawardana, A. D., 
Premakumara, W. D., Perera, S. N., Settinayake, S., Miller, J. P. & Weil, G. J. 2014. A 
comprehensive assessment of lymphatic filariasis in Sri Lanka six years after 
cessation of mass drug administration. PLoS Negl Trop Dis, 8, e3281. 
Rao, R. U., Samarasekera, S. D., Nagodavithana, K. C., Dassanayaka, T. D. M., 
Punchihewa, M. W., Ranasinghe, U. S. B. & Weil, G. J. 2017. Reassessment of areas 
with persistent Lymphatic Filariasis nine years after cessation of mass drug 
administration in Sri Lanka. PLoS Negl Trop Dis, 11, e0006066. 
Rascoe, L. N., Price, C., Shin, S. H., McAuliffe, I., Priest, J. W. & Handali, S. 2015. 
Development of Ss-NIE-1 recombinant antigen based assays for immunodiagnosis of 
strongyloidiasis. PLoS Negl Trop Dis, 9, e0003694. 
Raso, G., Luginbühl, A., Adjoua, C. A., Tian-Bi, N. T., Silué, K. D., Matthys, B., Vounatsou, 
P., Wang, Y., Dumas, M. E., Holmes, E., Singer, B. H., Tanner, M., N'Goran E. K. & 
Utzinger, J. 2004. Multiple parasite infections and their relationship to self-reported 
morbidity in a community of rural Cote d'Ivoire. Int J Epidemiol, 33, 1092-102. 
Rawlins, S. C., Chailett, P., Ragoonanansingh, R. N., Baboolal, S. & Stroom, V. 1994. 
Microscopical and serological diagnosis of Wuchereria bancrofti. West Indian Med J, 
43, 75-9. 
Rebollo, M. P., Sambou, S. M., Thomas, B., Biritwum, N. K., Jaye, M. C., Kelly-Hope, L., 
Escalada, A. G., Molyneux, D. H. & Bockarie, M. J. 2015. Elimination of lymphatic 
filariasis in the Gambia. PLoS Negl Trop Dis, 9, e0003642. 
Ridley, D. S. 1956. The complement-fixation test in filariasis. Transactions of the Royal 
Society of Tropical Medicine and Hygiene, 50, 255-257. 
Rogier, E., Moss, D. M., Chard, A. N., Trinies, V., Doumbia, S., Freeman, M. C. & Lammie, P. 
J. 2017. Evaluation of Immunoglobulin G Responses to Plasmodium falciparum and 
Plasmodium vivax in Malian School Children Using Multiplex Bead Assay. Am J Trop 
Med Hyg, 96, 312-318. 
Rossignol, J. F. & Maisonneuve, H. 1983. Albendazole: placebo-controlled study in 870 
patients with intestinal helminthiasis. Trans R Soc Trop Med Hyg, 77, 707-11. 
Rwegoshora, R. T., Pedersen, E. M., Mukoko, D. A., Meyrowitsch, D. W., Masese, N., 
Malecela-Lazaro, M. N., Ouma, J. H., Michael, E. & Simonsen, P. E. 2005. 
Bancroftian filariasis: patterns of vector abundance and transmission in two East 
African communities with different levels of endemicity. Ann Trop Med Parasitol, 99, 
253-65. 
Samarawickrema, W. A., Sone, F. & Cummings, R. F. 1987. Natural infections of Wuchereria 
bancrofti in Aedes (Stegomyia) polynesiensis and Aedes (Finlaya) samoanus in 
Samoa. Trans R Soc Trop Med Hyg, 81, 124-8. 
Sang, H. C., Muchiri, G., Ombok, M., Odiere, M. R. & Mwinzi, P. N. 2014. Schistosoma 
haematobium hotspots in south Nyanza, western Kenya: prevalence, distribution and 
co-endemicity with Schistosoma mansoni and soil-transmitted helminths. Parasit 
Vectors, 7, 125. 
Sasa, M. 1976. Human filariasis : a global survey of epidemiology and control Baltimore : 
University Park Press, c1976. 
Scheifele, D. & Ochnio, J. 2009. The immunological basis for immunization series. Module 2: 
Diphtheria - update 2009. 
Schmaedick, M. A., Koppel, A. L., Pilotte, N., Torres, M., Williams, S. A., Dobson, S. L., 
Lammie, P. J. & Won, K. Y. 2014. Molecular xenomonitoring using mosquitoes to map 
lymphatic filariasis after mass drug administration in American Samoa. PLoS Negl 
Trop Dis, 8, e3087. 
Scobie, H. M., Mao, B., Buth, S., Wannemuehler, K. A., Sorensen, C., Kannarath, C., Jenks, 
M. H., Moss, D. M., Priest, J. W., Soeung, S. C., Deming, M. S., Lammie, P. J. & 
12. References 
___________________________________________________________________________ 
225 
  
 
Gregory, C. J. 2016. Tetanus Immunity among Women Aged 15 to 39 Years in 
Cambodia: a National Population-Based Serosurvey, 2012. Clin Vaccine Immunol, 
23, 546-54. 
Secor, W. E. 2015. Early lessons from schistosomiasis mass drug administration programs. 
F1000Res, 4. 
Shawa, S. T., Mwase, E. T., Pedersen, E. M. & Simonsen, P. E. 2013. Lymphatic filariasis in 
Luangwa District, South-East Zambia. Parasit Vectors, 6, 299. 
Shenoy, R. K., Sandhya, K., Suma, T. K. & Kumaraswami, V. 1995. A preliminary study of 
filariasis related acute adenolymphangitis with special reference to precipitating 
factors and treatment modalities. Southeast Asian J Trop Med Public Health, 26, 301-
5. 
Shenoy, R. K. 2008. Clinical and pathological aspects of filarial lymphedema and its 
management. Korean J Parasitol, 46, 119-25. 
Shenoy, R. K., Suma, T. K., Kumaraswami, V., Rahmah, N., Dhananjayan, G. & Padma, S. 
2009. Antifilarial drugs, in the doses employed in mass drug administrations by the 
Global Programme to Eliminate Lymphatic Filariasis, reverse lymphatic pathology in 
children with Brugia malayi infection. Ann Trop Med Parasitol, 103, 235-47. 
Shenoy, R. K. & Bockarie, M. J. 2011. Lymphatic filariasis in children: clinical features, 
infection burdens and future prospects for elimination. Parasitology, 138, 1559-68. 
Simonsen, P. E., Meyrowitsch, D. W., Makunde, W. H. & Magnussen, P. 1995. Bancroftian 
filariasis: the pattern of microfilaraemia and clinical manifestations in three endemic 
communities of Northeastern Tanzania. Acta Trop, 60, 179-87. 
Simonsen, P. E., Bernhard, P., Jaoko, W. G., Meyrowitsch, D. W., Malecela-Lazaro, M. N., 
Magnussen, P. & Michael, E. 2002. Filaria dance sign and subclinical hydrocoele in 
two east African communities with bancroftian filariasis. Trans R Soc Trop Med Hyg, 
96, 649-53. 
Simonsen, P. E., Magesa, S. M., Meyrowitsch, D. W., Malecela-Lazaro, M. N., Rwegoshora, 
R. T., Jaoko, W. G. & Michael, E. 2005. The effect of eight half-yearly single-dose 
treatments with DEC on Wuchereria bancrofti circulating antigenaemia. Trans R Soc 
Trop Med Hyg, 99, 541-7. 
Snow, R. W., Lindsay, S. W., Hayes, R. J. & Greenwood, B. M. 1988. Permethrin-treated bed 
nets (mosquito nets) prevent malaria in Gambian children. Trans R Soc Trop Med 
Hyg, 82, 838-42. 
Sodahlon, Y. K., Dorkenoo, A. M., Morgah, K., Nabiliou, K., Agbo, K., Miller, R., Datagni, M., 
Seim, A. & Mathieu, E. 2013. A success story: Togo is moving toward becoming the 
first sub-Saharan African nation to eliminate lymphatic filariasis through mass drug 
administration and countrywide morbidity alleviation. PLoS Negl Trop Dis, 7, e2080. 
Solomon, A. W., Peeling, R. W., Foster, A. & Mabey, D. C. 2004. Diagnosis and assessment 
of trachoma. Clin Microbiol Rev, 17, 982-1011, table of contents. 
Solomon, A. W., Engels, D., Bailey, R. L., Blake, I. M., Brooker, S., Chen, J. X., Chen, J. H., 
Churcher, T. S., Drakeley, C. J., Edwards, T., Fenwick, A., French, M., Gabrielli, A. F., 
Grassly, N. C., Harding-Esch, E. M., Holland, M. J., Koukounari, A., Lammie, P. J., 
Leslie, J., Mabey, D. C., Rhajaoui, M., Secor, W. E., Stothard, J. R., Wei, H., 
Willingham, A. L., Zhou, X. N. & Peeling, R. W. 2012. A diagnostics platform for the 
integrated mapping, monitoring, and surveillance of neglected tropical diseases: 
rationale and target product profiles. PLoS Negl Trop Dis, 6, e1746. 
Sousa-Figueiredo, J. C., Pleasant, J., Day, M., Betson, M., Rollinson, D., Montresor, A., 
Kazibwe, F., Kabatereine, N. B. & Stothard, J. R. 2010. Treatment of intestinal 
schistosomiasis in Ugandan preschool children: best diagnosis, treatment efficacy 
and side-effects, and an extended praziquantel dosing pole. Int Health, 2, 103-13. 
Statistics, K. N. B. o. 2009. Kenya Population and housing census: Analytical report on 
population projections. XIV. 
12. References 
___________________________________________________________________________ 
226 
  
 
Steel, C., Kubofcik, J., Ottesen, E. A. & Nutman, T. B. 2012. Antibody to the filarial antigen 
Wb123 reflects reduced transmission and decreased exposure in children born 
following single mass drug administration (MDA). PLoS Negl Trop Dis, 6, e1940. 
Steel, C., Golden, A., Kubofcik, J., LaRue, N., de Los Santos, T., Domingo, G. J. & Nutman, 
T. B. 2013. Rapid Wuchereria bancrofti-specific antigen Wb123-based IgG4 
immunoassays as tools for surveillance following mass drug administration programs 
on lymphatic filariasis. Clin Vaccine Immunol, 20, 1155-61. 
Steinmann, P., Zhou, X. N., Du, Z. W., Jiang, J. Y., Wang, L. B., Wang, X. Z., Li, L. H., Marti, 
H. & Utzinger, J. 2007. Occurrence of Strongyloides stercoralis in Yunnan Province, 
China, and comparison of diagnostic methods. PLoS Negl Trop Dis, 1, e75. 
Stolk, W. A., Swaminathan, S., van Oortmarssen, G. J., Das, P. K. & Habbema, J. D. 2003. 
Prospects for elimination of bancroftian filariasis by mass drug treatment in 
Pondicherry, India: a simulation study. J Infect Dis, 188, 1371-81. 
Stoll, N. R. 1947. This wormy world. J Parasitol, 33, 1-18. 
Stothard, J. R., Sousa-Figueiredo, J. C., Betson, M., Adriko, M., Arinaitwe, M., Rowell, C., 
Besiyge, F. & Kabatereine, N. B. 2011. Schistosoma mansoni Infections in young 
children: when are schistosome antigens in urine, eggs in stool and antibodies to 
eggs first detectable? PLoS Negl Trop Dis, 5, e938. 
Stothard, J. R., Sousa-Figueiredo, J. C., Betson, M., Bustinduy, A. & Reinhard-Rupp, J. 
2013. Schistosomiasis in African infants and preschool children: let them now be 
treated! Trends Parasitol, 29, 197-205. 
Suma, T. K., Shenoy, R. K. & Kumaraswami, V. 2002. Efficacy and sustainability of a 
footcare programme in preventing acute attacks of adenolymphangitis in Brugian 
filariasis. Trop Med Int Health, 7, 763-6. 
Sunish, I. P., Rajendran, R., Mani, T. R., Munirathinam, A., Dash, A. P. & Tyagi, B. K. 2007. 
Vector control complements mass drug administration against bancroftian filariasis in 
Tirukoilur, India. Bull World Health Organ, 85, 138-45. 
Suresh, S., Kumaraswami, V., Suresh, I., Rajesh, K., Suguna, G., Vijayasekaran, V., 
Ruckmani, A. & Rajamanickam, M. G. 1997. Ultrasonographic diagnosis of subclinical 
filariasis. J Ultrasound Med, 16, 45-9. 
Taleo, F., Taleo, G., Graves, P. M., Wood, P., Kim, S. H., Ozaki, M., Joseph, H., Chu, B., 
Pavluck, A., Yajima, A., Melrose, W., Ichimori, K. & Capuano, C. 2017. Surveillance 
efforts after mass drug administration to validate elimination of lymphatic filariasis as 
a public health problem in Vanuatu. Trop Med Health, 45, 18. 
Taylor, M. J., Hoerauf, A. & Bockarie, M. 2010. Lymphatic filariasis and onchocerciasis. 
Lancet, 376, 1175-85. 
Tchuem Tchuenté, L. A., Kuete Fouodo, C. J., Kamwa Ngassam, R. I., Sumo, L., Dongmo 
Noumedem, C., Kenfack, C. M., Gipwe, N. F., Nana, E. D., Stothard, J. R. & 
Rollinson, D. 2012. Evaluation of circulating cathodic antigen (CCA) urine-tests for 
diagnosis of Schistosoma mansoni infection in Cameroon. PLoS Negl Trop Dis, 6, 
e1758. 
Team, R. C. 2016. R: A language and environment for statistical computing. Vienna, Austria: 
R Foundation for Statistical Computing. 
Thiongo, F. W. & Ouma, J. H. 1987. Prevalence of schistosomes and other parasites in Taita 
division of Taita-Taveta district. East Afr Med J, 64, 665-71. 
Thomsen, E. K., Sanuku, N., Baea, M., Satofan, S., Maki, E., Lombore, B., Schmidt, M. S., 
Siba, P. M., Weil, G. J., Kazura, J. W., Fleckenstein, L. L. & King, C. L. 2016. Efficacy, 
Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, 
and Ivermectin for Treatment of Bancroftian Filariasis. Clin Infect Dis, 62, 334-341. 
Tsang, V. C., Hancock, K., Kelly, M. A., Wilson, B. C. & Maddison, S. E. 1983. Schistosoma 
mansoni adult microsomal antigens, a serologic reagent. II. Specificity of antibody 
responses to the S. mansoni microsomal antigen (MAMA). J Immunol, 130, 1366-70. 
12. References 
___________________________________________________________________________ 
227 
  
 
Utzinger, J., Becker, S. L., Knopp, S., Blum, J., Neumayr, A. L., Keiser, J. & Hatz, C. F. 2012. 
Neglected tropical diseases: diagnosis, clinical management, treatment and control. 
Swiss Med Wkly, 142, w13727. 
Utzinger, J., Becker, S. L., van Lieshout, L., van Dam, G. J. & Knopp, S. 2015. New 
diagnostic tools in schistosomiasis. Clin Microbiol Infect, 21, 529-42. 
van Gageldonk, P. G., von Hunolstein, C., van der Klis, F. R. & Berbers, G. A. 2011. 
Improved specificity of a multiplex immunoassay for quantitation of anti-diphtheria 
toxin antibodies with the use of diphtheria toxoid. Clin Vaccine Immunol, 18, 1183-6. 
Verani, J. R., Abudho, B., Montgomery, S. P., Mwinzi, P. N., Shane, H. L., Butler, S. E., 
Karanja, D. M. & Secor, W. E. 2011. Schistosomiasis among young children in 
Usoma, Kenya. Am J Trop Med Hyg, 84, 787-91. 
Vlaminck, J., Nejsum, P., Vangroenweghe, F., Thamsborg, S. M., Vercruysse, J. & Geldhof, 
P. 2012. Evaluation of a serodiagnostic test using Ascaris suum haemoglobin for the 
detection of roundworm infections in pig populations. Vet Parasitol, 189, 267-73. 
Vlaminck, J., Supali, T., Geldhof, P., Hokke, C. H., Fischer, P. U. & Weil, G. J. 2016. 
Community Rates of IgG4 Antibodies to Ascaris Haemoglobin Reflect Changes in 
Community Egg Loads Following Mass Drug Administration. PLoS Negl Trop Dis, 10, 
e0004532. 
Wamae, C. N., Roberts, J. M., Eberhard, M. L. & Lammie, P. J. 1992. Kinetics of circulating 
human IgG4 after diethylcarbamazine and ivermectin treatment of bancroftian 
filariasis. J Infect Dis, 165, 1158-60. 
Wamae, C. N., Gatika, S. M., Roberts, J. M. & Lammie, P. J. 1998. Wuchereria bancrofti in 
Kwale District, Coastal Kenya: patterns of focal distribution of infection, clinical 
manifestations and anti-filarial IgG responsiveness. Parasitology, 116 ( Pt 2), 173-82. 
Wanji, S., Amvongo-Adjia, N., Koudou, B., Njouendou, A. J., Chounna Ndongmo, P. W., 
Kengne-Ouafo, J. A., Datchoua-Poutcheu, F. R., Fovennso, B. A., Tayong, D. B., 
Fombad, F. F., Fischer, P. U., Enyong, P. I. & Bockarie, M. 2015. Cross-Reactivity of 
Filariais ICT Cards in Areas of Contrasting Endemicity of Loa loa and Mansonella 
perstans in Cameroon: Implications for Shrinking of the Lymphatic Filariasis Map in 
the Central African Region. PLoS Negl Trop Dis, 9, e0004184. 
Wanji, S., Amvongo-Adjia, N., Njouendou, A. J., Kengne-Ouafo, J. A., Ndongmo, W. P., 
Fombad, F. F., Koudou, B., Enyong, P. A. & Bockarie, M. 2016. Further evidence of 
the cross-reactivity of the Binax NOW(R) Filariasis ICT cards to non-Wuchereria 
bancrofti filariae: experimental studies with Loa loa and Onchocerca ochengi. Parasit 
Vectors, 9, 267. 
Weil, G. J., Kumar, H., Santhanam, S., Sethumadhavan, K. V. & Jain, D. C. 1986. Detection 
of circulating parasite antigen in bancroftian filariasis by 
counterimmunoelectrophoresis. Am J Trop Med Hyg, 35, 565-70. 
Weil, G. J., Jain, D. C., Santhanam, S., Malhotra, A., Kumar, H., Sethumadhavan, K. V., 
Liftis, F. & Ghosh, T. K. 1987. A monoclonal antibody-based enzyme immunoassay 
for detecting parasite antigenemia in bancroftian filariasis. J Infect Dis, 156, 350-5. 
Weil, G. J. & Liftis, F. 1987. Identification and partial characterization of a parasite antigen in 
sera from humans infected with Wuchereria bancrofti. J Immunol, 138, 3035-41. 
Weil, G. J., Sethumadhavan, K. V., Santhanam, S., Jain, D. C. & Ghosh, T. K. 1988. 
Persistence of parasite antigenemia following diethylcarbamazine therapy of 
bancroftian filariasis. Am J Trop Med Hyg, 38, 589-95. 
Weil, G. J., Ramzy, R. M., Chandrashekar, R., Gad, A. M., Lowrie, R. C., Jr. & Faris, R. 1996. 
Parasite antigenemia without microfilaremia in bancroftian filariasis. Am J Trop Med 
Hyg, 55, 333-7. 
Weil, G. J., Lammie, P. J. & Weiss, N. 1997. The ICT Filariasis Test: A rapid-format antigen 
test for diagnosis of bancroftian filariasis. Parasitol Today, 13, 401-4. 
Weil, G. J. & Ramzy, R. M. 2007. Diagnostic tools for filariasis elimination programs. Trends 
Parasitol, 23, 78-82. 
12. References 
___________________________________________________________________________ 
228 
  
 
Weil, G. J., Kastens, W., Susapu, M., Laney, S. J., Williams, S. A., King, C. L., Kazura, J. W. 
& Bockarie, M. J. 2008. The impact of repeated rounds of mass drug administration 
with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New 
Guinea. PLoS Negl Trop Dis, 2, e344. 
Weil, G. J., Curtis, K. C., Fischer, P. U., Won, K. Y., Lammie, P. J., Joseph, H., Melrose, W. 
D. & Brattig, N. W. 2011. A multicenter evaluation of a new antibody test kit for 
lymphatic filariasis employing recombinant Brugia malayi antigen Bm-14. Acta Trop, 
120 Suppl 1, S19-22. 
Weil, G. J., Curtis, K. C., Fakoli, L., Fischer, K., Gankpala, L., Lammie, P. J., Majewski, A. C., 
Pelletreau, S., Won, K. Y., Bolay, F. K. & Fischer, P. U. 2013. Laboratory and field 
evaluation of a new rapid test for detecting Wuchereria bancrofti antigen in human 
blood. Am J Trop Med Hyg, 89, 11-5. 
WHO 1991. Basic laboratory methods in medical parasitology, Geneva, World Health 
Organization. 
WHO 1997. Fiftieth World Health Assembly: Elimination of lymphatic filariasis as a public 
health problem (50.29). Vol. III (3rd edition). 
WHO 2000. Lymphatic filariasis. Wkly Epidemiol Rec, 75, 206-8. 
WHO 2001. Lymphatic filariasis. Wkly Epidemiol Rec, 76, 149-54. 
WHO 2006a. Strategic and techincal meeting on intensified control of neglected tropical 
diseases - Berlin, 18-20 April 2005. 
WHO 2006b. The Role of Polymerase Chain Reaction Techniques for Assessing Lymphatic 
Filariasis Transmission. 
WHO 2008. World Health Organization position statement on integrated vector management. 
Weekly Epidemiological Record, 20, 177-81. 
WHO 2010. Progress report 2000-2009 and strategic plan 2010-2020 of the global 
programme to eliminate lymphatic filariasis: halfway towards eliminating lymphatic 
filariasis. 
WHO 2011a. Monitoring and epidemiological assessment of mass drug administration in the 
global programme to eliminate lymphatic filariasis: a manual for national elimination 
programmes. 
WHO 2011b. Integrated vector management to control malaria and lymphatic filariasis: WHO 
position statement. 
WHO 2011c. Helminth Control in School-Age Children: A Guide for Managers of Control 
Programmes. 
WHO 2011d. Haemoglobin concentrations for the diagnosis of anaemia and assessment of 
severity. 
WHO 2012a. Global programme to eliminate lymphatic filariasis: progress report, 2011. Wkly 
Epidemiol Rec, 87, 346-56. 
WHO 2012b. Soil-transmitted helminthiases : eliminating as public health problem soil-
transmitted helminthiases in children : progress report 2001-2010 and strategic plan 
2011-2020. . 
WHO 2013. Global programme to eliminate lymphatic filariasis: progress report for 2012. 
Wkly Epidemiol Rec, 88, 389-99. 
WHO 2014. Guide for mapping neglected tropical diseases targeted by preventive 
chemotherapy in the African Region. Brazzaville: WHO Regional Office for Africa. 
WHO 2015a. Schistosomiasis: number of people treated worldwide in 2013. Wkly Epidemiol 
Rec, 90, 25-32. 
WHO 2015b. Soil-transmitted helminthiases: number of children treated in 2014. Wkly 
Epidemiol Rec, 90, 705-11. 
WHO 2015c. Global Malaria Programme: World Malaria Report 2015. 
WHO 2015d. Global Technical Strategy for Malaria 2016-2030. 
12. References 
___________________________________________________________________________ 
229 
  
 
WHO 2015e. Assessing the Epidemiology of Soil-Transmitted Helminths During a 
Transmission Assesment Survey in the Global Programme for the Elimination of 
Lymphatic Filariasis. 
WHO 2016a. Global programme to eliminate lymphatic filariasis: progress report, 2015. Wkly 
Epidemiol Rec, 91, 441-55. 
WHO 2016b. Lymphatic Filariasis - Research 2016. 
WHO 2016c. Onchocerciasis: Guidelines for Stopping Mass Drug Administration and 
Verifying Elimination of Human Onchocerciasis, Geneva, Switzerland, WHO. 
WHO 2017a. Summary of global update on preventive chemotherapy implementation in 
2016: crossing the billion. Wkly Epidemiol Rec, 92, 589-93. 
WHO 2017b. Integrating neglected tropical diseases in global health and development: 
Fourth WHO report on neglected tropical diseases. 
WHO 2017c. Global programme to eliminate lymphatic filariasis: progress report, 2016. Wkly 
Epidemiol Rec, 92, 594-607. 
WHO 2017d. Guideline ‒ Alternative mass drug administration regimens to eliminate 
lymphatic filariasis. 
WHO 2017e. Validation of elimination of lymphatic filariasis as a public health problem, 
Geneva, Switzerland, WHO. 
WHO 2017f. Togo: first country in sub-Saharan Africa to eliminate lymphatic filariasis  
WHO. 2018. Neglected Tropical Diseases [Online]. Available: 
http://www.who.int/neglected_diseases/diseases/en/ [Accessed]. 
Wijers, D. J. 1977. Bancroftian filariasis in Kenya I. Prevalence survey among adult males in 
the Coast Province. Ann Trop Med Parasitol, 71, 313-31. 
Wijers, D. J. & Kaleli, N. 1984. Bancroftian filariasis in Kenya. V. Mass treatment given by 
members of the local community. Ann Trop Med Parasitol, 78, 383-94. 
Williams, S. A., Laney, S. J., Bierwert, L. A., Saunders, L. J., Boakye, D. A., Fischer, P., 
Goodman, D., Helmy, H., Hoti, S. L., Vasuki, V., Lammie, P. J., Plichart, C., Ramzy, 
R. M. & Ottesen, E. A. 2002. Development and standardization of a rapid, PCR-based 
method for the detection of Wuchereria bancrofti in mosquitoes, for xenomonitoring 
the human prevalence of bancroftian filariasis. Ann Trop Med Parasitol, 96 Suppl 2, 
S41-6. 
Wipasa, J., Suphavilai, C., Okell, L. C., Cook, J., Corran, P. H., Thaikla, K., Liewsaree, W., 
Riley, E. M. & Hafalla, J. C. 2010. Long-lived antibody and B Cell memory responses 
to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS 
Pathog, 6, e1000770. 
Witt, C. & Ottesen, E. A. 2001. Lymphatic filariasis: an infection of childhood. Trop Med Int 
Health, 6, 582-606. 
Won, K. Y., Beau de Rochars, M., Kyelem, D., Streit, T. G. & Lammie, P. J. 2009. Assessing 
the impact of a missed mass drug administration in Haiti. PLoS Negl Trop Dis, 3, 
e443. 
Won, K. Y., Kanyi, H. M., Mwende, F. M., Wiegand, R. E., Goodhew, E. B., Priest, J. W., Lee, 
Y. M., Njenga, S. M., Secor, W. E., Lammie, P. J. & Odiere, M. R. 2017. Multiplex 
Serologic Assessment of Schistosomiasis in Western Kenya: Antibody Responses in 
Preschool Aged Children as a Measure of Reduced Transmission. Am J Trop Med 
Hyg, 96, 1460-1467. 
Wong, J., Hamel, M. J., Drakeley, C. J., Kariuki, S., Shi, Y. P., Lal, A. A., Nahlen, B. L., 
Bloland, P. B., Lindblade, K. A., Were, V., Otieno, K., Otieno, P., Odero, C., Slutsker, 
L., Vulule, J. M. & Gimnig, J. E. 2014. Serological markers for monitoring historical 
changes in malaria transmission intensity in a highly endemic region of Western 
Kenya, 1994-2009. Malar J, 13, 451. 
Woodhall, D. M., Wiegand, R. E., Wellman, M., Matey, E., Abudho, B., Karanja, D. M., 
Mwinzi, P. M., Montgomery, S. P. & Secor, W. E. 2013. Use of geospatial modeling to 
12. References 
___________________________________________________________________________ 
230 
  
 
predict Schistosoma mansoni prevalence in Nyanza Province, Kenya. PLoS One, 8, 
e71635. 
Yahathugoda, T. C., Supali, T., Rao, R. U., Djuardi, Y., Stefani, D., Pical, F., Fischer, P. U., 
Lloyd, M. M., Premaratne, P. H., Weerasooriya, M. V. & Weil, G. J. 2015. A 
comparison of two tests for filarial antigenemia in areas in Sri Lanka and Indonesia 
with low-level persistence of lymphatic filariasis following mass drug administration. 
Parasit Vectors, 8, 369. 
Yong, W. K. 1973. Indirect fluorescent antibody technique with micro-fragments of 
Wuchereria bancrofti. Transactions of The Royal Society of Tropical Medicine and 
Hygiene, 67, 338-344. 
Zhang, S., Li, B. & Weil, G. J. 1999. Human antibody responses to Brugia malayi antigens in 
brugian filariasis. Int J Parasitol, 29, 429-36. 
Zhong, M., McCarthy, J., Bierwert, L., Lizotte-Waniewski, M., Chanteau, S., Nutman, T. B., 
Ottesen, E. A. & Williams, S. A. 1996. A polymerase chain reaction assay for 
detection of the parasite Wuchereria bancrofti in human blood samples. Am J Trop 
Med Hyg, 54, 357-63. 
